type	clinical_trial_id	title	last_update_posted	recruitment_status	project.project_id
clinical_trial	NCT03278340	Using Technology to Scale-Up an Occupational Sun Protection Policy Program (SSW-T)	9-Jul-21	Enrolling by invitation	1R01CA210259-01A1
clinical_trial	NCT03278340	Using Technology to Scale-Up an Occupational Sun Protection Policy Program (SSW-T)	9-Jul-21	Enrolling by invitation	1R01CA210259-01A1
clinical_trial	NCT04131062	Trial to Compare eConsent With Standard Consent Among Prospective Biobank Participants	22-Jan-21	Enrolling by invitation	1R01CA211723-01A1
clinical_trial	NCT00106015	Diamond Blackfan Anemia Registry (DBAR) (DBAR)	4-Mar-21	Recruiting	1R01CA211723-01A1
clinical_trial	NCT03478397	Evaluation of a mHealth Intervention to Increase Adherence to Triage of Self-collected HPV+ Women (ATICA Project) (ATICA)	6-Apr-21	Completed	1R01CA218306-01
clinical_trial	NCT03478397	Evaluation of a mHealth Intervention to Increase Adherence to Triage of Self-collected HPV+ Women (ATICA Project) (ATICA)	6-Apr-21	Completed	1R01CA218306-01
clinical_trial	NCT03478397	Evaluation of a mHealth Intervention to Increase Adherence to Triage of Self-collected HPV+ Women (ATICA Project) (ATICA)	6-Apr-21	Completed	1R01CA218306-01
clinical_trial	NCT01714739	A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors	14-Dec-20	Completed	1R33CA225291-01
clinical_trial	NCT01714739	A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors	14-Dec-20	Completed	1U54CA224070-01
clinical_trial	NCT01714739	A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors	14-Dec-20	Completed	1U54CA232561-01A1
clinical_trial	NCT02083484	Program for Pembrolizumab (MK-3475) in Participants With Metastatic Melanoma Who Have Failed Standard of Care Therapy Including Ipilimumab (MK-3475-030)	26-Jan-18	No longer available	1R33CA225291-01
clinical_trial	NCT02083484	Program for Pembrolizumab (MK-3475) in Participants With Metastatic Melanoma Who Have Failed Standard of Care Therapy Including Ipilimumab (MK-3475-030)	26-Jan-18	No longer available	1U54CA224070-01
clinical_trial	NCT01543698	A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors	6-Oct-21	"Active, not recruiting"	1R33CA225291-01
clinical_trial	NCT01543698	A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors	6-Oct-21	"Active, not recruiting"	1U54CA224070-01
clinical_trial	NCT01072175	"Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 &amp; GSK1120212"	5-Jul-19	Completed	1R33CA225291-01
clinical_trial	NCT01072175	"Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 &amp; GSK1120212"	5-Jul-19	Completed	1U54CA224070-01
clinical_trial	NCT00949702	A Study of Vemurafenib in Previously Treated Patients With Metastatic Melanoma	25-Jul-17	Completed	1R33CA225291-01
clinical_trial	NCT00949702	A Study of Vemurafenib in Previously Treated Patients With Metastatic Melanoma	25-Jul-17	Completed	1U54CA224070-01
clinical_trial	NCT01783938	Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)	13-Aug-21	Completed	1R33CA225291-01
clinical_trial	NCT01783938	Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)	13-Aug-21	Completed	1U54CA224070-01
clinical_trial	NCT01006980	A Study of Vemurafenib (RO5185426) in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)	28-Sep-16	Completed	1R33CA225291-01
clinical_trial	NCT01006980	A Study of Vemurafenib (RO5185426) in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)	28-Sep-16	Completed	1U54CA224070-01
clinical_trial	NCT01195922	Rapamycin Therapy in Head and Neck Squamous Cell Carcinoma	6-Dec-17	Completed	1R33CA225291-01
clinical_trial	NCT01195922	Rapamycin Therapy in Head and Neck Squamous Cell Carcinoma	6-Dec-17	Completed	1R33CA225291-01
clinical_trial	NCT02358031	A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048)	23-Oct-20	"Active, not recruiting"	1R33CA225291-01
clinical_trial	NCT02358031	A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048)	23-Oct-20	"Active, not recruiting"	1U01DE028227-01
clinical_trial	NCT02741570	Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (CheckMate 651)	19-Apr-21	"Active, not recruiting"	1R33CA225291-01
clinical_trial	NCT02741570	Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (CheckMate 651)	19-Apr-21	"Active, not recruiting"	1U01DE028227-01
clinical_trial	NCT00771641	Fractionated Radiation Therapy in Treating Advanced Squamous Cell Carcinoma of the Head and Neck	24-Jan-14	Completed	1R33CA225291-01
clinical_trial	NCT00771641	Fractionated Radiation Therapy in Treating Advanced Squamous Cell Carcinoma of the Head and Neck	24-Jan-14	Completed	1U01DE028227-01
clinical_trial	NCT03383094	Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer	8-Oct-21	Recruiting	1R33CA225291-01
clinical_trial	NCT03383094	Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer	8-Oct-21	Recruiting	1U01DE028227-01
clinical_trial	NCT03317327	REirradiation and Programmed Cell Death Protein 1 (PD-1) Blockade On Recurrent Squamous Cell Head and Neck Tumors (REPORT)	30-Sep-19	Recruiting	1R33CA225291-01
clinical_trial	NCT03317327	REirradiation and Programmed Cell Death Protein 1 (PD-1) Blockade On Recurrent Squamous Cell Head and Neck Tumors (REPORT)	30-Sep-19	Recruiting	1U01DE028227-01
clinical_trial	NCT03546582	SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma (KEYSTROKE)	3-Aug-21	Recruiting	1R33CA225291-01
clinical_trial	NCT03546582	SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma (KEYSTROKE)	3-Aug-21	Recruiting	1U01DE028227-01
clinical_trial	NCT02296684	Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma	30-Aug-21	"Active, not recruiting"	1R33CA225291-01
clinical_trial	NCT02296684	Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma	30-Aug-21	"Active, not recruiting"	1U01DE028227-01
clinical_trial	NCT03051906	"Durvalumab, Cetuximab and Radiotherapy in Head Neck Cancer (DUCRO-HN)"	22-Nov-17	Not yet recruiting	1R33CA225291-01
clinical_trial	NCT03051906	"Durvalumab, Cetuximab and Radiotherapy in Head Neck Cancer (DUCRO-HN)"	22-Nov-17	Not yet recruiting	1U01DE028227-01
clinical_trial	NCT02999087	Randomized Trial of Avelumab-cetuximab-radiotherapy Versus SOCs in LA SCCHN (REACH) (REACH)	4-Nov-20	"Active, not recruiting"	1R33CA225291-01
clinical_trial	NCT02999087	Randomized Trial of Avelumab-cetuximab-radiotherapy Versus SOCs in LA SCCHN (REACH) (REACH)	4-Nov-20	"Active, not recruiting"	1U01DE028227-01
clinical_trial	NCT02764593	Safety Testing of Adding Nivolumab to Chemotherapy in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Cancer	3-Aug-21	"Active, not recruiting"	1R33CA225291-01
clinical_trial	NCT02764593	Safety Testing of Adding Nivolumab to Chemotherapy in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Cancer	3-Aug-21	"Active, not recruiting"	1U01DE028227-01
clinical_trial	NCT03247712	Neoadjuvant Immunoradiotherapy in Head &amp; Neck Cancer	20-May-21	"Active, not recruiting"	1R33CA225291-01
clinical_trial	NCT03247712	Neoadjuvant Immunoradiotherapy in Head &amp; Neck Cancer	20-May-21	"Active, not recruiting"	1U01DE028227-01
clinical_trial	NCT03673735	Maintenance Immune Check-point Inhibitor Following Post-operative Chemo-radiation in Subjects With HPV-negative HNSCC (ADHERE)	10-May-21	Withdrawn	1R33CA225291-01
clinical_trial	NCT03673735	Maintenance Immune Check-point Inhibitor Following Post-operative Chemo-radiation in Subjects With HPV-negative HNSCC (ADHERE)	10-May-21	Withdrawn	1U01DE028227-01
clinical_trial	NCT03529422	Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN	11-May-21	Recruiting	1R33CA225291-01
clinical_trial	NCT03529422	Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN	11-May-21	Recruiting	1U01DE028227-01
clinical_trial	NCT03426657	Radiotherapy With Double Checkpoint Blockade of Locally Advanced HNSCC	28-Sep-21	"Active, not recruiting"	1R33CA225291-01
clinical_trial	NCT03426657	Radiotherapy With Double Checkpoint Blockade of Locally Advanced HNSCC	28-Sep-21	"Active, not recruiting"	1U01DE028227-01
clinical_trial	NCT03509012	Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors (CLOVER)	11-Oct-21	"Active, not recruiting"	1R33CA225291-01
clinical_trial	NCT03509012	Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors (CLOVER)	11-Oct-21	"Active, not recruiting"	1U01DE028227-01
clinical_trial	NCT03539198	Study of Proton SBRT and Immunotherapy for Recurrent/Progressive Locoregional or Metastatic Head and Neck Cancer	27-Sep-21	"Active, not recruiting"	1R33CA225291-01
clinical_trial	NCT03539198	Study of Proton SBRT and Immunotherapy for Recurrent/Progressive Locoregional or Metastatic Head and Neck Cancer	27-Sep-21	"Active, not recruiting"	1U01DE028227-01
clinical_trial	NCT03085719	Targeting PD-1 Therapy Resistance With Focused High or High and Low Dose Radiation in SCCHN	13-Nov-20	Recruiting	1R33CA225291-01
clinical_trial	NCT03085719	Targeting PD-1 Therapy Resistance With Focused High or High and Low Dose Radiation in SCCHN	13-Nov-20	Recruiting	1U01DE028227-01
clinical_trial	NCT03283605	Immunotherapy and SBRT for Metastatic Head and Neck Carcinomas	27-May-21	Recruiting	1R33CA225291-01
clinical_trial	NCT03283605	Immunotherapy and SBRT for Metastatic Head and Neck Carcinomas	27-May-21	Recruiting	1U01DE028227-01
clinical_trial	NCT03313804	Priming Immunotherapy in Advanced Disease With Radiation	14-Jun-21	Recruiting	1R33CA225291-01
clinical_trial	NCT03313804	Priming Immunotherapy in Advanced Disease With Radiation	14-Jun-21	Recruiting	1U01DE028227-01
clinical_trial	NCT02777385	Pembrolizumab in Combination With Cisplatin and Intensity Modulated Radiotherapy (IMRT) in Head and Neck Cancer	6-Apr-21	Recruiting	1R33CA225291-01
clinical_trial	NCT02777385	Pembrolizumab in Combination With Cisplatin and Intensity Modulated Radiotherapy (IMRT) in Head and Neck Cancer	6-Apr-21	Recruiting	1U01DE028227-01
clinical_trial	NCT03349710	"Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer"	9-Aug-21	Completed	1R33CA225291-01
clinical_trial	NCT03349710	"Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer"	9-Aug-21	Completed	1U01DE028227-01
clinical_trial	NCT02892201	Pembrolizumab in HNSCC With Residual Disease After Radiation	15-Jul-21	"Active, not recruiting"	1R33CA225291-01
clinical_trial	NCT02892201	Pembrolizumab in HNSCC With Residual Disease After Radiation	15-Jul-21	"Active, not recruiting"	1U01DE028227-01
clinical_trial	NCT02841748	"A Randomized, Double-Blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence- the PATHWay Study"	7-Jan-21	Recruiting	1R33CA225291-01
clinical_trial	NCT02841748	"A Randomized, Double-Blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence- the PATHWay Study"	7-Jan-21	Recruiting	1U01DE028227-01
clinical_trial	NCT03040999	Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)	19-Apr-21	"Active, not recruiting"	1R33CA225291-01
clinical_trial	NCT03040999	Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)	19-Apr-21	"Active, not recruiting"	1U01DE028227-01
clinical_trial	NCT02952586	Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100)	22-Sep-21	Terminated	1R33CA225291-01
clinical_trial	NCT02952586	Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100)	22-Sep-21	Terminated	1U01DE028227-01
clinical_trial	NCT02952586	Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100)	22-Sep-21	Terminated	1U01DE029188-01
clinical_trial	NCT03452137	A Study of Atezolizumab (Anti-Pd-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck	29-Sep-21	Recruiting	1R33CA225291-01
clinical_trial	NCT03452137	A Study of Atezolizumab (Anti-Pd-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck	29-Sep-21	Recruiting	1U01DE028227-01
clinical_trial	NCT01302834	Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer	23-Feb-21	"Active, not recruiting"	1R33CA225291-01
clinical_trial	NCT01302834	Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer	23-Feb-21	"Active, not recruiting"	1U01DE028227-01
clinical_trial	NCT01040832	EMD 1201081 in Combination With Cetuximab in Second-Line Cetuximab-Na&#239;ve Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck	30-Jan-17	Completed	1R33CA225291-01
clinical_trial	NCT01040832	EMD 1201081 in Combination With Cetuximab in Second-Line Cetuximab-Na&#239;ve Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck	30-Jan-17	Completed	1U01DE028227-01
clinical_trial	NCT01334177	"TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck"	5-Mar-15	Completed	1R33CA225291-01
clinical_trial	NCT01334177	"TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck"	5-Mar-15	Completed	1U01DE028227-01
clinical_trial	NCT01360827	EMD 1201081 + 5-FU + Cisplatin + Cetuximab in Subjects With Recurrent / Metastatic Squamous Cell Carcinoma of the Head and Neck	17-Jun-14	Terminated	1R33CA225291-01
clinical_trial	NCT01360827	EMD 1201081 + 5-FU + Cisplatin + Cetuximab in Subjects With Recurrent / Metastatic Squamous Cell Carcinoma of the Head and Neck	17-Jun-14	Terminated	1U01DE028227-01
clinical_trial	NCT01468896	"Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery"	24-Sep-21	"Active, not recruiting"	1R33CA225291-01
clinical_trial	NCT01468896	"Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery"	24-Sep-21	"Active, not recruiting"	1U01DE028227-01
clinical_trial	NCT01836029	Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck	29-Oct-19	Completed	1R33CA225291-01
clinical_trial	NCT01836029	Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck	29-Oct-19	Completed	1U01DE028227-01
clinical_trial	NCT01935921	"Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck Cancer"	15-Jun-21	"Active, not recruiting"	1R33CA225291-01
clinical_trial	NCT01935921	"Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck Cancer"	15-Jun-21	"Active, not recruiting"	1U01DE028227-01
clinical_trial	NCT02110082	Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer	19-Apr-17	Completed	1R33CA225291-01
clinical_trial	NCT02110082	Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer	19-Apr-17	Completed	1U01DE028227-01
clinical_trial	NCT02124850	A Phase Ib Study of Neoadjuvant of Cetuximab Plus Motolimod and Cetuximab Plus Motolimod Plus Nivolumab	25-Oct-19	Terminated	1R33CA225291-01
clinical_trial	NCT02124850	A Phase Ib Study of Neoadjuvant of Cetuximab Plus Motolimod and Cetuximab Plus Motolimod Plus Nivolumab	25-Oct-19	Terminated	1U01DE028227-01
clinical_trial	NCT02633800	Patritumab With Cetuximab and a Platinum Agent for Squamous Cell Carcinoma (Cancer) of the Head and Neck (SCCHN )	7-Jan-19	Terminated	1R33CA225291-01
clinical_trial	NCT02633800	Patritumab With Cetuximab and a Platinum Agent for Squamous Cell Carcinoma (Cancer) of the Head and Neck (SCCHN )	7-Jan-19	Terminated	1U01DE028227-01
clinical_trial	NCT02643550	Study of Monalizumab and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck	9-Feb-21	"Active, not recruiting"	1R33CA225291-01
clinical_trial	NCT02643550	Study of Monalizumab and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck	9-Feb-21	"Active, not recruiting"	1U01DE028227-01
clinical_trial	NCT02938273	Bioimmunoradiotherapy (Cetuximab/RT/Avelumab)	11-Dec-19	Completed	1R33CA225291-01
clinical_trial	NCT02938273	Bioimmunoradiotherapy (Cetuximab/RT/Avelumab)	11-Dec-19	Completed	1U01DE028227-01
clinical_trial	NCT03082534	Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head &amp; Neck Squamous Cell Carcinoma	11-Mar-21	Recruiting	1R33CA225291-01
clinical_trial	NCT03082534	Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head &amp; Neck Squamous Cell Carcinoma	11-Mar-21	Recruiting	1U01DE028227-01
clinical_trial	NCT03370276	Cetuximab &amp; Nivolumab in Patients With Recurrent/Metastatic Head &amp; Neck Squamous Cell Carcinoma	20-Sep-21	"Active, not recruiting"	1R33CA225291-01
clinical_trial	NCT03370276	Cetuximab &amp; Nivolumab in Patients With Recurrent/Metastatic Head &amp; Neck Squamous Cell Carcinoma	20-Sep-21	"Active, not recruiting"	1U01DE028227-01
clinical_trial	NCT03494322	EACH: Evaluating Avelumab in Combination With Cetuximab in Head and Neck Cancer (EACH)	5-Nov-20	"Active, not recruiting"	1R33CA225291-01
clinical_trial	NCT03494322	EACH: Evaluating Avelumab in Combination With Cetuximab in Head and Neck Cancer (EACH)	5-Nov-20	"Active, not recruiting"	1U01DE028227-01
clinical_trial	NCT03498378	"Avelumab, Cetuximab, and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma"	7-Oct-21	"Active, not recruiting"	1R33CA225291-01
clinical_trial	NCT03498378	"Avelumab, Cetuximab, and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma"	7-Oct-21	"Active, not recruiting"	1U01CA233100-01
clinical_trial	NCT03498378	"Avelumab, Cetuximab, and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma"	7-Oct-21	"Active, not recruiting"	1U01DE028227-01
clinical_trial	NCT01860430	"Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck Cancer"	15-Jun-21	"Active, not recruiting"	1R33CA225291-01
clinical_trial	NCT01860430	"Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck Cancer"	15-Jun-21	"Active, not recruiting"	1U01DE028227-01
clinical_trial	NCT02581137	Metformin Hydrochloride in Preventing Oral Cancer in Patients With an Oral Premalignant Lesion	16-Sep-21	"Active, not recruiting"	1R33CA225291-01
clinical_trial	NCT02581137	Metformin Hydrochloride in Preventing Oral Cancer in Patients With an Oral Premalignant Lesion	16-Sep-21	"Active, not recruiting"	1U01DE028227-01
clinical_trial	NCT03074513	Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors	24-Feb-21	"Active, not recruiting"	1R33CA225291-01
clinical_trial	NCT03074513	Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors	24-Feb-21	"Active, not recruiting"	1U01DE028227-01
clinical_trial	NCT02233595	Evaluation of Rectal Cancer Treatment Response Using PET/MRI (Rectal PET/MRI)	13-Aug-19	Terminated	1R33CA225310-01
clinical_trial	NCT02902757	FDG PET/CT in Monitoring Very Early Therapy Response in Patients With Glioblastoma	4-Feb-21	Recruiting	1R33CA225310-01
clinical_trial	NCT02773238	FLARE RT for Patients With Stage IIB-IIIB Non-small Cell Lung Cancer: Personalizing Radiation Therapy Using PET/CT and SPECT/CT Imaging	9-Jul-21	"Active, not recruiting"	1R33CA225310-01
clinical_trial	NCT02492867	A Pilot Study of Response-Driven Adaptive Radiation Therapy for Patients With Locally Advanced Non-Small Cell Lung Cancer	10-Feb-21	"Active, not recruiting"	1R33CA225310-01
clinical_trial	NCT02492867	A Pilot Study of Response-Driven Adaptive Radiation Therapy for Patients With Locally Advanced Non-Small Cell Lung Cancer	10-Feb-21	"Active, not recruiting"	3P30CA046592-31S8
clinical_trial	NCT02492867	A Pilot Study of Response-Driven Adaptive Radiation Therapy for Patients With Locally Advanced Non-Small Cell Lung Cancer	10-Feb-21	"Active, not recruiting"	3P30CA046592-31S4
clinical_trial	NCT00574353	Study Using Fluorine-18-Labeled Fluoro-Misonidazole Positron Emission Tomography to Detect Hypoxia in Locally Advanced (T3-T4 and./or N1)Primary Rectal Cancer Patients	8-Apr-20	Withdrawn	1R33CA225310-01
clinical_trial	NCT02016872	"Prognostic Value of Tumor Hypoxia, as Measured by 18F-FMISO Breath Hold PET/CT, in Non-Small-Cell-Lung Cancer (NSCLC) Patients"	5-Jan-21	"Active, not recruiting"	1R33CA225310-01
clinical_trial	NCT01212354	Impact of Selective Radiation Dose Escalation and Tumour Hypoxia Status on Locoregional Tumour Control After Radiochemotherapy of HNT (Escalox)	9-Feb-16	Recruiting	1R33CA225310-01
clinical_trial	NCT01507428	Study of Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy in Patients With Stage III Non-small Cell Lung Cancer	29-Apr-21	"Active, not recruiting"	1R33CA225310-01
clinical_trial	NCT01542177	A Study Using 18F-FAZA and PET Scans to Study Hypoxia in Pancreatic Cancer	16-Dec-19	"Active, not recruiting"	1R33CA225310-01
clinical_trial	NCT01549730	Cervix Hypoxia FAZA	6-Oct-21	"Active, not recruiting"	1R33CA225310-01
clinical_trial	NCT02328300	FLT PET/MR for Evaluation of Pseudoprogression in Patients With Brain Lesions	14-Nov-18	Withdrawn	1R33CA225310-01
clinical_trial	NCT02456246	Piloting the Feasibility of FLT-PET/CT Non-Small Cell Lung Cancer Managed With SBRT (SBRT FLT-PET)	5-Oct-21	"Active, not recruiting"	1R33CA225310-01
clinical_trial	NCT01666808	FACBC Outcomes for Post Prostatectomy	2-Feb-21	"Active, not recruiting"	1R33CA225310-01
clinical_trial	NCT03115333	DSC-MRI in Measuring Relative Cerebral Blood Volume for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma	21-May-20	Recruiting	1R33CA225310-01
clinical_trial	NCT02031250	Randomized Phase II Study of DCE-MRI-based Dose Escalation for Poor-prognosis and Neck Cancer	28-Jan-21	"Active, not recruiting"	1R33CA225310-01
clinical_trial	NCT03151642	A PILOT STUDY OF DIFFUSION WEIGHTED MRI TO ASSESS ESOPHAGEAL TUMOR RESONSE TO NEOADJUVANT CHEMORADIATION	26-Apr-21	Completed	1R33CA225310-01
clinical_trial	NCT02497573	Can DW MRI Predict Outcome During Radiotherapy for Head and Neck Cancer? (MeRInO)	2-Nov-16	Unknown	1R33CA225310-01
clinical_trial	NCT00581906	Dynamic Contrast Enhanced MRI (DCE-MRI) Diffusion Weighted MRI (DW-MRI) and Magnetic Resonance Spectroscopy (MRS) of Head and Neck Tumors	2-Mar-21	"Active, not recruiting"	1R33CA225310-01
clinical_trial	NCT02319239	Prostate Cancer Stereotactic Radiotherapy (ESKO)	28-Oct-20	Completed	1R33CA225310-01
clinical_trial	NCT02233374	Predicting RadIotherapy ReSponse of Rectal Cancer With MRI and PET (PRISM)	18-Sep-19	Completed	1R33CA225310-01
clinical_trial	NCT02415816	Diffusion Weighted Magnetic Resonance in Imaging Younger Patients With Newly Diagnosed Bone or Soft Tissue Sarcomas	7-Jan-21	Recruiting	1R33CA225310-01
clinical_trial	NCT01992861	MRI and PET Imaging in Predicting Treatment Response in Patients With Stage IB-IVA Cervical Cancer	22-Sep-21	Suspended	1R33CA225310-01
clinical_trial	NCT02137759	MRSI to Predict Response to RT/TMZ &#177; Belinostat in GBM	5-Sep-21	"Active, not recruiting"	1R33CA225310-01
clinical_trial	NCT01507506	Phase III Study Comparing 2 Brain Conformational Radiotherapy in Combination With Chemotherapy in the Treatment of Glioblastoma (SPECTRO GLIO)	12-Jan-21	Terminated	1R33CA225310-01
clinical_trial	NCT03137888	Spectroscopic MRI-Guided Radiation Therapy Planning in Glioblastoma	1-Mar-21	"Active, not recruiting"	1R33CA225310-01
clinical_trial	NCT03698162	Precise DCE-MRI in Diagnosing Participants With Recurrent High Grade Glioma or Melanoma Brain Metastases	18-Oct-21	Recruiting	1R33CA225400-01
clinical_trial	NCT02184195	Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy (POLO)	28-Sep-21	"Active, not recruiting"	1U01CA224146-01
clinical_trial	NCT02639026	"Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers"	14-Oct-21	"Active, not recruiting"	1U01CA224146-01
clinical_trial	NCT02639026	"Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers"	14-Oct-21	"Active, not recruiting"	1U01CA224175-01
clinical_trial	NCT02639026	"Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers"	14-Oct-21	"Active, not recruiting"	1U01CA224193-01
clinical_trial	NCT02648282	"Study With CY, Pembrolizumab, GVAX, and SBRT in Patients With Locally Advanced Pancreatic Cancer"	9-Aug-21	"Active, not recruiting"	1U01CA224146-01
clinical_trial	NCT02648282	"Study With CY, Pembrolizumab, GVAX, and SBRT in Patients With Locally Advanced Pancreatic Cancer"	9-Aug-21	"Active, not recruiting"	1U01CA224175-01
clinical_trial	NCT02648282	"Study With CY, Pembrolizumab, GVAX, and SBRT in Patients With Locally Advanced Pancreatic Cancer"	9-Aug-21	"Active, not recruiting"	1U01CA224193-01
clinical_trial	NCT02648282	"Study With CY, Pembrolizumab, GVAX, and SBRT in Patients With Locally Advanced Pancreatic Cancer"	9-Aug-21	"Active, not recruiting"	3P30CA125123-14S6
clinical_trial	NCT03245541	Radiation Therapy in Combination With Durvalumab for People With Pancreatic Cancer	5-Oct-21	Recruiting	1U01CA224146-01
clinical_trial	NCT03245541	Radiation Therapy in Combination With Durvalumab for People With Pancreatic Cancer	5-Oct-21	Recruiting	1U01CA224175-01
clinical_trial	NCT03245541	Radiation Therapy in Combination With Durvalumab for People With Pancreatic Cancer	5-Oct-21	Recruiting	1U01CA224193-01
clinical_trial	NCT03190265	"Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer"	20-Aug-21	Recruiting	1U01CA224146-01
clinical_trial	NCT03190265	"Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer"	20-Aug-21	Recruiting	1U01CA224175-01
clinical_trial	NCT03190265	"Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer"	20-Aug-21	Recruiting	1U01CA224193-01
clinical_trial	NCT02451982	Neoadjuvant/Adjuvant GVAX Pancreas Vaccine (With CY) With or Without Nivolumab and Urelumab Trial for Surgically Resectable Pancreatic Cancer	22-Mar-21	Recruiting	1U01CA224146-01
clinical_trial	NCT02451982	Neoadjuvant/Adjuvant GVAX Pancreas Vaccine (With CY) With or Without Nivolumab and Urelumab Trial for Surgically Resectable Pancreatic Cancer	22-Mar-21	Recruiting	1U01CA224175-01
clinical_trial	NCT02451982	Neoadjuvant/Adjuvant GVAX Pancreas Vaccine (With CY) With or Without Nivolumab and Urelumab Trial for Surgically Resectable Pancreatic Cancer	22-Mar-21	Recruiting	1U01CA224193-01
clinical_trial	NCT03153410	"Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas"	19-Aug-21	"Active, not recruiting"	1U01CA224146-01
clinical_trial	NCT03153410	"Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas"	19-Aug-21	"Active, not recruiting"	1U01CA224175-01
clinical_trial	NCT03153410	"Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas"	19-Aug-21	"Active, not recruiting"	1U01CA224193-01
clinical_trial	NCT03006302	"Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas Cancer"	20-Aug-21	Recruiting	1U01CA224146-01
clinical_trial	NCT03006302	"Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas Cancer"	20-Aug-21	Recruiting	1U01CA224175-01
clinical_trial	NCT03006302	"Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas Cancer"	20-Aug-21	Recruiting	1U01CA224193-01
clinical_trial	NCT03214250	Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma	14-Oct-21	"Active, not recruiting"	1U01CA224146-01
clinical_trial	NCT03214250	Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma	14-Oct-21	"Active, not recruiting"	1U01CA224175-01
clinical_trial	NCT03214250	Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma	14-Oct-21	"Active, not recruiting"	1U01CA224193-01
clinical_trial	NCT03214250	Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma	14-Oct-21	"Active, not recruiting"	1U01CA224193-01
clinical_trial	NCT03214250	Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma	14-Oct-21	"Active, not recruiting"	1U24CA224285-01
clinical_trial	NCT03214250	Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma	14-Oct-21	"Active, not recruiting"	3P30CA016520-44S5
clinical_trial	NCT03214250	Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma	14-Oct-21	"Active, not recruiting"	3P30CA016520-44S5
clinical_trial	NCT03214250	Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma	14-Oct-21	"Active, not recruiting"	3P30CA016520-44S6
clinical_trial	NCT03214250	Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma	14-Oct-21	"Active, not recruiting"	3P30CA016520-44S6
clinical_trial	NCT02758587	Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1)	19-Mar-18	Recruiting	1U01CA224146-01
clinical_trial	NCT02758587	Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1)	19-Mar-18	Recruiting	1U01CA224175-01
clinical_trial	NCT02758587	Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1)	19-Mar-18	Recruiting	1U01CA224193-01
clinical_trial	NCT02546531	Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer	20-Jul-21	Completed	1U01CA224146-01
clinical_trial	NCT02546531	Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer	20-Jul-21	Completed	1U01CA224175-01
clinical_trial	NCT02546531	Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer	20-Jul-21	Completed	1U01CA224193-01
clinical_trial	NCT02546531	Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer	20-Jul-21	Completed	1U54CA224083-01
clinical_trial	NCT03481920	A Trial of PEGPH20 in Combination With Avelumab in Chemotherapy Resistant Pancreatic Cancer	22-Aug-19	Terminated	1U01CA224146-01
clinical_trial	NCT03481920	A Trial of PEGPH20 in Combination With Avelumab in Chemotherapy Resistant Pancreatic Cancer	22-Aug-19	Terminated	1U01CA224175-01
clinical_trial	NCT03481920	A Trial of PEGPH20 in Combination With Avelumab in Chemotherapy Resistant Pancreatic Cancer	22-Aug-19	Terminated	1U01CA224193-01
clinical_trial	NCT03193190	A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)	5-Aug-21	"Active, not recruiting"	1U01CA224146-01
clinical_trial	NCT03193190	A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)	5-Aug-21	"Active, not recruiting"	1U01CA224175-01
clinical_trial	NCT03193190	A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)	5-Aug-21	"Active, not recruiting"	1U01CA224193-01
clinical_trial	NCT03193190	A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)	5-Aug-21	"Active, not recruiting"	1U01CA224193-01
clinical_trial	NCT03634332	Second-line Study of PEGPH20 and Pembro for HA High Metastatic PDAC	7-May-19	Unknown	1U01CA224146-01
clinical_trial	NCT03634332	Second-line Study of PEGPH20 and Pembro for HA High Metastatic PDAC	7-May-19	Unknown	1U01CA224175-01
clinical_trial	NCT03634332	Second-line Study of PEGPH20 and Pembro for HA High Metastatic PDAC	7-May-19	Unknown	1U01CA224193-01
clinical_trial	NCT02777710	Evaluation of Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With CSF-1R TKI (PEXIDARTINIB) in Patients With Metastatic/Advanced Pancreatic or Colorectal Cancers (MEDIPLEX)	5-Sep-21	Completed	1U01CA224146-01
clinical_trial	NCT02777710	Evaluation of Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With CSF-1R TKI (PEXIDARTINIB) in Patients With Metastatic/Advanced Pancreatic or Colorectal Cancers (MEDIPLEX)	5-Sep-21	Completed	1U01CA224175-01
clinical_trial	NCT02777710	Evaluation of Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With CSF-1R TKI (PEXIDARTINIB) in Patients With Metastatic/Advanced Pancreatic or Colorectal Cancers (MEDIPLEX)	5-Sep-21	Completed	1U01CA224193-01
clinical_trial	NCT02777710	Evaluation of Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With CSF-1R TKI (PEXIDARTINIB) in Patients With Metastatic/Advanced Pancreatic or Colorectal Cancers (MEDIPLEX)	5-Sep-21	Completed	1U01CA224193-01
clinical_trial	NCT02777710	Evaluation of Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With CSF-1R TKI (PEXIDARTINIB) in Patients With Metastatic/Advanced Pancreatic or Colorectal Cancers (MEDIPLEX)	5-Sep-21	Completed	1U01CA224348-01
clinical_trial	NCT02526017	Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers (FPA008-003)	31-Jul-20	Completed	1U01CA224146-01
clinical_trial	NCT02526017	Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers (FPA008-003)	31-Jul-20	Completed	1U01CA224160-01
clinical_trial	NCT02526017	Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers (FPA008-003)	31-Jul-20	Completed	1U01CA224175-01
clinical_trial	NCT02526017	Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers (FPA008-003)	31-Jul-20	Completed	1U01CA224193-01
clinical_trial	NCT02526017	Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers (FPA008-003)	31-Jul-20	Completed	1U01CA224193-01
clinical_trial	NCT02526017	Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers (FPA008-003)	31-Jul-20	Completed	1U01CA224348-01
clinical_trial	NCT02436668	"Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE)"	30-Dec-20	Completed	1U01CA224146-01
clinical_trial	NCT02436668	"Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE)"	30-Dec-20	Completed	1U01CA224175-01
clinical_trial	NCT02436668	"Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE)"	30-Dec-20	Completed	1U01CA224193-01
clinical_trial	NCT03496662	BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)	23-Jul-21	Recruiting	1U01CA224146-01
clinical_trial	NCT03496662	BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)	23-Jul-21	Recruiting	1U01CA224175-01
clinical_trial	NCT03496662	BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)	23-Jul-21	Recruiting	1U01CA224193-01
clinical_trial	NCT03404960	Niraparib + Ipilimumab or Nivolumab in Progression Free Pancreatic Adenocarcinoma After Platinum-Based Chemotherapy (Parpvax)	10-Jun-21	Recruiting	1U01CA224146-01
clinical_trial	NCT03404960	Niraparib + Ipilimumab or Nivolumab in Progression Free Pancreatic Adenocarcinoma After Platinum-Based Chemotherapy (Parpvax)	10-Jun-21	Recruiting	1U01CA224175-01
clinical_trial	NCT03404960	Niraparib + Ipilimumab or Nivolumab in Progression Free Pancreatic Adenocarcinoma After Platinum-Based Chemotherapy (Parpvax)	10-Jun-21	Recruiting	1U01CA224193-01
clinical_trial	NCT03404960	Niraparib + Ipilimumab or Nivolumab in Progression Free Pancreatic Adenocarcinoma After Platinum-Based Chemotherapy (Parpvax)	10-Jun-21	Recruiting	1U01CA224193-01
clinical_trial	NCT01560923	Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer	3-Apr-20	Completed	1U01CA224151-01
clinical_trial	NCT02073123	Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma	5-Jun-20	Completed	1U01CA224151-01
clinical_trial	NCT02835729	A Study of Indoximod in Combination With (7+3) Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia	4-Jun-20	Completed	1U01CA224151-01
clinical_trial	NCT02052648	Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors	28-May-20	Completed	1U01CA224151-01
clinical_trial	NCT03301636	A Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab for Subjects With Unresectable or Metastatic Melanoma (NLG2107)	5-Jun-20	Terminated	1U01CA224151-01
clinical_trial	NCT02502708	"Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors"	4-Jun-20	Completed	1U01CA224151-01
clinical_trial	NCT02502708	"Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors"	4-Jun-20	Completed	1U54CA232561-01A1
clinical_trial	NCT02502648	N/A	N/A	N/A	1U01CA224151-01
clinical_trial	NCT01920191	Phase I/II Trial of IMA950 Multi-peptide Vaccine Plus Poly-ICLC in Glioblastoma	20-Apr-16	Completed	1U01CA224160-01
clinical_trial	NCT02454634	Phase I Trial of IDH1 Peptide Vaccine in IDH1R132H-mutated Grade III-IV Gliomas (NOA-16)	7-Nov-18	Completed	1U01CA224160-01
clinical_trial	NCT02794883	Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma	5-Apr-19	Unknown	1U01CA224160-01
clinical_trial	NCT02017717	A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients (CheckMate 143)	19-Apr-21	"Active, not recruiting"	1U01CA224160-01
clinical_trial	NCT02017717	A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients (CheckMate 143)	19-Apr-21	"Active, not recruiting"	1U01CA224160-01
clinical_trial	NCT02337491	Pembrolizumab +/- Bevacizumab for Recurrent GBM	22-Dec-20	Completed	1U01CA224160-01
clinical_trial	NCT02337491	Pembrolizumab +/- Bevacizumab for Recurrent GBM	22-Dec-20	Completed	1U01CA224348-01
clinical_trial	NCT02311582	MK-3475 in Combination With MRI-guided Laser Ablation in Recurrent Malignant Gliomas	5-Sep-21	"Active, not recruiting"	1U01CA224160-01
clinical_trial	NCT01952769	Anti PD1 Antibody in Diffuse Intrinsic Pontine Glioma	13-Sep-16	Unknown	1U01CA224160-01
clinical_trial	NCT02336165	Phase 2 Study of Durvalumab (MEDI4736) in Patients With Glioblastoma	15-Jul-21	Completed	1U01CA224160-01
clinical_trial	NCT02336165	Phase 2 Study of Durvalumab (MEDI4736) in Patients With Glioblastoma	15-Jul-21	Completed	1U01CA224348-01
clinical_trial	NCT02327078	"A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)"	28-Aug-20	Completed	1U01CA224160-01
clinical_trial	NCT02313272	Hypofractionated Stereotactic Irradiation (HFSRT) With Pembrolizumab and Bevacizumab for Recurrent High Grade Gliomas	10-Aug-21	Completed	1U01CA224160-01
clinical_trial	NCT02335918	A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors	9-Dec-19	Completed	1U01CA224160-01
clinical_trial	NCT02337686	Pembrolizumab in Treating Patients With Recurrent Glioblastoma	29-Jan-20	"Active, not recruiting"	1U01CA224160-01
clinical_trial	NCT02550249	Neoadjuvant Nivolumab in Glioblastoma (Neo-nivo)	11-Apr-17	Completed	1U01CA224160-01
clinical_trial	NCT02529072	Nivolumab With DC Vaccines for Recurrent Brain Tumors (AVERT)	26-Mar-20	Completed	1U01CA224160-01
clinical_trial	NCT02529072	Nivolumab With DC Vaccines for Recurrent Brain Tumors (AVERT)	26-Mar-20	Completed	1U24CA224285-01
clinical_trial	NCT02617589	"An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) (CheckMate 498)"	3-Feb-21	"Active, not recruiting"	1U01CA224160-01
clinical_trial	NCT02617589	"An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) (CheckMate 498)"	3-Feb-21	"Active, not recruiting"	1U01CA224348-01
clinical_trial	NCT02617589	"An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) (CheckMate 498)"	3-Feb-21	"Active, not recruiting"	1U2CCA233262-01
clinical_trial	NCT02617589	"An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) (CheckMate 498)"	3-Feb-21	"Active, not recruiting"	3P30CA006516-55S9
clinical_trial	NCT02648633	Stereotactic Radiosurgery With Nivolumab and Valproate in Patients With Recurrent Glioblastoma	31-May-17	Terminated	1U01CA224160-01
clinical_trial	NCT02658279	Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype	22-Sep-21	Recruiting	1U01CA224160-01
clinical_trial	NCT02658981	Anti-LAG-3 Alone &amp; in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18)	10-Sep-21	"Active, not recruiting"	1U01CA224160-01
clinical_trial	NCT02667587	"An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) (CheckMate548)"	11-Sep-20	"Active, not recruiting"	1U01CA224160-01
clinical_trial	NCT02798406	Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects (CAPTIVE)	15-Jul-21	Completed	1U01CA224160-01
clinical_trial	NCT02829723	A Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors	30-Sep-21	"Active, not recruiting"	1U01CA224160-01
clinical_trial	NCT02829723	A Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors	30-Sep-21	"Active, not recruiting"	1U01CA224193-01
clinical_trial	NCT02852655	"A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma"	12-Oct-21	Completed	1U01CA224160-01
clinical_trial	NCT02937844	Pilot Study of Autologous Chimeric Switch Receptor Modified T Cells in Recurrent Glioblastoma Multiforme	19-Oct-16	Unknown	1U01CA224160-01
clinical_trial	NCT02866747	A Study Evaluating the Association of Hypofractionated Stereotactic Radiation Therapy and Durvalumab for Patients With Recurrent Glioblastoma (STERIMGLI)	28-Jul-21	Recruiting	1U01CA224160-01
clinical_trial	NCT02968940	Avelumab With Hypofractionated Radiation Therapy in Adults With Isocitrate Dehydrogenase (IDH) Mutant Glioblastoma	18-Jun-21	Completed	1U01CA224160-01
clinical_trial	NCT00643097	Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme (ACTIVATe)	1-Feb-17	Completed	1U01CA224160-01
clinical_trial	NCT00458601	Phase II Study of Rindopepimut (CDX-110) in Patients With Glioblastoma Multiforme (ACT III)	16-Jan-18	Completed	1U01CA224160-01
clinical_trial	NCT00458601	Phase II Study of Rindopepimut (CDX-110) in Patients With Glioblastoma Multiforme (ACT III)	16-Jan-18	Completed	1U01CA224160-01
clinical_trial	NCT01480479	Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma (ACT IV)	16-Jan-18	Completed	1U01CA224160-01
clinical_trial	NCT01498328	A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma (ReACT)	17-Feb-20	Completed	1U01CA224160-01
clinical_trial	NCT01130077	A Pilot Study of Glioma Associated Antigen Vaccines in Conjunction With Poly-ICLC in Pediatric Gliomas	10-Aug-21	"Active, not recruiting"	1U01CA224160-01
clinical_trial	NCT02078648	"Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme"	26-Jan-18	Completed	1U01CA224160-01
clinical_trial	NCT02149225	GAPVAC Phase I Trial in Newly Diagnosed Glioblastoma Patients	7-Aug-18	Completed	1U01CA224160-01
clinical_trial	NCT02287428	Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM	21-May-21	Recruiting	1U01CA224160-01
clinical_trial	NCT02193347	IDH1 Peptide Vaccine for Recurrent Grade II Glioma (RESIST)	15-Mar-21	"Active, not recruiting"	1U01CA224160-01
clinical_trial	NCT00293423	GP96 Heat Shock Protein-Peptide Complex Vaccine in Treating Patients With Recurrent or Progressive Glioma	13-May-21	Completed	1U01CA224160-01
clinical_trial	NCT01814813	Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery	18-Aug-21	"Active, not recruiting"	1U01CA224160-01
clinical_trial	NCT02546102	"Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma"	13-Aug-18	Suspended	1U01CA224160-01
clinical_trial	NCT00045968	Study of a Drug [DCVax&#174;-L] to Treat Newly Diagnosed GBM Brain Cancer (GBM)	14-Oct-16	Unknown	1U01CA224160-01
clinical_trial	NCT00846456	Safe Study of Dendritic Cell (DC) Based Therapy Targeting Tumor Stem Cells in Glioblastoma	20-Oct-15	Completed	1U01CA224160-01
clinical_trial	NCT02049489	A Study of ICT-121 Dendritic Cell Vaccine in Recurrent Glioblastoma	13-Aug-18	Completed	1U01CA224160-01
clinical_trial	NCT00626483	Basiliximab in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Undergoing Targeted Immunotherapy and Temozolomide-Caused Lymphopenia (REGULATe)	9-Mar-21	Completed	1U01CA224160-01
clinical_trial	NCT00639639	Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme (ATTAC)	26-Jan-21	"Active, not recruiting"	1U01CA224160-01
clinical_trial	NCT02366728	DC Migration Study for Newly-Diagnosed GBM (ELEVATE)	7-Nov-19	"Active, not recruiting"	1U01CA224160-01
clinical_trial	NCT00345163	A Study to Evaluate Bevacizumab Alone or in Combination With Irinotecan for Treatment of Glioblastoma Multiforme (BRAIN) (BRAIN)	16-May-17	Completed	1U01CA224160-01
clinical_trial	NCT00612430	Ph II Bevacizumab + Etoposide for Pts w Recurrent MG	12-Aug-13	Completed	1U01CA224160-01
clinical_trial	NCT00595322	Bevacizumab in the Radiation Treatment of Recurrent Malignant Glioma	23-May-17	Completed	1U01CA224160-01
clinical_trial	NCT01238237	Super-Selective Intraarterial Cerebral Infusion of Cetuximab (Erbitux) for Treatment of Relapsed/Refractory GBM and AA	1-Feb-17	Completed	1U01CA224160-01
clinical_trial	NCT01884740	Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22	20-Apr-21	Recruiting	1U01CA224160-01
clinical_trial	NCT00753246	Nimotuzumab in Adults With Glioblastoma Multiforma	3-Dec-12	Completed	1U01CA224160-01
clinical_trial	NCT02573324	A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance1)	24-May-21	"Active, not recruiting"	1U01CA224160-01
clinical_trial	NCT02573324	A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance1)	24-May-21	"Active, not recruiting"	1U01CA224160-01
clinical_trial	NCT00730613	Cellular Adoptive Immunotherapy Using Genetically Modified T-Lymphocytes in Treating Patients With Recurrent or Refractory High-Grade Malignant Glioma	9-Oct-17	Completed	1U01CA224160-01
clinical_trial	NCT02209376	Autologous T Cells Redirected to EGFRVIII-With a Chimeric Antigen Receptor in Patients With EGFRVIII+ Glioblastoma	5-Mar-19	Terminated	1U01CA224160-01
clinical_trial	NCT01109095	CMV-specific Cytotoxic T Lymphocytes Expressing CAR Targeting HER2 in Patients With GBM (HERT-GBM)	25-Apr-19	Completed	1U01CA224160-01
clinical_trial	NCT01491893	PVSRIPO for Recurrent Glioblastoma (GBM) (PVSRIPO)	12-Jan-21	"Active, not recruiting"	1U01CA224160-01
clinical_trial	NCT01491893	PVSRIPO for Recurrent Glioblastoma (GBM) (PVSRIPO)	12-Jan-21	"Active, not recruiting"	1U01CA224160-01
clinical_trial	NCT01301430	Parvovirus H-1 (ParvOryx) in Patients With Progressive Primary or Recurrent Glioblastoma Multiforme. (ParvOryx01)	4-Dec-15	Completed	1U01CA224160-01
clinical_trial	NCT00390299	Viral Therapy in Treating Patients With Recurrent Glioblastoma Multiforme	2-Jan-20	Completed	1U01CA224160-01
clinical_trial	NCT01174537	"New Castle Disease Virus (NDV) in Glioblastoma Multiforme (GBM), Sarcoma and Neuroblastoma"	11-Jun-15	Withdrawn	1U01CA224160-01
clinical_trial	NCT01811992	Combined Cytotoxic and Immune-Stimulatory Therapy for Glioma	31-Aug-21	Completed	1U01CA224160-01
clinical_trial	NCT01811992	Combined Cytotoxic and Immune-Stimulatory Therapy for Glioma	31-Aug-21	Completed	1U01CA224160-01
clinical_trial	NCT00002824	Gene Therapy in Treating Patients With Primary Brain Tumors	13-Mar-19	Completed	1U01CA224160-01
clinical_trial	NCT02311920	Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma	6-Jul-21	"Active, not recruiting"	1U01CA224160-01
clinical_trial	NCT02414165	The Toca 5 Trial: Toca 511 &amp; Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma (Toca5)	7-Feb-20	Terminated	1U01CA224160-01
clinical_trial	NCT00805376	DNX-2401 (Formerly Known as Delta-24-RGD-4C) for Recurrent Malignant Gliomas	16-Jul-18	Completed	1U01CA224160-01
clinical_trial	NCT01472003	An Evaluation of the Biodistribution and Imaging Characteristics of ABT-806i (111In-ABT-806) in Subjects With Advanced Solid Tumor Types	14-Jan-13	Completed	1U01CA224160-01
clinical_trial	NCT01255657	A Study of ABT-806 in Subjects With Advanced Solid Tumor Types	21-Nov-17	Completed	1U01CA224160-01
clinical_trial	NCT01406119	An Extension Study of ABT-806 in Subjects With Advanced Solid Tumors	27-Jan-17	Completed	1U01CA224160-01
clinical_trial	NCT02381886	A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations	26-Jul-21	"Active, not recruiting"	1U01CA224160-01
clinical_trial	NCT02381886	A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations	26-Jul-21	"Active, not recruiting"	3P30CA082103-21S9
clinical_trial	NCT02381886	A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations	26-Jul-21	"Active, not recruiting"	3P30CA082103-21S6
clinical_trial	NCT02977689	Trial of IDH305 in IDH1 Mutant Grade II or III Glioma	20-Dec-17	Withdrawn	1U01CA224160-01
clinical_trial	NCT02253212	Safety of BBB Opening With the SonoCloud (SONOCLOUD)	12-Oct-18	Completed	1U01CA224160-01
clinical_trial	NCT02343406	Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas (INTELLANCE-2)	22-May-20	Completed	1U01CA224160-01
clinical_trial	NCT03899857	Pembrolizumab for Newly Diagnosed Glioblastoma (PERGOLA)	16-Dec-20	Recruiting	1U01CA224160-01
clinical_trial	NCT03726515	CART-EGFRvIII + Pembrolizumab in GBM	3-Mar-21	Completed	1U01CA224160-01
clinical_trial	NCT03726515	CART-EGFRvIII + Pembrolizumab in GBM	3-Mar-21	Completed	1U01CA239258-01
clinical_trial	NCT02661282	Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma	8-Oct-21	"Active, not recruiting"	1U01CA224160-01
clinical_trial	NCT02255461	"Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors"	2-Mar-21	Terminated	1U01CA224160-01
clinical_trial	NCT02255461	"Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors"	2-Mar-21	Terminated	2UM1CA081457-21
clinical_trial	NCT03387020	Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors	27-Aug-21	Completed	1U01CA224160-01
clinical_trial	NCT03355794	A Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG)	27-Aug-21	"Active, not recruiting"	1U01CA224160-01
clinical_trial	NCT02644460	Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors (AflacST1501)	4-Mar-21	Recruiting	1U01CA224160-01
clinical_trial	NCT02717455	Trial of Panobinostat in Children With Diffuse Intrinsic Pontine Glioma (PBTC-047)	22-Sep-21	Recruiting	1U01CA224160-01
clinical_trial	NCT03632317	A Study of Panobinostat in Combination With Everolimus for Children and Young Adults With Gliomas	19-Aug-19	Withdrawn	1U01CA224160-01
clinical_trial	NCT03566199	MTX110 by Convection-Enhanced Delivery in Treating Participants With Newly-Diagnosed Diffuse Intrinsic Pontine Glioma (PNOC015)	15-Oct-21	Completed	1U01CA224160-01
clinical_trial	NCT03927105	Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma	10-Sep-21	"Active, not recruiting"	1U01CA224193-01
clinical_trial	NCT03697564	Nivolumab + Cabiralizumab + Gemcitabine in Patients With Stage IV Pancreatic Cancer Achieving Disease Control in Response to First-line Chemotherapy (GemCaN Trial).	7-May-20	Suspended	1U01CA224193-01
clinical_trial	NCT02880371	A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors	22-Mar-21	Completed	1U01CA224193-01
clinical_trial	NCT03502330	"APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma"	22-Dec-20	Recruiting	1U01CA224193-01
clinical_trial	NCT03502330	"APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma"	22-Dec-20	Recruiting	1U24CA224285-01
clinical_trial	NCT03238027	A Phase 1 Study to Investigate SNDX-6352 Alone or in Combination With Durvalumab in Patients With Solid Tumors	6-May-21	"Active, not recruiting"	1U01CA224193-01
clinical_trial	NCT03161431	SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab	23-Sep-21	Recruiting	1U01CA224193-01
clinical_trial	NCT03161431	SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab	23-Sep-21	Recruiting	3P30CA046592-31S8
clinical_trial	NCT03161431	SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab	23-Sep-21	Recruiting	3P30CA046592-31S4
clinical_trial	NCT03999749	A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma	1-Jun-21	Recruiting	1U01CA224193-01
clinical_trial	NCT01130142	A Study Evaluating IPI-926 in Combination With Gemcitabine in Patients With Metastatic Pancreatic Cancer	6-Mar-17	Completed	1U01CA224193-01
clinical_trial	NCT01130142	A Study Evaluating IPI-926 in Combination With Gemcitabine in Patients With Metastatic Pancreatic Cancer	6-Mar-17	Completed	1U01CA224348-01
clinical_trial	NCT01130142	A Study Evaluating IPI-926 in Combination With Gemcitabine in Patients With Metastatic Pancreatic Cancer	6-Mar-17	Completed	1U54CA224083-01
clinical_trial	NCT02588443	Study of Neo-adjuvant RO7009789 Alone or Neo-adjuvant RO7009789 Plus Nab-Paclitaxel and Gemcitabine Followed by Adjuvant RO7009789 Plus Nab-Paclitaxel and Gemcitabine for Patients With Newly Diagnosed Resectable Pancreatic Carcinoma	16-Apr-19	Completed	1U01CA224193-01
clinical_trial	NCT02588443	Study of Neo-adjuvant RO7009789 Alone or Neo-adjuvant RO7009789 Plus Nab-Paclitaxel and Gemcitabine Followed by Adjuvant RO7009789 Plus Nab-Paclitaxel and Gemcitabine for Patients With Newly Diagnosed Resectable Pancreatic Carcinoma	16-Apr-19	Completed	1U24CA224285-01
clinical_trial	NCT00633724	Multiple-Vaccine Therapy in Treating Patients With Non-small Cell Lung Cancer	15-Aug-13	Completed	1U01CA224348-01
clinical_trial	NCT00874588	Peptide Vaccine Targeting to Cancer Specific Antigen Combined With Anti-angiogenic Peptide Antigen in Treating Patients With Non-small Cell Lung Cancer	15-Aug-13	Completed	1U01CA224348-01
clinical_trial	NCT02562755	Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone (PHOCUS)	16-Dec-20	Completed	1U01CA224348-01
clinical_trial	NCT02562755	Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone (PHOCUS)	16-Dec-20	Completed	3P30CA008748-54S3
clinical_trial	NCT02616185	A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR)	9-Mar-21	Completed	1U01CA224348-01
clinical_trial	NCT01218867	CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer	10-Dec-19	Terminated	1U01CA224348-01
clinical_trial	NCT01218867	CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer	10-Dec-19	Terminated	1U01CA239258-01
clinical_trial	NCT02857920	Combination of Bevacizumab and Allogeneic NK Immunotherapy for Metastatic Solid Tumors	14-Sep-20	Completed	1U01CA224348-01
clinical_trial	NCT02857920	Combination of Bevacizumab and Allogeneic NK Immunotherapy for Metastatic Solid Tumors	14-Sep-20	Completed	1U24CA224285-01
clinical_trial	NCT00678119	Study Testing the Biologic Activity and Safety of a Immunotherapeutic in Patients With Newly Diagnosed Advanced Stage Kidney Cancer in Combination With a Marketed Renal Cell Carcinoma Treatment	15-Jul-13	Completed	1U01CA224348-01
clinical_trial	NCT01582672	Phase 3 Trial of Autologous Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma (ADAPT)	14-Jun-18	Terminated	1U01CA224348-01
clinical_trial	NCT01454102	"Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)"	12-Oct-21	Completed	1U01CA224348-01
clinical_trial	NCT02410512	A Study to Assess the Safety and Pharmacokinetics of MOXR0916 and Atezolizumab (Also Known as MPDL3280A or Anti-PD-L1) in Participants With Locally Advanced or Metastatic Solid Tumors	1-Mar-21	Completed	1U01CA224348-01
clinical_trial	NCT02754856	Tremelimumab and Durvalumab in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery	22-Jan-21	"Active, not recruiting"	1U01CA224348-01
clinical_trial	NCT02496208	Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors	4-Oct-21	"Active, not recruiting"	1U01CA224348-01
clinical_trial	NCT01688206	A Study of Vanucizumab (RO5520985) Alone or in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors	5-Oct-18	Completed	1U01CA224348-01
clinical_trial	NCT02665416	"Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of Selicrelumab (RO7009789) With Vanucizumab or Bevacizumab in Participants With Metastatic Solid Tumors"	7-Apr-20	Completed	1U01CA224348-01
clinical_trial	NCT02665416	"Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of Selicrelumab (RO7009789) With Vanucizumab or Bevacizumab in Participants With Metastatic Solid Tumors"	7-Apr-20	Completed	1U24CA224285-01
clinical_trial	NCT02715531	A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors	9-Jul-21	Completed	1U01CA224348-01
clinical_trial	NCT02942329	Exploratory Clinical Study of Apatinib and SHR-1210 in Treating Advanced Hepatocellular Carcinoma or Gastric Cancer	26-Feb-18	Unknown	1U01CA224348-01
clinical_trial	NCT02856425	Trial Of Pembrolizumab And Nintedanib (PEMBIB)	7-Apr-20	Recruiting	1U01CA224348-01
clinical_trial	NCT03081494	Phase Ib Study of PDR001 in Combination With Regorafenib in Adult Patients With Previously Treated Metastatic Colorectal Cancer	11-Dec-20	Completed	1U01CA224348-01
clinical_trial	NCT01472081	"Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)"	22-Apr-20	"Active, not recruiting"	1U01CA224348-01
clinical_trial	NCT02959554	Study in Which Therapy is Either Switched to Nivolumab After 3 Months of Treatment or Therapy is Continued With a Tyrosine Kinase Inhibitor in Patients With Metastatic Renal Cell Carcinoma (RCC) and Disease Control (NIVOSWITCH)	8-Sep-21	Terminated	1U01CA224348-01
clinical_trial	NCT02471716	Study of Cabiralizumab in Patients With Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cell Tumor (FPA008-002)	31-Aug-21	Completed	1U01CA224348-01
clinical_trial	NCT02141295	A Study Comparing the Efficacy and Safety of Vanucizumab and FOLFOX With Bevacizumab and FOLFOX in Participants With Untreated Metastatic Colorectal Cancer (McCAVE)	25-Mar-20	Terminated	1U01CA224348-01
clinical_trial	NCT01831505	Feasibility of Assessing Lymphoma Response to Precise Local Injection of Candidate Chemotherapy Agents	27-Feb-17	Completed	1U01CA224348-01
clinical_trial	NCT03056599	Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma	24-Sep-21	Completed	1U01CA224348-01
clinical_trial	NCT03127631	A RAndomizeD Intervention for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients (RADICALPC)	28-Aug-18	Unknown	1U01CA224348-01
clinical_trial	NCT02907021	Safety of Continuing CHemotherapy in Overt Left Ventricular Dysfunction Using Antibodies to HER-2 (SCHOLAR)	9-Oct-20	Completed	1U01CA224348-01
clinical_trial	NCT02236806	Cardiotoxicity Prevention in Breast Cancer Patients Treated With Anthracyclines and/or Trastuzumab (SAFE)	7-Jan-21	"Active, not recruiting"	1U01CA224348-01
clinical_trial	NCT01904903	Cardiac Safety Study in Patients With HER2 + Breast Cancer (SAFE-HEaRt)	2-Feb-21	Completed	1U01CA224348-01
clinical_trial	NCT03265574	PROACT: Can we Prevent Chemotherapy-related Heart Damage in Patients With Breast Cancer and Lymphoma? (PROACT)	17-Jul-20	Recruiting	1U01CA224348-01
clinical_trial	NCT01968200	Prevention of Anthracycline-induced Cardiotoxicity (ICOS-ONE)	13-Aug-21	"Active, not recruiting"	1U01CA224348-01
clinical_trial	NCT01009918	Lisinopril or Coreg CR&#174; in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab	30-Mar-21	Completed	1U01CA224348-01
clinical_trial	NCT01805453	"Angiotensin II Receptor Blockers, Steroids and Radiotherapy in Glioblastoma (ASTER)"	8-May-20	Completed	1U01CA224348-01
clinical_trial	NCT01754909	Mitigation of Radiation Pneumonitis and Fibrosis	8-Oct-19	Completed	1U01CA224348-01
clinical_trial	NCT01880528	Lisinopril in Reducing Shortness of Breath Caused by Radiation Therapy in Patients With Lung Cancer	2-Jan-20	Completed	1U01CA224348-01
clinical_trial	NCT00004230	Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation	6-Jun-12	Completed	1U01CA224348-01
clinical_trial	NCT02651415	Phase II Study of Perindopril and Regorafenib in mCRC (PARICCA)	12-Sep-19	Completed	1U01CA224348-01
clinical_trial	NCT01705392	Bevacizumab vs Dacarbazine in Metastatic Melanoma	24-Feb-17	Terminated	1U01CA224348-01
clinical_trial	NCT02259621	"Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLC (NA_00092076)"	27-Jul-21	Recruiting	1U01CA224348-01
clinical_trial	NCT02259621	"Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLC (NA_00092076)"	27-Jul-21	Recruiting	3P30CA008748-54S3
clinical_trial	NCT03123783	CD40 Agonistic Antibody APX005M in Combination With Nivolumab	4-May-21	Completed	1U01CA224348-01
clinical_trial	NCT03123783	CD40 Agonistic Antibody APX005M in Combination With Nivolumab	4-May-21	Completed	1U24CA224285-01
clinical_trial	NCT02376699	Safety Study of SEA-CD40 in Cancer Patients	21-Sep-21	"Active, not recruiting"	1U01CA224348-01
clinical_trial	NCT02376699	Safety Study of SEA-CD40 in Cancer Patients	21-Sep-21	"Active, not recruiting"	1U24CA224285-01
clinical_trial	NCT03270176	A Dose-Finding Study of the Second Mitochondrial Activator of Caspases (SMAC) Mimetic Debio 1143 When Given in Combination With Avelumab to Participants With Advanced Solid Malignancies and to Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Platinum-Based Therapy	23-Sep-21	"Active, not recruiting"	1U01CA224348-01
clinical_trial	NCT01502293	Trial of pIL-12 Electroporation Malignant Melanoma (IL-12MEL)	9-Oct-19	Completed	1U01CA224348-01
clinical_trial	NCT01747551	FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer	10-Feb-20	Completed	1U01CA224348-01
clinical_trial	NCT00756106	MRI Scans in Evaluating the Effects of Radiation Therapy and Chemotherapy in Patients With Newly Diagnosed Glioblastoma Multiforme or Anaplastic Glioma	13-May-20	Terminated	1U01CA224348-01
clinical_trial	NCT01004172	Carboplatin and Bevacizumab for Progressive Breast Cancer Brain Metastases	14-Dec-18	Completed	1U01CA224348-01
clinical_trial	NCT01821729	Proton w/FOLFIRINOX-Losartan for Pancreatic Cancer	25-Sep-20	"Active, not recruiting"	1U01CA224348-01
clinical_trial	NCT01821729	Proton w/FOLFIRINOX-Losartan for Pancreatic Cancer	25-Sep-20	"Active, not recruiting"	1U54CA224083-01
clinical_trial	NCT03563248	Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer	20-Jan-21	Recruiting	1U01CA224348-01
clinical_trial	NCT03563248	Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer	20-Jan-21	Recruiting	1U01CA224348-01
clinical_trial	NCT03563248	Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer	20-Jan-21	Recruiting	1U54CA224083-01
clinical_trial	NCT03744247	Lenvatinib Plus PD-1 Antibody Versus Lenvtinib Alone for Advanced HCC	2-May-19	Withdrawn	1U01CA224348-01
clinical_trial	NCT03434379	A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma [IMbrave150] (IMbrave150)	22-Jul-21	"Active, not recruiting"	1U01CA224348-01
clinical_trial	NCT01140347	A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib (REACH)	28-Dec-15	Completed	1U01CA224348-01
clinical_trial	NCT02435433	A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (REACH-2)	30-Jul-21	"Active, not recruiting"	1U01CA224348-01
clinical_trial	NCT02410733	Evaluation of the Safety and Tolerability of i.v. Administration of a Cancer Vaccine in Patients With Advanced Melanoma (Lipo-MERIT)	13-Oct-21	"Active, not recruiting"	1U01CA224348-01
clinical_trial	NCT03729245	A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)	7-Oct-21	"Active, not recruiting"	1U01CA224348-01
clinical_trial	NCT01753089	Dendritic Cell Activating Scaffold in Melanoma	20-Jul-21	"Active, not recruiting"	1U01CA224348-01
clinical_trial	NCT04320238	Experimental Trial of rhIFN&#945; Nasal Drops to Prevent 2019-nCOV in Medical Staff	31-Mar-20	Recruiting	1U01CA224348-01
clinical_trial	NCT01239134	Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid Tumors (TRX518-001)	14-Aug-19	Completed	1U01CA224348-01
clinical_trial	NCT01239134	Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid Tumors (TRX518-001)	14-Aug-19	Completed	1U2CCA233262-01
clinical_trial	NCT01239134	Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid Tumors (TRX518-001)	14-Aug-19	Completed	3P30CA006516-55S9
clinical_trial	NCT04021043	"BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers"	6-Oct-21	Recruiting	1U01CA224348-01
clinical_trial	NCT04021043	"BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers"	6-Oct-21	Recruiting	1U2CCA233262-01
clinical_trial	NCT04021043	"BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers"	6-Oct-21	Recruiting	3P30CA006516-55S9
clinical_trial	NCT02740270	Phase I/Ib Study of GWN323 Alone and in Combination With PDR001 in Patients With Advanced Malignancies and Lymphomas	21-Feb-21	Completed	1U01CA224348-01
clinical_trial	NCT02740270	Phase I/Ib Study of GWN323 Alone and in Combination With PDR001 in Patients With Advanced Malignancies and Lymphomas	21-Feb-21	Completed	1U2CCA233262-01
clinical_trial	NCT02740270	Phase I/Ib Study of GWN323 Alone and in Combination With PDR001 in Patients With Advanced Malignancies and Lymphomas	21-Feb-21	Completed	3P30CA006516-55S9
clinical_trial	NCT02628574	"Phase 1 Open-label Study of TRX518 Monotherapy and TRX518 in Combination With Gemcitabine, Pembrolizumab, or Nivolumab"	26-Oct-20	Completed	1U01CA224348-01
clinical_trial	NCT02628574	"Phase 1 Open-label Study of TRX518 Monotherapy and TRX518 in Combination With Gemcitabine, Pembrolizumab, or Nivolumab"	26-Oct-20	Completed	1U2CCA233262-01
clinical_trial	NCT02628574	"Phase 1 Open-label Study of TRX518 Monotherapy and TRX518 in Combination With Gemcitabine, Pembrolizumab, or Nivolumab"	26-Oct-20	Completed	3P30CA006516-55S9
clinical_trial	NCT02598960	"An Investigational Immuno-therapy Study of Experimental Medication BMS-986156, Given by Itself or in Combination With Nivolumab in Patients With Solid Cancers or Cancers That Have Spread."	21-Dec-20	Completed	1U01CA224348-01
clinical_trial	NCT02598960	"An Investigational Immuno-therapy Study of Experimental Medication BMS-986156, Given by Itself or in Combination With Nivolumab in Patients With Solid Cancers or Cancers That Have Spread."	21-Dec-20	Completed	1U2CCA233262-01
clinical_trial	NCT02598960	"An Investigational Immuno-therapy Study of Experimental Medication BMS-986156, Given by Itself or in Combination With Nivolumab in Patients With Solid Cancers or Cancers That Have Spread."	21-Dec-20	Completed	3P30CA006516-55S9
clinical_trial	NCT04225039	"Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma"	5-Feb-21	Recruiting	1U01CA224348-01
clinical_trial	NCT04225039	"Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma"	5-Feb-21	Recruiting	1U2CCA233262-01
clinical_trial	NCT04225039	"Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma"	5-Feb-21	Recruiting	3P30CA006516-55S9
clinical_trial	NCT00546156	Preoperative Dose-dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab in Operable Breast Cancer	18-May-21	Completed	1U01CA224348-01
clinical_trial	NCT00798213	SCH 727965 in Patients With Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia (P04717AM2)(TERMINATED)	4-Feb-15	Terminated	1U24CA224067-01
clinical_trial	NCT00937937	Dinaciclib in Treating Patients With Stage IV Melanoma	5-Aug-21	"Active, not recruiting"	1U24CA224067-01
clinical_trial	NCT03253679	AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification	4-Oct-21	Suspended	1U24CA224067-01
clinical_trial	NCT02465060	"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)"	19-Oct-21	Recruiting	1U24CA224067-01
clinical_trial	NCT02465060	"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)"	19-Oct-21	Recruiting	1U54CA224070-01
clinical_trial	NCT02465060	"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)"	19-Oct-21	Recruiting	1U54CA224083-01
clinical_trial	NCT02465060	"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)"	19-Oct-21	Recruiting	1U54CA233223-01
clinical_trial	NCT02465060	"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)"	19-Oct-21	Recruiting	1U54CA233306-01
clinical_trial	NCT02465060	"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)"	19-Oct-21	Recruiting	3U54CA224065-01S1
clinical_trial	NCT02465060	"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)"	19-Oct-21	Recruiting	3U54CA224076-01S2
clinical_trial	NCT02465060	"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)"	19-Oct-21	Recruiting	3P30CA125123-14S6
clinical_trial	NCT02465060	"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)"	19-Oct-21	Recruiting	3P30CA042014-31S5
clinical_trial	NCT02675439	Safety and Efficacy of MIW815 (ADU-S100) +/- Ipilimumab in Patients With Advanced/Metastatic Solid Tumors or Lymphomas	9-Jul-20	"Active, not recruiting"	1U24CA224285-01
clinical_trial	NCT02675439	Safety and Efficacy of MIW815 (ADU-S100) +/- Ipilimumab in Patients With Advanced/Metastatic Solid Tumors or Lymphomas	9-Jul-20	"Active, not recruiting"	1U01CA233100-01
clinical_trial	NCT02675439	Safety and Efficacy of MIW815 (ADU-S100) +/- Ipilimumab in Patients With Advanced/Metastatic Solid Tumors or Lymphomas	9-Jul-20	"Active, not recruiting"	1U01DE029255-01
clinical_trial	NCT03172936	Study of the Safety and Efficacy of MIW815 With PDR001 in Patients With Advanced/Metastatic Solid Tumors or Lymphomas	12-Oct-21	Terminated	1U24CA224285-01
clinical_trial	NCT03172936	Study of the Safety and Efficacy of MIW815 With PDR001 in Patients With Advanced/Metastatic Solid Tumors or Lymphomas	12-Oct-21	Terminated	1U01CA233100-01
clinical_trial	NCT03172936	Study of the Safety and Efficacy of MIW815 With PDR001 in Patients With Advanced/Metastatic Solid Tumors or Lymphomas	12-Oct-21	Terminated	1U01DE029255-01
clinical_trial	NCT03172936	Study of the Safety and Efficacy of MIW815 With PDR001 in Patients With Advanced/Metastatic Solid Tumors or Lymphomas	12-Oct-21	Terminated	1U54CA244719-01
clinical_trial	NCT03010176	Study of Ulevostinag (MK-1454) Alone or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001)	13-Oct-21	"Active, not recruiting"	1U24CA224285-01
clinical_trial	NCT03010176	Study of Ulevostinag (MK-1454) Alone or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001)	13-Oct-21	"Active, not recruiting"	1U01CA233100-01
clinical_trial	NCT03010176	Study of Ulevostinag (MK-1454) Alone or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001)	13-Oct-21	"Active, not recruiting"	1U01DE028227-01
clinical_trial	NCT03010176	Study of Ulevostinag (MK-1454) Alone or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001)	13-Oct-21	"Active, not recruiting"	1U01DE029255-01
clinical_trial	NCT03010176	Study of Ulevostinag (MK-1454) Alone or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001)	13-Oct-21	"Active, not recruiting"	1U54CA244719-01
clinical_trial	NCT02953509	Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma	24-Sep-21	Recruiting	1U24CA224285-01
clinical_trial	NCT04313881	Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS) (ENHANCE)	4-Oct-21	Recruiting	1U24CA224285-01
clinical_trial	NCT03248479	Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Participants With Hematological Malignancies	19-Jul-21	Recruiting	1U24CA224285-01
clinical_trial	NCT03056339	Umbilical &amp; Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies	19-Jul-21	Recruiting	1U24CA224285-01
clinical_trial	NCT03056339	Umbilical &amp; Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies	19-Jul-21	Recruiting	1U01CA239258-01
clinical_trial	NCT03056339	Umbilical &amp; Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies	19-Jul-21	Recruiting	3P30CA021765-41S3
clinical_trial	NCT04004637	"CD7 CAR-T Cells for Patients With R/R CD7+ NK/T Cell Lymphoma,T-lymphoblastic Lymphoma and Acute Lymphocytic Leukemia"	28-Sep-20	Recruiting	1U24CA224285-01
clinical_trial	NCT04052061	QUILT 3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell Lymphoma	18-May-21	Withdrawn	1U24CA224285-01
clinical_trial	NCT04050709	QUILT 3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers	18-Mar-21	"Active, not recruiting"	1U24CA224285-01
clinical_trial	NCT03532451	Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer (PrE0807)	1-Sep-21	"Active, not recruiting"	1U24CA224285-01
clinical_trial	NCT03341936	"Neodjuvant Nivolumab and Lirilumab, Followed by Surgery, Followed by Adjuvant Nivolumab and Lirilumab, in SCCHN"	23-Jul-21	"Active, not recruiting"	1U24CA224285-01
clinical_trial	NCT03489343	Sym023 (Anti-TIM-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas	12-Oct-21	Completed	1U24CA224285-01
clinical_trial	NCT03005782	Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers	26-Jul-21	Recruiting	1U24CA224285-01
clinical_trial	NCT04354246	COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies	5-Oct-21	Recruiting	1U24CA224285-01
clinical_trial	NCT04370704	"Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies"	11-Aug-21	Recruiting	1U24CA224285-01
clinical_trial	NCT04150965	"Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT"	10-Sep-21	Recruiting	1U24CA224285-01
clinical_trial	NCT03214666	GTB-3550 Tri-Specific Killer Engager (TriKE&#174;) for High Risk Hematological Malignancies	21-Sep-21	"Active, not recruiting"	1U24CA224285-01
clinical_trial	NCT02304393	A Study of Selicrelumab (RO7009789) in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Solid Tumors	13-Dec-19	Completed	1U24CA224285-01
clinical_trial	NCT02482168	Study of the CD40 Agonistic Monoclonal Antibody APX005M	28-Apr-20	Completed	1U24CA224285-01
clinical_trial	NCT03719430	APX005M and Doxorubicin in Advanced Sarcoma	19-Apr-21	Recruiting	1U24CA224285-01
clinical_trial	NCT03165994	APX005M With Concurrent Chemoradiation for Resectable Esophageal and Gastroesophageal Junction Cancers	30-Jun-21	Recruiting	1U24CA224285-01
clinical_trial	NCT02706353	APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma	14-Dec-20	Recruiting	1U24CA224285-01
clinical_trial	NCT03597282	A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma	3-Sep-20	Terminated	1U24CA224285-01
clinical_trial	NCT03389802	Phase I Study of APX005M in Pediatric CNS Tumors	22-Sep-21	Recruiting	1U24CA224285-01
clinical_trial	NCT02379741	ADC-1013 First-in-Human Study	27-Mar-17	Completed	1U24CA224285-01
clinical_trial	NCT02829099	"A Study of Safety, Pharmacokinetics and Pharmacodynamics of JNJ-64457107 in Participants With Advanced Stage Tumors"	31-Aug-21	Completed	1U24CA224285-01
clinical_trial	NCT02955251	"A Study of ABBV-428, an Immunotherapy, in Subjects With Advanced Solid Tumors"	20-Jul-20	Completed	1U24CA224285-01
clinical_trial	NCT02001974	Pilot Study to Evaluate Reparixin With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC)	27-Sep-21	Completed	1U24CA224285-01
clinical_trial	NCT02001974	Pilot Study to Evaluate Reparixin With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC)	27-Sep-21	Completed	3P30CA046592-31S8
clinical_trial	NCT02001974	Pilot Study to Evaluate Reparixin With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC)	27-Sep-21	Completed	3P30CA046592-31S4
clinical_trial	NCT02370238	A Double-blind Study of Paclitaxel in Combination With Reparixin or Placebo for Metastatic Triple-Negative Breast Cancer (FRIDA)	2-Jun-21	Completed	1U24CA224285-01
clinical_trial	NCT01736813	CCR5-blockade in Metastatic Colorectal Cancer (MARACON)	22-Mar-17	Completed	1U24CA224285-01
clinical_trial	NCT03274804	Combined PD-1 and CCR5 Inhibition for the Treatment of Refractory Microsatellite Stable mCRC (PICCASSO)	22-Apr-21	Completed	1U24CA224285-01
clinical_trial	NCT02216409	"Phase 1 Trial of Hu5F9-G4, a CD47-targeting Antibody"	5-Feb-19	Completed	1U24CA224285-01
clinical_trial	NCT03717103	"A Phase 1 Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-cluster Differentiation Antigen 47 (CD47) Monoclonal Antibody Injection (IBI188) in Patients With Advanced Malignancies"	21-Jul-21	"Active, not recruiting"	1U24CA224285-01
clinical_trial	NCT02367196	"A Phase 1, Dose Finding Study of CC-90002 in Subjects With Advanced Solid and Hematologic Cancers"	12-Aug-21	Completed	1U24CA224285-01
clinical_trial	NCT02076451	"Open-label Study of DS-8273a to Assess Its Safety and Tolerability, and Assess Its Pharmacokinetic and Pharmacodynamic Properties in Subjects With Advanced Solid Tumors or Lymphomas"	12-Feb-19	Completed	1U24CA224285-01
clinical_trial	NCT03371979	Pegzilarginase and Pembrolizumab for Extensive Disease Small Cell Lung Cancer	12-May-21	Completed	1U24CA224285-01
clinical_trial	NCT02903914	Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors	19-Oct-21	"Active, not recruiting"	1U24CA224285-01
clinical_trial	NCT03361228	"A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors"	21-May-20	Terminated	1U24CA224285-01
clinical_trial	NCT03314935	A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors	20-Jul-20	"Active, not recruiting"	1U24CA224285-01
clinical_trial	NCT03665129	IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors (STELLAR-001)	22-Jan-21	"Active, not recruiting"	1U24CA224285-01
clinical_trial	NCT00356460	Safety and Efficacy Study of GC1008 to Treat Renal Cell Carcinoma or Malignant Melanoma	19-Mar-14	Completed	1U24CA224285-01
clinical_trial	NCT01582269	A Study in Recurrent Glioblastoma (GB)	23-Aug-21	"Active, not recruiting"	1U24CA224285-01
clinical_trial	NCT01682187	A Dose-Escalation Study in Participants With Recurrent Malignant Glioma	18-Aug-21	"Active, not recruiting"	1U24CA224285-01
clinical_trial	NCT01220271	A Study Combining LY2157299 With Temozolomide-based Radiochemotherapy in Patients With Newly Diagnosed Malignant Glioma	16-Feb-17	Completed	1U24CA224285-01
clinical_trial	NCT01373164	A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer	16-May-18	Completed	1U24CA224285-01
clinical_trial	NCT01373164	A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer	16-May-18	Completed	1U54CA224083-01
clinical_trial	NCT01246986	A Study of LY2157299 in Participants With Hepatocellular Carcinoma	12-Jan-21	Completed	1U24CA224285-01
clinical_trial	NCT02423343	"A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma"	9-Sep-21	Completed	1U24CA224285-01
clinical_trial	NCT02423343	"A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma"	9-Sep-21	Completed	1U01CA233100-01
clinical_trial	NCT03059485	DC/AML Fusion Cell Vaccine vs Observation in Patients Who Achieve a Chemotherapy-induced Remission	22-Oct-20	Recruiting	1U24CA224285-01
clinical_trial	NCT03059485	DC/AML Fusion Cell Vaccine vs Observation in Patients Who Achieve a Chemotherapy-induced Remission	22-Oct-20	Recruiting	1U54CA224019-01
clinical_trial	NCT03152565	Avelumab Plus Autologous Dendritic Cell Vaccine in Pre-treated Metastatic Colorectal Cancer Patients (AVEVAC)	6-Oct-20	Completed	1U24CA224285-01
clinical_trial	NCT01973322	Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumor Lysate or Homogenate Combined With Immunomodulating Radiotherapy and/or Preleukapheresis IFN-alfa in Patients With Metastatic Melanoma: a Randomized &quot;Proof-of-principle&quot; Phase II Study (ABSIDE)	26-Feb-21	Recruiting	1U24CA224285-01
clinical_trial	NCT03035331	"Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma"	13-Sep-21	Recruiting	1U24CA224285-01
clinical_trial	NCT03360630	Anti-PD-1 Alone or Combined With Autologous Cell Therapy in Advanced NSCLC	6-Nov-19	Recruiting	1U24CA224285-01
clinical_trial	NCT01302496	Autologous TriMix-DC Therapeutic Vaccine in Combination With Ipilimumab in Patients With Previously Treated Unresectable Stage III or IV Melanoma (TriMix-Ipi)	29-Mar-21	Completed	1U24CA224285-01
clinical_trial	NCT04203901	Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma	25-Sep-20	Recruiting	1U24CA224285-01
clinical_trial	NCT01876212	Dendritic Cell Vaccines + Dasatinib for Metastatic Melanoma	22-Aug-19	Completed	1U24CA224285-01
clinical_trial	NCT02030561	NK Cell Infusions With Trastuzumab for Patients With HER2+ Breast and Gastric Cancer	22-Jun-16	Unknown	1U24CA224285-01
clinical_trial	NCT02843126	Combination of Trastuzumab and NK Immunotherapy for Recurrent Breast Cancer	12-Sep-19	Completed	1U24CA224285-01
clinical_trial	NCT02805829	Combination Trastuzumab With Expanded Natural Killer Cells for Treating HER2-positive Gastric Cancer	22-Jun-16	Unknown	1U24CA224285-01
clinical_trial	NCT02843061	Combination of Rituximab and NK Immunotherapy for B Lymphoma	12-Sep-19	Completed	1U24CA224285-01
clinical_trial	NCT02507154	Reactivating NK Cells in Treating Refractory Head and Neck Cancer (NKEXPHNC)	21-Aug-18	Unknown	1U24CA224285-01
clinical_trial	NCT02845856	Combination of Cetuximab and NK Immunotherapy for Recurrent Non-small Cell Lung Cancer	12-Sep-19	Completed	1U24CA224285-01
clinical_trial	NCT03003728	2015-10: Expanded Natural Killer Cells and Elotuzumab for High-Risk Myeloma Post- Autologous Stem Cell Transplant (ASCT)	10-Jul-20	Withdrawn	1U24CA224285-01
clinical_trial	NCT03319459	FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors	9-Jan-20	"Active, not recruiting"	1U24CA224285-01
clinical_trial	NCT03242603	Immunotherapy of Neuroblastoma Patients Using a Combination of Anti-GD2 and NK Cells (NKEXPGD2)	30-Mar-18	Unknown	1U24CA224285-01
clinical_trial	NCT02843204	Combination of Anti-PD-1 and NK Immunotherapy for Recurrent Solid Tumors	28-May-20	Completed	1U24CA224285-01
clinical_trial	NCT02890758	Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803	27-Jul-21	"Active, not recruiting"	1U24CA224285-01
clinical_trial	NCT04134325	Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma	15-Jul-21	Recruiting	1U24CA224285-01
clinical_trial	NCT02650999	Pembrolizumab in Patients Failing to Respond to or Relapsing After CAR T Cell Therapy for Relapsed or Refractory Lymphomas	22-Jul-21	Completed	1U24CA224285-01
clinical_trial	NCT00586391	"CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL &amp; CLL (CRETI-NH)"	10-Mar-21	"Active, not recruiting"	1U24CA224285-01
clinical_trial	NCT02706405	JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma	16-Jul-21	"Active, not recruiting"	1U24CA224285-01
clinical_trial	NCT02706405	JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma	16-Jul-21	"Active, not recruiting"	1U01CA247548-01
clinical_trial	NCT02706405	JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma	16-Jul-21	"Active, not recruiting"	3P30CA008748-54S3
clinical_trial	NCT04539366	"Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, The GD2-CAR PERSIST Trial"	18-Oct-21	Recruiting	1U24CA224309-01
clinical_trial	NCT04539366	"Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, The GD2-CAR PERSIST Trial"	18-Oct-21	Recruiting	2UM1CA154967-07
clinical_trial	NCT01881867	CYT107 After Vaccine Treatment (Provenge&#174;) in Patients With Metastatic Castration-Resistant Prostate Cancer	9-Jul-19	Completed	1U24CA224309-01
clinical_trial	NCT01881867	CYT107 After Vaccine Treatment (Provenge&#174;) in Patients With Metastatic Castration-Resistant Prostate Cancer	9-Jul-19	Completed	2UM1CA154967-07
clinical_trial	NCT00065442	Provenge&#174; (Sipuleucel-T) Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy	6-Sep-10	Completed	1U24CA224309-01
clinical_trial	NCT00065442	Provenge&#174; (Sipuleucel-T) Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy	6-Sep-10	Completed	2UM1CA154967-07
clinical_trial	NCT03184571	Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced NSCLC	14-Oct-21	Recruiting	1U24CA224316-01
clinical_trial	NCT01415882	Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib	20-Oct-21	Recruiting	1U54CA224018-01
clinical_trial	NCT03066648	Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS	15-Oct-21	"Active, not recruiting"	1U54CA224019-01
clinical_trial	NCT03381118	Haploidentical Lymphocytes With Nivolumab/Ara-C as Consolidation in Elderly AML Patients	5-Apr-19	Terminated	1U54CA224019-01
clinical_trial	NCT01096602	Blockade of PD-1 in Conjunction With the Dendritic Cell/AML Vaccine Following Chemotherapy Induced Remission	3-Aug-21	"Active, not recruiting"	1U54CA224019-01
clinical_trial	NCT01822509	Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant	24-Jun-21	Completed	1U54CA224019-01
clinical_trial	NCT01919619	Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies	13-Aug-21	"Active, not recruiting"	1U54CA224019-01
clinical_trial	NCT01953692	A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013/KEYNOTE-013)	4-Aug-21	Completed	1U54CA224019-01
clinical_trial	NCT02117219	Phase 1 Study to Evaluate MEDI4736 in Subjects With Myelodysplastic Syndrome	10-May-19	Completed	1U54CA224019-01
clinical_trial	NCT02275533	Nivolumab in Eliminating Minimal Residual Disease and Preventing Relapse in Patients With Acute Myeloid Leukemia in Remission After Chemotherapy	2-Sep-21	"Active, not recruiting"	1U54CA224019-01
clinical_trial	NCT02397720	Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia	15-Jan-21	Recruiting	1U54CA224019-01
clinical_trial	NCT02464657	"Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)"	7-Oct-21	Completed	1U54CA224019-01
clinical_trial	NCT02530463	Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome	15-Jan-21	Recruiting	1U54CA224019-01
clinical_trial	NCT02532231	Nivolumab in AML in Remission at High Risk for Relapse	13-Feb-20	Recruiting	1U54CA224019-01
clinical_trial	NCT02599649	Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS)	14-Jan-20	Terminated	1U54CA224019-01
clinical_trial	NCT02708641	A Phase II Study of Pembrolizumab as Post-Remission Treatment of Patients &#8805; 60 With AML	10-Aug-21	Completed	1U54CA224019-01
clinical_trial	NCT02768792	High Dose Cytarabine Followed by Pembrolizumab in Relapsed/Refractory AML	5-Sep-21	"Active, not recruiting"	1U54CA224019-01
clinical_trial	NCT02771197	Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in AML Patient Not Eligible for Transplant	5-Sep-21	"Active, not recruiting"	1U54CA224019-01
clinical_trial	NCT02775903	An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML)	23-Aug-21	"Active, not recruiting"	1U54CA224019-01
clinical_trial	NCT02845297	Study of Azacitidine in Combination With Pembrolizumab in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients and in Newly Diagnosed Older (&#8805;65 Years) AML Patients	19-May-21	"Active, not recruiting"	1U54CA224019-01
clinical_trial	NCT02846376	Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant (CPIT-002)	5-Oct-21	"Active, not recruiting"	1U54CA224019-01
clinical_trial	NCT02890329	Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia	8-Sep-21	Recruiting	1U54CA224019-01
clinical_trial	NCT02935361	Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed	6-Apr-21	"Active, not recruiting"	1U54CA224019-01
clinical_trial	NCT02936752	Testing the Safety and Efficacy of the Combination of the Antibody Pembrolizumab and Entinostat in Patients With Myelodysplastic Syndrome Who Are Not Responding to Hypomethylating Agents	2-Jul-21	"Active, not recruiting"	1U54CA224019-01
clinical_trial	NCT02953561	Avelumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia	22-Oct-20	Terminated	1U54CA224019-01
clinical_trial	NCT02981914	Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation	30-Jun-21	Recruiting	1U54CA224019-01
clinical_trial	NCT02985554	Phase I Study to Assess the Tolerability and Efficacy of Nivolumab in Patients With Hematologic Malignancies	25-Jun-20	Terminated	1U54CA224019-01
clinical_trial	NCT02996474	Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia	9-Jun-20	Completed	1U54CA224019-01
clinical_trial	NCT02996474	Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia	9-Jun-20	Completed	3P30CA016056-43S5
clinical_trial	NCT03092674	"Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome"	8-Sep-21	"Active, not recruiting"	1U54CA224019-01
clinical_trial	NCT03094637	Azacitidine and Pembrolizumab in Treating Patients With Myelodysplastic Syndrome	1-Oct-21	"Active, not recruiting"	1U54CA224019-01
clinical_trial	NCT03146468	Nivolumab for Relapsed or Residual Haematological Malignancies After Allogeneic Stem Cell Transplantation (NIVALLO)	23-Sep-21	"Active, not recruiting"	1U54CA224019-01
clinical_trial	NCT03154827	"A Phase Ib/II, Multicenter, Single Arm, Open-Label Study, To Evaluate the Safety, Tolerability and Efficacy of the BL-8040 and Atezolizumab Combination for Maintenance Treatment in Subjects With Acute Myeloid Leukemia Who Are 60 Years or Older - The BATTLE Study"	18-May-20	Terminated	1U54CA224019-01
clinical_trial	NCT03259516	Nivolumab With Chemotherapy in Refractory MDS	5-Apr-19	Terminated	1U54CA224019-01
clinical_trial	NCT03286114	Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab	27-May-21	Recruiting	1U54CA224019-01
clinical_trial	NCT03291353	Phase 0- Pilot Study of Pembrolizumab on Immune Cells in Patient With Refractory Acute Myeloid Leukemia	19-Apr-19	Withdrawn	1U54CA224019-01
clinical_trial	NCT03358719	"DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia"	5-Oct-21	Completed	1U54CA224019-01
clinical_trial	NCT03390296	"OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia"	12-Feb-21	Recruiting	1U54CA224019-01
clinical_trial	NCT03395873	"Avelumab With Decitabine as First Line for AML Treatment of Patients With AML, Who Are Unfit for Intensive Chemotherapy"	21-Aug-19	Terminated	1U54CA224019-01
clinical_trial	NCT02996500	"Safety and Efficacy of Pf-06650833 In Subjects With Rheumatoid Arthritis, With An Inadequate Response To Methotrexate"	27-Feb-20	Completed	1U54CA224019-01
clinical_trial	NCT03328078	A Study of CA-4948 in Patients With Relapsed or Refractory Hematologic Malignancies	5-May-21	Recruiting	1U54CA224019-01
clinical_trial	NCT03328078	A Study of CA-4948 in Patients With Relapsed or Refractory Hematologic Malignancies	5-May-21	Recruiting	1U54CA224083-01
clinical_trial	NCT02891603	A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression	12-Oct-21	Recruiting	1U54CA224019-01
clinical_trial	NCT01235871	A Single and Multiple-Dose Study of SB1578	20-Apr-12	Completed	1U54CA224019-01
clinical_trial	NCT01728402	Pathogenesis of Hematologic Malignancies	30-Aug-21	Enrolling by invitation	1U54CA224019-01
clinical_trial	NCT01728402	Pathogenesis of Hematologic Malignancies	30-Aug-21	Enrolling by invitation	1U54CA224019-01
clinical_trial	NCT02158858	A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis	25-Aug-21	Recruiting	1U54CA224019-01
clinical_trial	NCT01713582	A Dose-finding Study of the Bromodomain (Brd) Inhibitor OTX015/ Birabresib (MK-8628) in Hematologic Malignancies (MK-8628-001)	26-Jan-21	Completed	1U54CA224019-01
clinical_trial	NCT01713582	A Dose-finding Study of the Bromodomain (Brd) Inhibitor OTX015/ Birabresib (MK-8628) in Hematologic Malignancies (MK-8628-001)	26-Jan-21	Completed	5R01CA176745-09
clinical_trial	NCT02698189	A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Hematologic Malignancies (MK-8628-005)	19-Oct-21	Terminated	1U54CA224019-01
clinical_trial	NCT02698189	A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Hematologic Malignancies (MK-8628-005)	19-Oct-21	Terminated	5R01CA176745-09
clinical_trial	NCT02308761	A Study of RO6870810/TEN-010 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndrome	11-Dec-17	Completed	1U54CA224019-01
clinical_trial	NCT02308761	A Study of RO6870810/TEN-010 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndrome	11-Dec-17	Completed	5R01CA176745-09
clinical_trial	NCT02431260	"An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies"	14-Jun-19	Terminated	1U54CA224019-01
clinical_trial	NCT02391480	A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer	29-Nov-19	Completed	1U54CA224019-01
clinical_trial	NCT01943851	"A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies"	19-May-21	Completed	1U54CA224019-01
clinical_trial	NCT02683395	A Study of PLX51107 in Advanced Malignancies	24-Dec-18	Terminated	1U54CA224019-01
clinical_trial	NCT01522469	Phase II Study of Crenolanib in Subjects With Relapsed/Refractory AML With FLT3 Activating Mutations	28-Jun-18	Completed	1U54CA224019-01
clinical_trial	NCT01657682	A Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients With FLT3 Activating Mutations	20-Jul-20	Completed	1U54CA224019-01
clinical_trial	NCT01657682	A Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients With FLT3 Activating Mutations	20-Jul-20	Completed	3R01CA182543-05S2
clinical_trial	NCT02092324	Ruxolitinib Phosphate in Treating Patients With Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia	16-Nov-20	Completed	1U54CA224019-01
clinical_trial	NCT01750918	BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC)	19-Apr-21	Completed	1U54CA224068-01
clinical_trial	NCT01719380	"Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer"	23-Jun-21	Completed	1U54CA224068-01
clinical_trial	NCT02974725	A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma	8-Sep-21	Recruiting	1U54CA224068-01
clinical_trial	NCT01032122	Rituximab in Metastatic Melanoma	25-Apr-13	Terminated	1U54CA224068-01
clinical_trial	NCT01376713	Anti-CD20 (Cluster of Differentiation Antigen 20) Therapy to Treat Metastatic Melanoma	6-Oct-15	Completed	1U54CA224068-01
clinical_trial	NCT01376713	Anti-CD20 (Cluster of Differentiation Antigen 20) Therapy to Treat Metastatic Melanoma	6-Oct-15	Completed	1U54CA224070-01
clinical_trial	NCT01307267	A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab	17-Mar-20	Completed	1U54CA224068-01
clinical_trial	NCT03600883	"A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of AMG 510 in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)"	2-Sep-21	Recruiting	1U54CA224068-01
clinical_trial	NCT03785249	Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1	29-Sep-21	Recruiting	1U54CA224068-01
clinical_trial	NCT01659151	Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer &amp; High Dose IL-2 Metastatic Melanoma	15-Jun-21	"Active, not recruiting"	1U54CA224070-01
clinical_trial	NCT01390818	Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors	7-Mar-17	Completed	1U54CA224070-01
clinical_trial	NCT00831792	TKI258 in Castrate Resistant Prostate Cancer	11-Sep-19	Completed	1U54CA224079-01
clinical_trial	NCT02122913	A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer	12-May-21	Completed	1U54CA224079-01
clinical_trial	NCT02637687	A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children (SCOUT)	12-Oct-21	Recruiting	1U54CA224079-01
clinical_trial	NCT02576431	A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors (NAVIGATE)	8-Sep-21	Recruiting	1U54CA224079-01
clinical_trial	NCT03213704	"Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)"	19-Oct-21	Recruiting	1U54CA224079-01
clinical_trial	NCT03215511	A Study to Test the Safety of the Investigational Drug Selitrectinib in Children and Adults That May Treat Cancer	13-Oct-21	"Active, not recruiting"	1U54CA224079-01
clinical_trial	NCT02097810	"Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer Targeting NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations. (STARTRK-1)"	9-Jun-21	Completed	1U54CA224079-01
clinical_trial	NCT02568267	"Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) (STARTRK-2)"	30-Aug-21	Recruiting	1U54CA224079-01
clinical_trial	NCT02650401	Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options (STARTRK-NG)	30-Sep-21	Recruiting	1U54CA224079-01
clinical_trial	NCT03093116	"A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)"	1-Feb-21	Recruiting	1U54CA224079-01
clinical_trial	NCT02920996	Merestinib In Non-Small Cell Lung Cancer And Solid Tumors	31-Aug-21	"Active, not recruiting"	1U54CA224079-01
clinical_trial	NCT02675491	Phase 1 Study of DS-6051b in Japanese Subjects With Advanced Solid Malignant Tumors	13-Jan-21	"Active, not recruiting"	1U54CA224079-01
clinical_trial	NCT02279433	"A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b"	22-Sep-20	Completed	1U54CA224079-01
clinical_trial	NCT01804530	Phase 1 Study of PLX7486 as Single Agent in Patients With Advanced Solid Tumors	2-Aug-18	Terminated	1U54CA224079-01
clinical_trial	NCT02219711	Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer	30-Jan-20	"Active, not recruiting"	1U54CA224079-01
clinical_trial	NCT01482962	Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma	31-Jul-18	Completed	1U54CA224079-01
clinical_trial	NCT02606123	Safety and Anti-Tumor Study of Oral EPI-506 for Patients With Metastatic Castration-Resistant Prostate Cancer	1-Mar-18	Terminated	1U54CA224079-01
clinical_trial	NCT02952534	A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency (TRITON2)	30-Aug-21	Completed	1U54CA224079-01
clinical_trial	NCT02952534	A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency (TRITON2)	30-Aug-21	Completed	1U01CA233100-01
clinical_trial	NCT02987543	Study of Olaparib (Lynparza&#8482;) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)	4-Aug-21	"Active, not recruiting"	1U54CA224079-01
clinical_trial	NCT02854436	An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies (Galahad)	8-Oct-21	"Active, not recruiting"	1U54CA224079-01
clinical_trial	NCT02525068	A Study of Enzalutamide in Combination With AZD5363 in Patients With mCRPC (RE-AKT)	8-Aug-18	Unknown	1U54CA224079-01
clinical_trial	NCT03310541	AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations	6-Jul-21	"Active, not recruiting"	1U54CA224079-01
clinical_trial	NCT03567642	"A Study of the Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung Cancers"	19-Mar-21	Recruiting	1U54CA224079-01
clinical_trial	NCT03263650	Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC	6-Apr-21	"Active, not recruiting"	1U54CA224079-01
clinical_trial	NCT03582475	Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate	14-Jul-21	Recruiting	1U54CA224079-01
clinical_trial	NCT03582475	Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate	14-Jul-21	Recruiting	1U01CA233100-01
clinical_trial	NCT03582475	Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate	14-Jul-21	Recruiting	1U01CA244452-01
clinical_trial	NCT01391143	Safety Study of MGA271 in Refractory Cancer	10-Jan-20	Completed	1U54CA224079-01
clinical_trial	NCT04129320	Enoblituzumab Plus MGA012 or MGD013 in Squamous Cell Carcinoma of the Head and Neck	14-Oct-20	Withdrawn	1U54CA224079-01
clinical_trial	NCT00410059	BATTLE Program: Erlotinib in Previously Treated Subjects With Advanced NSCLC	2-Aug-17	Completed	1U54CA224081-01
clinical_trial	NCT00411671	BATTLE Program: Sorafenib in Patients With NSCLC	11-Feb-16	Completed	1U54CA224081-01
clinical_trial	NCT03630120	Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer	14-Jul-21	Terminated	1U54CA224081-01
clinical_trial	NCT03543969	Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma	14-Sep-21	Recruiting	1U54CA224081-01
clinical_trial	NCT03511196	Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer	19-Jul-21	"Active, not recruiting"	1U54CA224081-01
clinical_trial	NCT02415621	Adaptive Abiraterone Therapy for Metastatic Castration Resistant Prostate Cancer	12-Oct-21	"Active, not recruiting"	1U54CA224081-01
clinical_trial	NCT03227926	Rechallenge With Panitumumab Driven by RAS Dynamic of Resistance (CHRONOS)	31-Aug-21	"Active, not recruiting"	1U54CA224081-01
clinical_trial	NCT03259009	RAS Mutations in ctDNA and Anti-EGFR reINTROduction in mCRC (RASINTRO) (RASINTRO)	11-Sep-17	Unknown	1U54CA224081-01
clinical_trial	NCT02296203	"Cetuximab Rechallenge in Irinotecan-pretreated mCRC, KRAS, NRAS and BRAF Wild-type Treated in 1st Line With Anti-EGFR Therapy (CRICKET). (CRICKET)"	15-Feb-18	Unknown	1U54CA224081-01
clinical_trial	NCT01158521	Pazopanib Hydrochloride Before Surgery in Treating Patients With Kidney Cancer	12-Sep-18	Completed	1U54CA224081-01
clinical_trial	NCT03088930	Evaluating Crizotinib in the Neoadjuvant Setting in Patients With Non-small Cell Lung Cancer	23-Apr-21	Completed	1U54CA224081-01
clinical_trial	NCT03088930	Evaluating Crizotinib in the Neoadjuvant Setting in Patients With Non-small Cell Lung Cancer	23-Apr-21	Completed	1U54CA224081-01
clinical_trial	NCT03433469	Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery	3-Jun-21	Recruiting	1U54CA224081-01
clinical_trial	NCT03433469	Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery	3-Jun-21	Recruiting	1U54CA224081-01
clinical_trial	NCT02443948	Circulating Cell-free Tumor DNA in the Plasma of Patients With Gastrointestinal Stromal Tumors (GIST)	14-Feb-17	Unknown	1U54CA224081-01
clinical_trial	NCT03691012	Circulating Tumour DNA as a Marker of Residual Disease &amp; Response to Adjuvant Chemotherapy in Stage I-IV Ovarian Cancer	3-Nov-20	Recruiting	1U54CA224081-01
clinical_trial	NCT02245100	Circulating Tumor DNA in Predicting Outcomes in Patients With Stage IV Head and Neck Cancer or Stage III-IV Non-small Cell Lung Cancer	1-Sep-21	"Active, not recruiting"	1U54CA224081-01
clinical_trial	NCT03637686	Circulating Tumor DNA Analysis to Optimize Treatment for Patients With Colorectal Cancer (IMPROVE)	14-Jan-21	Recruiting	1U54CA224081-01
clinical_trial	NCT02883517	Cell-free Circulating DNA in Primary Cutaneous Lymphomas (MATULILA)	23-Feb-17	Unknown	1U54CA224081-01
clinical_trial	NCT02424617	A Study of BGB324(Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer	18-Oct-21	Completed	1U54CA224081-01
clinical_trial	NCT01781429	"Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies"	20-Mar-20	Completed	1U54CA224083-01
clinical_trial	NCT02608229	BVD-523 Plus Nab-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer	21-Apr-21	Terminated	1U54CA224083-01
clinical_trial	NCT02889978	The Circulating Cell-free Genome Atlas Study (CCGA)	12-Jul-21	"Active, not recruiting"	1U54CA224083-01
clinical_trial	NCT02124902	Neoadjuvant Treatment of Triple Negative Breast Cancer Patients With Docetaxel and Carboplatin to Assess Anti-tumor Activity	23-Jul-21	"Active, not recruiting"	1U54CA224083-01
clinical_trial	NCT02550327	"Gemcitabine, Nab-Paclitaxel, Cisplatin and Anakinra Treatment on Patients With Pancreatic Cancer"	22-Jun-21	Completed	1U54CA224083-01
clinical_trial	NCT02550327	"Gemcitabine, Nab-Paclitaxel, Cisplatin and Anakinra Treatment on Patients With Pancreatic Cancer"	22-Jun-21	Completed	1U54CA224083-01
clinical_trial	NCT01383538	FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma	8-Aug-17	Completed	1U54CA224083-01
clinical_trial	NCT01195415	Vismodegib and Gemcitabine Hydrochloride in Treating Patients With Advanced Pancreatic Cancer	7-Aug-17	Completed	1U54CA224083-01
clinical_trial	NCT01064622	Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer	14-Aug-15	Completed	1U54CA224083-01
clinical_trial	NCT01088815	Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas	26-Apr-19	Completed	1U54CA224083-01
clinical_trial	NCT01487785	"Dose-escalation, and Safety Study of LDE225 and Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer Patients"	19-Dec-20	Completed	1U54CA224083-01
clinical_trial	NCT02358161	Phase I/II Study of LDE225 With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer (MATRIX)	9-Jan-20	Completed	1U54CA224083-01
clinical_trial	NCT02734160	A Study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in Participants With Metastatic Pancreatic Cancer	5-Aug-19	Completed	1U54CA224083-01
clinical_trial	NCT02734160	A Study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in Participants With Metastatic Pancreatic Cancer	5-Aug-19	Completed	1U01CA233100-01
clinical_trial	NCT03941093	Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Locally Advanced Pancreatic Cancer	17-Sep-21	Recruiting	1U54CA224083-01
clinical_trial	NCT04054362	Paricalcitol Addition to Chemotherapy in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (PINBALL)	16-Dec-19	Unknown	1U54CA224083-01
clinical_trial	NCT04524702	Paricalcitol and Hydroxychloroquine in Combination With Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced or Metastatic Pancreatic Cancer	21-Feb-21	Recruiting	1U54CA224083-01
clinical_trial	NCT03883919	Liposomal Irinotecan Plus 5-FU / LV Combined With Paricalcitol in Patients With Advanced Pancreatic Cancer Progressed on Gemcitabine-based Therapy	7-Oct-21	"Active, not recruiting"	1U54CA224083-01
clinical_trial	NCT03331562	A SU2C Catalyst&#174; Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic Cancer	8-Oct-20	Completed	1U54CA224083-01
clinical_trial	NCT03307148	Stromal TARgeting for PAncreatic Cancer (STAR_PAC) (STAR_PAC)	22-Jan-20	Completed	1U54CA224083-01
clinical_trial	NCT02715804	A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma	14-Jul-20	Terminated	1U54CA224083-01
clinical_trial	NCT01959139	"S1313, PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer"	5-Jan-21	"Active, not recruiting"	1U54CA224083-01
clinical_trial	NCT01472198	A Study to Evaluate the Efficacy and Safety of Simtuzumab Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma	10-Mar-15	Completed	1U54CA224083-01
clinical_trial	NCT02661022	SL-401 in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma	7-Apr-20	Completed	2P01CA155258-06
clinical_trial	NCT01309334	Imaging Young Myeloma (IMAgerie JEune My&#233;lome) (IMAJEM)	25-Aug-14	Completed	2P01CA155258-06
clinical_trial	NCT01191060	Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years (IFM/DFCI2009)	18-Apr-19	Completed	2P01CA155258-06
clinical_trial	NCT01191060	Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years (IFM/DFCI2009)	18-Apr-19	Completed	2P01CA155258-06
clinical_trial	NCT01191060	Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years (IFM/DFCI2009)	18-Apr-19	Completed	2P01CA155258-06
clinical_trial	NCT01191060	Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years (IFM/DFCI2009)	18-Apr-19	Completed	2P01CA155258-06
clinical_trial	NCT01191060	Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years (IFM/DFCI2009)	18-Apr-19	Completed	2P01CA155258-06
clinical_trial	NCT01191060	Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years (IFM/DFCI2009)	18-Apr-19	Completed	2P01CA155258-06
clinical_trial	NCT01782963	Lenalidomide/Bortezomib/Dexamethasone for Multiple Myeloma (MM) (RVD Lite)	31-Oct-18	Completed	2P01CA155258-06
clinical_trial	NCT02252172	"Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma"	15-Oct-21	"Active, not recruiting"	2P01CA155258-06
clinical_trial	NCT02252172	"Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma"	15-Oct-21	"Active, not recruiting"	2P01CA155258-06
clinical_trial	NCT01850524	IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma	1-Feb-21	"Active, not recruiting"	2P01CA155258-06
clinical_trial	NCT01850524	IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma	1-Feb-21	"Active, not recruiting"	2P01CA155258-06
clinical_trial	NCT02702492	PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA) (PANAMA)	25-Jun-21	Terminated	2P01CA155258-06
clinical_trial	NCT03225716	A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom's Macroglobulinemia	27-May-21	"Active, not recruiting"	2P01CA155258-06
clinical_trial	NCT03464916	Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients	17-Mar-21	"Active, not recruiting"	2P01CA155258-06
clinical_trial	NCT03274219	Study of bb21217 in Multiple Myeloma	18-Mar-21	"Active, not recruiting"	2P01CA155258-06
clinical_trial	NCT03274219	Study of bb21217 in Multiple Myeloma	18-Mar-21	"Active, not recruiting"	2P01CA155258-06
clinical_trial	NCT03318861	Study to Evaluate the Safety and Efficacy of KITE-585 in Participants With Relapsed/Refractory Multiple Myeloma	28-Jun-21	"Active, not recruiting"	2P01CA155258-06
clinical_trial	NCT03318861	Study to Evaluate the Safety and Efficacy of KITE-585 in Participants With Relapsed/Refractory Multiple Myeloma	28-Jun-21	"Active, not recruiting"	1U01CA244291-01
clinical_trial	NCT02529813	CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies	24-Jul-19	"Active, not recruiting"	2P01CA155258-06
clinical_trial	NCT03019666	Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL	5-Aug-21	Recruiting	2P01CA155258-06
clinical_trial	NCT03288493	P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM)	14-Sep-21	Recruiting	2P01CA155258-06
clinical_trial	NCT03288493	P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM)	14-Sep-21	Recruiting	2P01CA155258-06
clinical_trial	NCT03288493	P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM)	14-Sep-21	Recruiting	1U01CA244291-01
clinical_trial	NCT03288493	P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM)	14-Sep-21	Recruiting	3P30CA021765-41S3
clinical_trial	NCT02955550	"A Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion With or Without Subcutaneous Recombinant Human Interleukin-2 (rhIL-2) Following Autologous Stem Cell Transplant for Multiple Myeloma (MM)"	22-Jul-20	Completed	2P01CA155258-06
clinical_trial	NCT02203825	Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands	1-Jun-18	Completed	2P01CA155258-06
clinical_trial	NCT03287804	APRIL CAR T Cells (AUTO2) Targeting BCMA and TACI for the Treatment of Multiple Myeloma (APRIL)	23-Oct-20	Terminated	2P01CA155258-06
clinical_trial	NCT03430011	Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple Myeloma (EVOLVE)	1-Jun-21	"Active, not recruiting"	2P01CA155258-06
clinical_trial	NCT03430011	Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple Myeloma (EVOLVE)	1-Jun-21	"Active, not recruiting"	2P01CA155258-06
clinical_trial	NCT03090659	LCAR-B38M Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma (LEGEND-2)	2-Sep-21	"Active, not recruiting"	2P01CA155258-06
clinical_trial	NCT03090659	LCAR-B38M Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma (LEGEND-2)	2-Sep-21	"Active, not recruiting"	2P01CA155258-06
clinical_trial	NCT03090659	LCAR-B38M Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma (LEGEND-2)	2-Sep-21	"Active, not recruiting"	1U01CA244291-01
clinical_trial	NCT03361748	Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma (KarMMa)	6-Aug-21	"Active, not recruiting"	2P01CA155258-06
clinical_trial	NCT03601078	An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma (KarMMa-2)	1-Sep-21	Recruiting	2P01CA155258-06
clinical_trial	NCT02658929	Study of bb2121 in Multiple Myeloma	4-Dec-20	"Active, not recruiting"	2P01CA155258-06
clinical_trial	NCT02658929	Study of bb2121 in Multiple Myeloma	4-Dec-20	"Active, not recruiting"	2P01CA155258-06
clinical_trial	NCT02658929	Study of bb2121 in Multiple Myeloma	4-Dec-20	"Active, not recruiting"	2P01CA155258-06
clinical_trial	NCT02658929	Study of bb2121 in Multiple Myeloma	4-Dec-20	"Active, not recruiting"	1U01CA244291-01
clinical_trial	NCT03445663	Study Evaluating AMG 424 in Subjects With Multiple Myeloma	10-May-21	Terminated	2P01CA155258-06
clinical_trial	NCT03111992	"Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma"	12-Oct-21	Completed	2P01CA155258-06
clinical_trial	NCT03111992	"Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma"	12-Oct-21	Completed	1U01CA244291-01
clinical_trial	NCT03111992	"Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma"	12-Oct-21	Completed	1U01CA244291-01
clinical_trial	NCT01457417	A Study of DKN-01 in Multiple Myeloma or Advanced Solid Tumors	28-Sep-16	Completed	2P01CA155258-06
clinical_trial	NCT03145181	"Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-1)"	8-Oct-21	Recruiting	2P01CA155258-06
clinical_trial	NCT03399799	Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma	8-Oct-21	Recruiting	2P01CA155258-06
clinical_trial	NCT02252263	A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma	1-Nov-17	Completed	2P01CA155258-06
clinical_trial	NCT02252263	A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma	1-Nov-17	Completed	1U01CA244291-01
clinical_trial	NCT03489525	MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma (MEDI2228)	5-Aug-21	"Active, not recruiting"	2P01CA155258-06
clinical_trial	NCT03489525	MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma (MEDI2228)	5-Aug-21	"Active, not recruiting"	2P01CA155258-06
clinical_trial	NCT03269136	PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma	2-Jul-21	"Active, not recruiting"	2P01CA155258-06
clinical_trial	NCT03269136	PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma	2-Jul-21	"Active, not recruiting"	2P01CA155258-06
clinical_trial	NCT03582033	A Safety Study of SEA-BCMA in Patients With Multiple Myeloma	8-Oct-21	Recruiting	2P01CA155258-06
clinical_trial	NCT03379584	A Safety Study of SGN-CD48A in Patients With Multiple Myeloma	18-Sep-19	Terminated	2P01CA155258-06
clinical_trial	NCT03424603	"Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies"	19-Oct-20	Recruiting	2P01CA155258-06
clinical_trial	NCT03287908	"A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma"	27-Aug-21	Recruiting	2P01CA155258-06
clinical_trial	NCT03287908	"A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma"	27-Aug-21	Recruiting	2P01CA155258-06
clinical_trial	NCT03486067	"Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma"	6-Oct-21	Recruiting	2P01CA155258-06
clinical_trial	NCT03486067	"Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma"	6-Oct-21	Recruiting	2P01CA155258-06
clinical_trial	NCT03340883	Safety and Tolerability of BION-1301 in Adults With Relapsed or Refractory Multiple Myeloma (MM)	1-Apr-21	Terminated	2P01CA155258-06
clinical_trial	NCT01001442	Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma	30-Jul-19	Completed	2P01CA155258-06
clinical_trial	NCT01638936	BT062 in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Patients With Multiple Myeloma	23-Jul-19	Completed	2P01CA155258-06
clinical_trial	NCT01421186	A Phase I/IIa Study of Human Anti-CD38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple Myeloma	16-Sep-20	Completed	2P01CA155258-06
clinical_trial	NCT01421186	A Phase I/IIa Study of Human Anti-CD38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple Myeloma	16-Sep-20	Completed	2P01CA155258-06
clinical_trial	NCT03439280	"A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM)"	19-Mar-21	"Active, not recruiting"	2P01CA155258-06
clinical_trial	NCT03439280	"A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM)"	19-Mar-21	"Active, not recruiting"	2P01CA155258-06
clinical_trial	NCT03215030	"A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-573 in Participants With Refractory Multiple Myeloma (MM)"	21-Dec-20	Recruiting	2P01CA155258-06
clinical_trial	NCT01302886	Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma	17-Dec-20	Completed	2P01CA155258-06
clinical_trial	NCT01337752	Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency	17-Dec-20	Completed	2P01CA155258-06
clinical_trial	NCT03525678	A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody	4-Oct-21	"Active, not recruiting"	2P01CA155258-06
clinical_trial	NCT03525678	A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody	4-Oct-21	"Active, not recruiting"	2P01CA155258-06
clinical_trial	NCT02462525	"Dose-Escalation Study of ABBV-838, an Antibody Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma"	13-Sep-18	Terminated	2P01CA155258-06
clinical_trial	NCT01232712	A Study to Assess the Safety and Efficacy of MUC1 Peptide Vaccine and hGM-CSF in Patients With MUC1-positive Tumor Malignancies	9-Aug-13	Completed	2P01CA155258-06
clinical_trial	NCT02886065	"A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM"	24-Feb-21	Recruiting	2P01CA155258-06
clinical_trial	NCT02886065	"A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM"	24-Feb-21	Recruiting	2P01CA155258-06
clinical_trial	NCT01670994	QUILT-3.020: A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma	28-Oct-16	Terminated	2P01CA155258-06
clinical_trial	NCT02978235	A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma	21-Jun-21	Terminated	2P01CA155258-06
clinical_trial	NCT02693535	TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (TAPUR)	20-Oct-21	Recruiting	2P01CA155258-06
clinical_trial	NCT03091257	A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma	24-Feb-21	Recruiting	2P01CA155258-06
clinical_trial	NCT02675452	AMG 176 First in Human Trial in Subjects With Relapsed or Refractory Multiple Myeloma and Subjects With Relapsed or Refractory Acute Myeloid Leukemia	16-Sep-21	Recruiting	2P01CA155258-06
clinical_trial	NCT02223598	A Phase 1 Study Evaluating CB-5083 in Subjects With Lymphoid Hematological Malignancies (CLC-102)	27-Feb-18	Terminated	2P01CA155258-06
clinical_trial	NCT01421524	"Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma"	29-Sep-21	"Active, not recruiting"	2P01CA155258-06
clinical_trial	NCT02157636	A Phase 1 Study Evaluating CPI-0610 in Patients With Previously Treated Multiple Myeloma	7-Jun-18	Completed	2P01CA155258-06
clinical_trial	NCT00891280	Dose-escalation Study of Oral CX-4945	15-Jun-11	Unknown	2P01CA155258-06
clinical_trial	NCT01199718	Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma	15-Jun-11	Unknown	2P01CA155258-06
clinical_trial	NCT03110822	"A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients"	11-Mar-20	Recruiting	2P01CA155258-06
clinical_trial	NCT02160951	Dose Escalation Study of LGH447 in Japanese Patients With Relapsed and/or Refractory Hematologic Malignancies	17-Dec-20	Completed	2P01CA155258-06
clinical_trial	NCT01794520	Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple Myeloma	7-Oct-21	"Active, not recruiting"	2P01CA155258-06
clinical_trial	NCT01794520	Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple Myeloma	7-Oct-21	"Active, not recruiting"	3P30CA013696-45S1
clinical_trial	NCT02992483	"Phase I Study of MIK665, a Mcl-1 Inhibitor, in Patients With Refractory or Relapsed Lymphoma or Multiple Myeloma"	3-Aug-21	Completed	2P01CA155258-06
clinical_trial	NCT01204164	Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies (TG02-101)	6-May-16	Completed	2P01CA155258-06
clinical_trial	NCT02389543	"Study of Selinexor (KPT- 330), Lenalidomide, &amp; Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients (SLAM)"	3-Sep-15	Withdrawn	2P01CA155258-06
clinical_trial	NCT02773030	"A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma"	4-Aug-21	Recruiting	2P01CA155258-06
clinical_trial	NCT03374085	"A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)"	14-Jul-21	Recruiting	2P01CA155258-06
clinical_trial	NCT02863991	Oral ONC201 in Relapsed/Refractory Multiple Myeloma	6-May-21	"Active, not recruiting"	2P01CA155258-06
clinical_trial	NCT01832727	"Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma"	13-Jul-20	Terminated	2P01CA155258-06
clinical_trial	NCT03288480	A Phase 1/2a Dose-Finding Study of PT-112 in Patients With Relapsed or Refractory Multiple Myeloma	15-Mar-21	"Active, not recruiting"	2P01CA155258-06
clinical_trial	NCT01997840	ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma	31-Aug-20	"Active, not recruiting"	2P01CA155258-06
clinical_trial	NCT02576496	"Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies"	2-Jun-21	Recruiting	2P01CA155258-06
clinical_trial	NCT01955434	SMAC Mimetic LCL161 Alone or With Cyclophosphamide in Treating Patients With Relapsed or Refractory Multiple Myeloma	10-Sep-19	Completed	2P01CA155258-06
clinical_trial	NCT02952508	Study of CLR 131 in Select B-Cell Malignancies (CLOVER-1) and Pivotal Expansion in Waldenstrom Macroglobulinemia (CLOVER-WaM)	4-Oct-21	Recruiting	2P01CA155258-06
clinical_trial	NCT01372540	Filanesib and Carfilzomib in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia	16-Jul-19	Completed	2P01CA155258-06
clinical_trial	NCT02235740	"A Study Conducted in Subjects With Relapsed/Refractory Multiple Myeloma (MM); to Determine Dose of Afuresertib in Combination With Carfilzomib (Part 1) and to Investigate the Safety, Pharmacokinetic and Clinical Activity of the Combination Compared With Carfilzomib Alone (Part 2)"	4-May-16	Terminated	2P01CA155258-06
clinical_trial	NCT00450814	Vaccine Therapy With or Without Cyclophosphamide in Treating Patients With Recurrent or Refractory Multiple Myeloma	16-Dec-19	Completed	2P01CA155258-06
clinical_trial	NCT00450814	Vaccine Therapy With or Without Cyclophosphamide in Treating Patients With Recurrent or Refractory Multiple Myeloma	16-Dec-19	Completed	1U01CA244291-01
clinical_trial	NCT02963493	A Study of Melphalan Flufenamide (Melflufen) in Combination With Dexamethasone in Relapsed Refractory Multiple Myeloma Patients (HORIZON)	2-Sep-21	"Active, not recruiting"	2P01CA155258-06
clinical_trial	NCT01335399	"Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma (ELOQUENT - 1)"	26-Oct-20	"Active, not recruiting"	2P01CA155258-06
clinical_trial	NCT01335399	"Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma (ELOQUENT - 1)"	26-Oct-20	"Active, not recruiting"	2P01CA155258-06
clinical_trial	NCT02279394	E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma	20-Sep-21	"Active, not recruiting"	2P01CA155258-06
clinical_trial	NCT01084252	Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies	20-Apr-21	"Active, not recruiting"	2P01CA155258-06
clinical_trial	NCT01084252	Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies	20-Apr-21	"Active, not recruiting"	2P01CA155258-06
clinical_trial	NCT02513186	Study of Isatuximab Combined With Bortezomib + Cyclophosphamide + Dexamethasone (VCD) and Bortezomib + Lenalidomide + Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) Non Eligible for Transplant or No Intent for Immediate Transplantation	4-Jun-20	"Active, not recruiting"	2P01CA155258-06
clinical_trial	NCT02513186	Study of Isatuximab Combined With Bortezomib + Cyclophosphamide + Dexamethasone (VCD) and Bortezomib + Lenalidomide + Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) Non Eligible for Transplant or No Intent for Immediate Transplantation	4-Jun-20	"Active, not recruiting"	2P01CA155258-06
clinical_trial	NCT02384083	Filanesib (ARRY-520) in Combination With Pomalidomide and Dexamethasone for Relapsed/Refractory (R/R) Multiple Myeloma (MM) Patients	10-Sep-21	Completed	2P01CA155258-06
clinical_trial	NCT01248923	A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma	30-Sep-20	Completed	2P01CA155258-06
clinical_trial	NCT00222053	IFM 99-02 Thalidomide in Myeloma	2-Apr-10	Completed	2P01CA155258-06
clinical_trial	NCT00367185	Treatment of Newly Diagnosed Elderly Patients With Multiple Myeloma	22-Aug-06	Completed	2P01CA155258-06
clinical_trial	NCT00200681	IFM 2005-01: Velcade/Dexamethasone Versus Vincristine/Adriamycin (Doxorubicin)/Dexamethasone (VAD) for the Treatment of Patients With Multiple Myeloma	5-Feb-09	Completed	2P01CA155258-06
clinical_trial	NCT01454297	Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile (CoMMpass)	16-Aug-18	"Active, not recruiting"	2P01CA155258-06
clinical_trial	NCT01454297	Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile (CoMMpass)	16-Aug-18	"Active, not recruiting"	2P01CA155258-06
clinical_trial	NCT01454297	Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile (CoMMpass)	16-Aug-18	"Active, not recruiting"	2P01CA155258-06
clinical_trial	NCT01454297	Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile (CoMMpass)	16-Aug-18	"Active, not recruiting"	1U2CCA233303-01
clinical_trial	NCT01454297	Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile (CoMMpass)	16-Aug-18	"Active, not recruiting"	1U2CCA233303-01
clinical_trial	NCT01454297	Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile (CoMMpass)	16-Aug-18	"Active, not recruiting"	3P30CA008748-54S3
clinical_trial	NCT01454297	Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile (CoMMpass)	16-Aug-18	"Active, not recruiting"	3P30CA016058-44S3
clinical_trial	NCT03733717	"Evaluation of Pharmacokinetics, Safety, and Preliminary Efficacy of Isatuximab in Chinese Patients With Relapsed and/or Refractory Multiple Myeloma"	21-Sep-21	"Active, not recruiting"	2P01CA155258-06
clinical_trial	NCT02812706	Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients (Islands)	15-Oct-21	"Active, not recruiting"	2P01CA155258-06
clinical_trial	NCT02514668	"A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Isatuximab in Patients With Multiple Myeloma"	27-Sep-21	"Active, not recruiting"	2P01CA155258-06
clinical_trial	NCT02960555	Isatuximab in Treating Patients With High Risk Smoldering Plasma Cell Myeloma	6-Oct-21	Recruiting	2P01CA155258-06
clinical_trial	NCT01749969	"SAR650984 (Isatuximab), Lenalidomide, and Dexamethasone in Combination in RRMM Patients"	21-Sep-21	"Active, not recruiting"	2P01CA155258-06
clinical_trial	NCT01749969	"SAR650984 (Isatuximab), Lenalidomide, and Dexamethasone in Combination in RRMM Patients"	21-Sep-21	"Active, not recruiting"	3P30CA082103-21S9
clinical_trial	NCT01749969	"SAR650984 (Isatuximab), Lenalidomide, and Dexamethasone in Combination in RRMM Patients"	21-Sep-21	"Active, not recruiting"	3P30CA082103-21S6
clinical_trial	NCT02283775	"SAR650984, Pomalidomide and Dexamethasone in Combination in RRMM Patients (PomdeSAR)"	9-Jul-21	Completed	2P01CA155258-06
clinical_trial	NCT02990338	"Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients (ICARIA-MM)"	24-Feb-21	"Active, not recruiting"	2P01CA155258-06
clinical_trial	NCT02332850	Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma	21-Jul-21	Recruiting	2P01CA155258-06
clinical_trial	NCT03275285	"Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients (IKEMA)"	8-Oct-21	"Active, not recruiting"	2P01CA155258-06
clinical_trial	NCT03319667	"Clinical Benefit of SAR650984, Bortezomib, Lenalidomide and Dexamethasone Combination in NDMM Patients Not Eligible for Transplant (IMROZ)"	15-Oct-21	"Active, not recruiting"	2P01CA155258-06
clinical_trial	NCT03319667	"Clinical Benefit of SAR650984, Bortezomib, Lenalidomide and Dexamethasone Combination in NDMM Patients Not Eligible for Transplant (IMROZ)"	15-Oct-21	"Active, not recruiting"	2P01CA155258-06
clinical_trial	NCT03617731	Trial on the Effect of Isatuximab to Lenaliodomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7)	8-Oct-20	"Active, not recruiting"	2P01CA155258-06
clinical_trial	NCT03617731	Trial on the Effect of Isatuximab to Lenaliodomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7)	8-Oct-20	"Active, not recruiting"	2P01CA155258-06
clinical_trial	NCT03104842	"Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and Dexamethasone"	3-Feb-21	"Active, not recruiting"	2P01CA155258-06
clinical_trial	NCT03194867	Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients	23-Sep-21	"Active, not recruiting"	2P01CA155258-06
clinical_trial	NCT04083898	"Isatuximab, Bendamustine, and Prednisone in Refractory Multiple Myeloma"	5-Apr-21	Recruiting	2P01CA155258-06
clinical_trial	NCT04045795	"Multi-center, Open-label, Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)"	21-Sep-21	Recruiting	2P01CA155258-06
clinical_trial	NCT02413489	"An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma"	26-Jun-18	Terminated	2P01CA155258-06
clinical_trial	NCT02927925	"A Study to Assess the Clinical Efficacy and Safety of Daratumumab in Participants With Relapsed or Refractory Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type"	14-Jan-21	Completed	2P01CA155258-06
clinical_trial	NCT02999633	Safety and Efficacy of Isatuximab in Lymphoblastic Leukemia (ISLAY)	18-Jan-20	Terminated	2P01CA155258-06
clinical_trial	NCT03860844	Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia (ISAKIDS)	8-Oct-21	Recruiting	2P01CA155258-06
clinical_trial	NCT03499808	S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis	10-Jun-21	"Active, not recruiting"	2P01CA155258-06
clinical_trial	NCT03769181	A Study of Isatuximab-based Therapy in Participants With Lymphoma	28-Sep-21	"Active, not recruiting"	2P01CA155258-06
clinical_trial	NCT03367819	Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced Malignancies	20-Oct-21	Completed	2P01CA155258-06
clinical_trial	NCT03637764	"Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies"	20-Oct-21	"Active, not recruiting"	2P01CA155258-06
clinical_trial	NCT03555149	A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC)	29-Sep-21	Recruiting	2P01CA155258-06
clinical_trial	NCT03869190	Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)	6-Oct-21	Recruiting	2P01CA155258-06
clinical_trial	NCT03201965	"A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis"	15-Oct-21	"Active, not recruiting"	2P01CA155258-06
clinical_trial	NCT03201965	"A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis"	15-Oct-21	"Active, not recruiting"	3P30CA013696-45S1
clinical_trial	NCT04131309	A Study of Daratumumab Monotherapy in Previously Untreated Patients With Stage 3B Light Chain (AL) Amyloidosis	7-Oct-21	Recruiting	2P01CA155258-06
clinical_trial	NCT03473730	Daratumumab in Treating Patients With Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer	13-May-21	"Active, not recruiting"	2P01CA155258-06
clinical_trial	NCT04088903	Study of Daratumumab for Decreasing Circulating Antibodies in Sensitized Patients Awaiting Heart Transplantation	28-Oct-20	Withdrawn	2P01CA155258-06
clinical_trial	NCT03277105	A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma	15-Oct-21	"Active, not recruiting"	2P01CA155258-06
clinical_trial	NCT02219256	"A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of TAK-079 in Healthy Participants"	3-May-17	Completed	2P01CA155258-06
clinical_trial	NCT03984097	A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)	5-Aug-21	"Active, not recruiting"	2P01CA155258-06
clinical_trial	NCT02076009	"A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma"	6-Oct-21	"Active, not recruiting"	2P01CA155258-06
clinical_trial	NCT02076009	"A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma"	6-Oct-21	"Active, not recruiting"	2P01CA155258-06
clinical_trial	NCT02076009	"A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma"	6-Oct-21	"Active, not recruiting"	1U01CA244291-01
clinical_trial	NCT02136134	Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma	20-Sep-21	"Active, not recruiting"	2P01CA155258-06
clinical_trial	NCT02136134	Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma	20-Sep-21	"Active, not recruiting"	1U01CA244291-01
clinical_trial	NCT02195479	A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma	6-Oct-21	"Active, not recruiting"	2P01CA155258-06
clinical_trial	NCT02541383	A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma (Cassiopeia)	7-Dec-20	"Active, not recruiting"	2P01CA155258-06
clinical_trial	NCT02541383	A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma (Cassiopeia)	7-Dec-20	"Active, not recruiting"	2P01CA155258-06
clinical_trial	NCT00531453	"A Study to Evaluate Two Different Regimens of VELCADE in Combination With Dexamethasone, Thalidomide and Cyclophosphamide (VDT vs VDTC) in Newly Diagnosed Multiple Myeloma"	26-Jan-12	Completed	2P01CA155258-06
clinical_trial	NCT01818752	"Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma (CLARION)"	26-Aug-19	Completed	2P01CA155258-06
clinical_trial	NCT02635061	Selective HDAC6 Inhibitor ACY 241 in Combination With Nivolumab in Patients With Unresectable Non Small Cell Lung Cancer	31-Aug-20	"Active, not recruiting"	2P01CA155258-06
clinical_trial	NCT01091831	"Cyclophosphamide, Lenalidomide and Dexamethasone (CRD) Versus Melphalan (200 mg/m2) Followed By Autologous Stem Cell Transplant (ASCT) In Newly Diagnosed Multiple Myeloma Subjects"	6-Nov-20	"Active, not recruiting"	2P01CA155258-06
clinical_trial	NCT02406144	"Trial Studying Maintenance Treatment With Lenalidomide and Dexamethasone Versus Lenalidomide, Dexamethasone and MLN9708 After Autologous Hematopoietic Stem Cell Transplantation in Patients With Newly-diagnosed Symptomatic Multiple Myeloma"	30-Nov-17	Completed	2P01CA155258-06
clinical_trial	NCT02253316	"Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma"	23-Sep-21	"Active, not recruiting"	2P01CA155258-06
clinical_trial	NCT02389517	Lenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple Myeloma After Donor Stem Cell Transplant	14-Oct-21	"Active, not recruiting"	2P01CA155258-06
clinical_trial	NCT02659293	"Trial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma"	30-Jun-21	"Active, not recruiting"	2P01CA155258-06
clinical_trial	NCT02203643	Evaluation of the Safety and the Efficacy of Carfilzomib Combined With Cyclophosphamide and Dexamethasone (CCyd) or Lenalidomide and Dex (CRd) Followed by ASCT or 12 Cycles of Carf Combined With Dex and Len for Patients Eligible for ASCT With Newly Diagnosed Multiple Myeloma. (FORTE)	29-Apr-21	"Active, not recruiting"	2P01CA155258-06
clinical_trial	NCT03896737	"Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara"	19-Aug-21	Recruiting	2P01CA155258-06
clinical_trial	NCT03901963	A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant (AURIGA)	15-Oct-21	Recruiting	2P01CA155258-06
clinical_trial	NCT02874742	"Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma"	8-Oct-21	"Active, not recruiting"	2P01CA155258-06
clinical_trial	NCT02495922	A Phase III Trial on the Effect of Elotuzumab in VRD Induction /Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG-HD6)	10-Sep-21	Completed	2P01CA155258-06
clinical_trial	NCT03729804	"Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA) ((COBRA))"	8-Jun-21	Recruiting	2P01CA155258-06
clinical_trial	NCT03742297	Treatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 Years	16-Mar-21	Recruiting	2P01CA155258-06
clinical_trial	NCT03710603	"Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma (Perseus)"	26-Aug-21	"Active, not recruiting"	2P01CA155258-06
clinical_trial	NCT03710603	"Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma (Perseus)"	26-Aug-21	"Active, not recruiting"	1U01CA244291-01
clinical_trial	NCT03652064	"A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy"	15-Oct-21	"Active, not recruiting"	2P01CA155258-06
clinical_trial	NCT01668719	"S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma"	6-Apr-20	"Active, not recruiting"	2P01CA155258-06
clinical_trial	NCT02312258	A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT)	10-Nov-20	"Active, not recruiting"	2P01CA155258-06
clinical_trial	NCT03748953	Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT)	8-Oct-21	Recruiting	2P01CA155258-06
clinical_trial	NCT03720041	Myeloma XIV: Frailty-adjusted Therapy in Transplant Non-Eligible Patients With Newly Diagnosed Multiple Myeloma (FiTNEss)	15-Jun-21	Recruiting	2P01CA155258-06
clinical_trial	NCT03733691	Ph 2 Maintenance Trial: Ixazomib vs Ixazomib-Lenalidomide for MM Patients	27-Oct-20	Recruiting	2P01CA155258-06
clinical_trial	NCT02891811	Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction Therapy and Investigating a K-mono Maintenance Strategy	19-May-21	Recruiting	2P01CA155258-06
clinical_trial	NCT02215967	Study of T Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple Myeloma	8-Oct-19	Completed	2P01CA155258-06
clinical_trial	NCT02215967	Study of T Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple Myeloma	8-Oct-19	Completed	1U01CA244291-01
clinical_trial	NCT03093168	BCMA Chimeric Antigen Receptor Expressing T Cells in Multiple Myeloma	27-Feb-19	Unknown	2P01CA155258-06
clinical_trial	NCT03093168	BCMA Chimeric Antigen Receptor Expressing T Cells in Multiple Myeloma	27-Feb-19	Unknown	1U01CA244291-01
clinical_trial	NCT03338972	Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma	10-Jun-21	"Active, not recruiting"	2P01CA155258-06
clinical_trial	NCT03338972	Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma	10-Jun-21	"Active, not recruiting"	1U01CA247548-01
clinical_trial	NCT03338972	Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma	10-Jun-21	"Active, not recruiting"	3P30CA008748-54S3
clinical_trial	NCT02546167	CART-BCMA Cells for Multiple Myeloma	4-Aug-20	Completed	2P01CA155258-06
clinical_trial	NCT03661554	BCMA Nano Antibody CAR-T Cells for Patients With Refractory and Relapsed Multiple Myeloma (BCMA CAR-T)	10-Sep-18	Unknown	2P01CA155258-06
clinical_trial	NCT03196414	Study of T Cells Targeting CD138/BCMA/CD19/More Antigens (CART-138/BCMA/19/More) for Chemotherapy Refractory and Relapsed Multiple Myeloma	2-May-19	Recruiting	2P01CA155258-06
clinical_trial	NCT03455972	Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed With Auto-HSCT	19-May-21	Recruiting	2P01CA155258-06
clinical_trial	NCT03455972	Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed With Auto-HSCT	19-May-21	Recruiting	1U01CA244291-01
clinical_trial	NCT03716856	Clinical Study of CAR-BCMA T in Patients With Refractory or Relapsed Multiple Myeloma	8-Oct-20	"Active, not recruiting"	2P01CA155258-06
clinical_trial	NCT03302403	Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors	8-Oct-20	"Active, not recruiting"	2P01CA155258-06
clinical_trial	NCT03380039	Clinical Study of CAR-BCMA T Cells in Patients With Refractory or Relapsed Multiple Myeloma	12-Oct-20	"Active, not recruiting"	2P01CA155258-06
clinical_trial	NCT03548207	"A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma (CARTITUDE-1)"	8-Oct-21	"Active, not recruiting"	2P01CA155258-06
clinical_trial	NCT02064387	"Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of GSK2857916"	11-Aug-20	Completed	2P01CA155258-06
clinical_trial	NCT02514239	Phase I Dose Escalation of i.v. BI 836909 Monotherapy in Last Line Multiple Myeloma Patients	29-Sep-21	Completed	2P01CA155258-06
clinical_trial	NCT04184050	"A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and PK of HPN217 in Patients With R/R MM"	10-Sep-21	Recruiting	2P01CA155258-06
clinical_trial	NCT03448978	Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma	10-Feb-21	Recruiting	2P01CA155258-06
clinical_trial	NCT03448978	Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma	10-Feb-21	Recruiting	2P01CA155258-06
clinical_trial	NCT03266692	Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple Myeloma	30-Mar-20	Terminated	2P01CA155258-06
clinical_trial	NCT03651128	Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (KarMMa-3)	11-Aug-20	Recruiting	2P01CA155258-06
clinical_trial	NCT04181827	"A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma (CARTITUDE-4)"	15-Oct-21	Recruiting	2P01CA155258-06
clinical_trial	NCT04126200	Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 5)	22-Sep-21	Recruiting	2P01CA155258-06
clinical_trial	NCT04246047	"Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma (DREAMM 7)"	22-Jul-21	"Active, not recruiting"	2P01CA155258-06
clinical_trial	NCT03502577	BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent Multiple Myeloma	2-Aug-21	Suspended	2P01CA155258-06
clinical_trial	NCT03502577	BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent Multiple Myeloma	2-Aug-21	Suspended	2P01CA155258-06
clinical_trial	NCT03502577	BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent Multiple Myeloma	2-Aug-21	Suspended	1U01CA244291-01
clinical_trial	NCT03502577	BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent Multiple Myeloma	2-Aug-21	Suspended	1U01CA247548-01
clinical_trial	NCT03502577	BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent Multiple Myeloma	2-Aug-21	Suspended	3P30CA008748-54S3
clinical_trial	NCT04093596	Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL) (UNIVERSAL)	14-Oct-21	"Active, not recruiting"	2P01CA155258-06
clinical_trial	NCT04093596	Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL) (UNIVERSAL)	14-Oct-21	"Active, not recruiting"	3P30CA021765-41S3
clinical_trial	NCT03940833	Clinical Research of Adoptive BCMA CAR-NK Cells on Relapse/Refractory MM	7-May-19	Recruiting	2P01CA155258-06
clinical_trial	NCT03848845	"Study Evaluating Safety, Tolerability and Clinical Activity of GSK2857916 in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 4)"	1-Oct-21	"Active, not recruiting"	2P01CA155258-06
clinical_trial	NCT03544281	"To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 6)"	19-May-21	Recruiting	2P01CA155258-06
clinical_trial	NCT03715478	Multi-Center Study of GSK2857916 in Combination With Pomalidomide and Dex	10-Aug-20	Recruiting	2P01CA155258-06
clinical_trial	NCT04091126	Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma (DREAMM 9)	20-Jul-21	Recruiting	2P01CA155258-06
clinical_trial	NCT04196491	"A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM) (KarMMa-4)"	18-May-21	Recruiting	2P01CA155258-06
clinical_trial	NCT02728102	Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401)	9-Sep-21	"Active, not recruiting"	2P01CA155258-06
clinical_trial	NCT02728102	Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401)	9-Sep-21	"Active, not recruiting"	1U01CA244291-01
clinical_trial	NCT03224507	Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple Myeloma (MASTER)	22-Sep-21	"Active, not recruiting"	2P01CA155258-06
clinical_trial	NCT04071457	"S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration (DRAMMATIC)"	12-Oct-21	Recruiting	2P01CA155258-06
clinical_trial	NCT04513639	The Relapse From MRD Negativity as Indication for Treatment (REMNANT) Study	18-Jun-21	Recruiting	2P01CA155258-06
clinical_trial	NCT03683277	IPD in RRMM Characterized With Genomic Abnormalities of Adverse Prognostic (IFM2014-01)	25-Sep-18	Not yet recruiting	2P01CA155258-06
clinical_trial	NCT01946789	A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors	17-Apr-19	Completed	2UM1CA154967-07
clinical_trial	NCT01961115	Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma	8-Jun-18	Completed	2UM1CA154967-07
clinical_trial	NCT04751383	Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma	20-Oct-21	Recruiting	2UM1CA154967-07
clinical_trial	NCT04500548	"Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study"	13-Oct-21	Recruiting	2UM1CA154967-07
clinical_trial	NCT03513952	"Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma"	14-Oct-21	Recruiting	2UM1CA154967-07
clinical_trial	NCT02243579	Pembrolizumab in Treating Patients With Relapsed or Refractory Stage IB-IVB Mycosis Fungoides or Sezary Syndrome	20-Sep-19	Completed	2UM1CA154967-07
clinical_trial	NCT02243579	Pembrolizumab in Treating Patients With Relapsed or Refractory Stage IB-IVB Mycosis Fungoides or Sezary Syndrome	20-Sep-19	Completed	2UM1CA154967-07
clinical_trial	NCT01727076	"Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer"	15-Sep-17	Completed	2UM1CA154967-07
clinical_trial	NCT01727076	"Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer"	15-Sep-17	Completed	2UM1CA154967-07
clinical_trial	NCT03063632	Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and S&#233;zary Syndrome and Advanced Synovial Sarcoma	14-May-21	"Active, not recruiting"	2UM1CA154967-07
clinical_trial	NCT03063632	Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and S&#233;zary Syndrome and Advanced Synovial Sarcoma	14-May-21	"Active, not recruiting"	1U01CA233100-01
clinical_trial	NCT02595866	"Pembrolizumab in Treating Patients With HIV and Relapsed, Refractory, or Disseminated Malignant Neoplasms"	5-Aug-21	Recruiting	2UM1CA154967-07
clinical_trial	NCT02595866	"Pembrolizumab in Treating Patients With HIV and Relapsed, Refractory, or Disseminated Malignant Neoplasms"	5-Aug-21	Recruiting	2UM1CA154967-07
clinical_trial	NCT02595866	"Pembrolizumab in Treating Patients With HIV and Relapsed, Refractory, or Disseminated Malignant Neoplasms"	5-Aug-21	Recruiting	2UM1CA154967-07
clinical_trial	NCT02339558	Nivolumab in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Cancer	13-Sep-19	Completed	2UM1CA154967-07
clinical_trial	NCT02267603	Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer	4-Oct-21	"Active, not recruiting"	2UM1CA154967-07
clinical_trial	NCT02267603	Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer	4-Oct-21	"Active, not recruiting"	2UM1CA154967-07
clinical_trial	NCT02267603	Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer	4-Oct-21	"Active, not recruiting"	2UM1CA154967-07
clinical_trial	NCT03271372	Adjuvant Avelumab in Merkel Cell Cancer (ADAM)	27-May-21	Recruiting	2UM1CA154967-07
clinical_trial	NCT02488759	"An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors (CheckMate358)"	10-Sep-20	"Active, not recruiting"	2UM1CA154967-07
clinical_trial	NCT02840058	Interest of Anti-telomerase T CD4 Immune Responses for Predicting the Effectiveness of Immunotherapies Targeting PD1 / PDL1 (ITHER)	2-Aug-21	Recruiting	2UM1CA154967-07
clinical_trial	NCT01495598	Pomalidomide for Kaposi Sarcoma in People With or Without HIV	15-Oct-21	"Active, not recruiting"	2UM1CA154967-07
clinical_trial	NCT02659930	Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma	5-Sep-21	Recruiting	2UM1CA154967-07
clinical_trial	NCT00006518	"Specimen Collections From Patients With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer"	15-Oct-21	Recruiting	2UM1CA154967-07
clinical_trial	NCT00092222	Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity	19-Oct-21	Recruiting	2UM1CA154967-07
clinical_trial	NCT01419561	History of the KSHV Inflammatory Cytokine Syndrome (KICS)	4-Oct-21	Recruiting	2UM1CA154967-07
clinical_trial	NCT03747484	Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer	8-Jul-21	Recruiting	2UM1CA154967-07
clinical_trial	NCT03098160	Immunotherapy Study of Evofosfamide in Combination With Ipilimumab	30-Oct-17	Unknown	3R01CA187532-03S1
clinical_trial	NCT01440088	A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma	2-Jun-16	Completed	3R01CA187532-03S1
clinical_trial	NCT01746979	Clinical Trial Testing TH-302 in Combination With Gemcitabine in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma (MAESTRO)	2-Dec-17	Completed	3R01CA187532-03S1
clinical_trial	NCT03125239	Combination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid Leukemia	30-Jun-20	Completed	3R01CA204396-02S1
clinical_trial	NCT02236195	Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes	1-Sep-17	Completed	3U24CA210999-02S1
clinical_trial	NCT02334527	Phase II Trial of Palbociclib in Patients With Metastatic Urothelial Cancer After Failure of First-Line Chemotherapy	16-Nov-18	Terminated	3U24CA210999-02S1
clinical_trial	NCT01747486	Dose Optimization Trial of CD19 Redirected Autologous T Cells	30-Aug-19	Completed	1R01CA226983-01
clinical_trial	NCT01747486	Dose Optimization Trial of CD19 Redirected Autologous T Cells	30-Aug-19	Completed	1R01CA226983-01
clinical_trial	NCT01747486	Dose Optimization Trial of CD19 Redirected Autologous T Cells	30-Aug-19	Completed	1U54CA244711-01
clinical_trial	NCT01029366	CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy	26-Jun-19	Completed	1R01CA226983-01
clinical_trial	NCT01029366	CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy	26-Jun-19	Completed	1R01CA226983-01
clinical_trial	NCT01029366	CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy	26-Jun-19	Completed	1U54CA244711-01
clinical_trial	NCT03089203	CART-PSMA-TGF&#946;RDN Cells for Castrate-Resistant Prostate Cancer	14-Jan-21	"Active, not recruiting"	1R01CA226983-01
clinical_trial	NCT03089203	CART-PSMA-TGF&#946;RDN Cells for Castrate-Resistant Prostate Cancer	14-Jan-21	"Active, not recruiting"	1U01CA233100-01
clinical_trial	NCT03089203	CART-PSMA-TGF&#946;RDN Cells for Castrate-Resistant Prostate Cancer	14-Jan-21	"Active, not recruiting"	1U01CA239258-01
clinical_trial	NCT03089203	CART-PSMA-TGF&#946;RDN Cells for Castrate-Resistant Prostate Cancer	14-Jan-21	"Active, not recruiting"	1U01CA244452-01
clinical_trial	NCT03089203	CART-PSMA-TGF&#946;RDN Cells for Castrate-Resistant Prostate Cancer	14-Jan-21	"Active, not recruiting"	1U54CA244711-01
clinical_trial	NCT03089203	CART-PSMA-TGF&#946;RDN Cells for Castrate-Resistant Prostate Cancer	14-Jan-21	"Active, not recruiting"	3P30CA013696-45S1
clinical_trial	NCT01626495	Phase I/IIA Study of CART19 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma (Pedi CART19)	23-Mar-20	Completed	1R01CA226983-01
clinical_trial	NCT01626495	Phase I/IIA Study of CART19 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma (Pedi CART19)	23-Mar-20	Completed	1R01CA226983-01
clinical_trial	NCT01626495	Phase I/IIA Study of CART19 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma (Pedi CART19)	23-Mar-20	Completed	1U01CA232361-01A1
clinical_trial	NCT01626495	Phase I/IIA Study of CART19 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma (Pedi CART19)	23-Mar-20	Completed	1U54CA244711-01
clinical_trial	NCT02640209	Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen Receptor (CART19)In Combination With Ibrutinib In Patients With Relapsed Or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)Or Small Lymphocytic Lymphoma (SLL)	7-May-20	Terminated	1R01CA226983-01
clinical_trial	NCT02640209	Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen Receptor (CART19)In Combination With Ibrutinib In Patients With Relapsed Or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)Or Small Lymphocytic Lymphoma (SLL)	7-May-20	Terminated	1U54CA244711-01
clinical_trial	NCT02435849	Determine Efficacy and Safety of CTL019 in Pediatric Patients With Relapsed and Refractory B-cell ALL and High Risk B-cell ALL at First Relapse. Determine Feasibility and Safety of CTL019 Therapy in Pediatric Patients With High Risk B-cell ALL That Relapsed &lt; 6 Months Post All-HSCT. (ELIANA)	30-Jun-21	"Active, not recruiting"	1R01CA226983-01
clinical_trial	NCT02435849	Determine Efficacy and Safety of CTL019 in Pediatric Patients With Relapsed and Refractory B-cell ALL and High Risk B-cell ALL at First Relapse. Determine Feasibility and Safety of CTL019 Therapy in Pediatric Patients With High Risk B-cell ALL That Relapsed &lt; 6 Months Post All-HSCT. (ELIANA)	30-Jun-21	"Active, not recruiting"	1U54CA232561-01A1
clinical_trial	NCT02228096	Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients (ENSIGN)	23-Nov-20	Completed	1R01CA226983-01
clinical_trial	NCT02030847	Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCR and 4-1BB Signaling Domains in Patients With Chemotherapy Resistant or Refractory Acute Lymphoblastic Leukemia	30-Aug-19	Completed	1R01CA226983-01
clinical_trial	NCT01371981	Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia	5-Aug-21	"Active, not recruiting"	1U01CA232486-01
clinical_trial	NCT01371981	Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia	5-Aug-21	"Active, not recruiting"	1U01CA232486-01
clinical_trial	NCT03190915	Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia	11-Oct-21	Recruiting	1U01CA232486-01
clinical_trial	NCT03190915	Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia	11-Oct-21	Recruiting	1U01CA232486-01
clinical_trial	NCT00372593	Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia	24-Mar-21	Completed	1U01CA232486-01
clinical_trial	NCT00372593	Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia	24-Mar-21	Completed	1U01CA232486-01
clinical_trial	NCT03126864	Study of Adoptive Cellular Therapy Using Autologous T Cells Transduced With Lentivirus to Express a CD33 Specific Chimeric Antigen Receptor in Patients With Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia	4-Nov-19	Terminated	1U01CA232486-01
clinical_trial	NCT03126864	Study of Adoptive Cellular Therapy Using Autologous T Cells Transduced With Lentivirus to Express a CD33 Specific Chimeric Antigen Receptor in Patients With Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia	4-Nov-19	Terminated	1U01CA232486-01
clinical_trial	NCT03126864	Study of Adoptive Cellular Therapy Using Autologous T Cells Transduced With Lentivirus to Express a CD33 Specific Chimeric Antigen Receptor in Patients With Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia	4-Nov-19	Terminated	1U01CA232486-01
clinical_trial	NCT03126864	Study of Adoptive Cellular Therapy Using Autologous T Cells Transduced With Lentivirus to Express a CD33 Specific Chimeric Antigen Receptor in Patients With Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia	4-Nov-19	Terminated	1U01CA232486-01
clinical_trial	NCT00283114	A Safety Study of Lintuzumab in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome	18-Dec-14	Completed	1U01CA232486-01
clinical_trial	NCT00283114	A Safety Study of Lintuzumab in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome	18-Dec-14	Completed	1U01CA232486-01
clinical_trial	NCT03915279	N/A	N/A	N/A	1U01CA232486-01
clinical_trial	NCT03915279	N/A	N/A	N/A	1U01CA232486-01
clinical_trial	NCT03441048	Lintuzumab-Ac225 in Combination With Cladribine + Cytarabine + Filgastrim + Mitoxantrone (CLAG-M) for Relapsed/Refractory Acute Myeloid Leukemia	18-May-21	Recruiting	1U01CA232486-01
clinical_trial	NCT03441048	Lintuzumab-Ac225 in Combination With Cladribine + Cytarabine + Filgastrim + Mitoxantrone (CLAG-M) for Relapsed/Refractory Acute Myeloid Leukemia	18-May-21	Recruiting	1U01CA232486-01
clinical_trial	NCT02575963	Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patients	20-Nov-20	"Active, not recruiting"	1U01CA232486-01
clinical_trial	NCT02575963	Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patients	20-Nov-20	"Active, not recruiting"	1U01CA232486-01
clinical_trial	NCT03867682	Venetoclax and Lintuzumab-Ac225 in AML Patients	2-Jul-20	Recruiting	1U01CA232486-01
clinical_trial	NCT03867682	Venetoclax and Lintuzumab-Ac225 in AML Patients	2-Jul-20	Recruiting	1U01CA232486-01
clinical_trial	NCT01902329	A Safety Study of SGN-CD33A in AML Patients	5-Jan-18	Completed	1U01CA232486-01
clinical_trial	NCT01902329	A Safety Study of SGN-CD33A in AML Patients	5-Jan-18	Completed	1U01CA232486-01
clinical_trial	NCT02326584	A Safety Study of SGN-CD33A in Combination With Standard-of-care in Patients With AML	9-May-18	Completed	1U01CA232486-01
clinical_trial	NCT02326584	A Safety Study of SGN-CD33A in Combination With Standard-of-care in Patients With AML	9-May-18	Completed	1U01CA232486-01
clinical_trial	NCT02614560	A Study of Vadastuximab Talirine Given Prior to or After Allogeneic Hematopoietic Stem Cell Transplant in AML Patients	9-Jan-19	Terminated	1U01CA232486-01
clinical_trial	NCT02614560	A Study of Vadastuximab Talirine Given Prior to or After Allogeneic Hematopoietic Stem Cell Transplant in AML Patients	9-Jan-19	Terminated	1U01CA232486-01
clinical_trial	NCT02785900	Vadastuximab Talirine (SGN-CD33A; 33A) Combined With Azacitidine or Decitabine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia (CASCADE)	12-Dec-18	Terminated	1U01CA232486-01
clinical_trial	NCT02785900	Vadastuximab Talirine (SGN-CD33A; 33A) Combined With Azacitidine or Decitabine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia (CASCADE)	12-Dec-18	Terminated	1U01CA232486-01
clinical_trial	NCT03386513	Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN	12-Jul-21	Recruiting	1U01CA232486-01
clinical_trial	NCT03386513	Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN	12-Jul-21	Recruiting	1U01CA232486-01
clinical_trial	NCT03386513	Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN	12-Jul-21	Recruiting	1U01CA232486-01
clinical_trial	NCT02520427	A Phase 1 Study of AMG 330 in Subjects With Myeloid Malignancies	1-Jul-21	Recruiting	1U01CA232486-01
clinical_trial	NCT02520427	A Phase 1 Study of AMG 330 in Subjects With Myeloid Malignancies	1-Jul-21	Recruiting	1U01CA232486-01
clinical_trial	NCT02520427	A Phase 1 Study of AMG 330 in Subjects With Myeloid Malignancies	1-Jul-21	Recruiting	1U01CA232486-01
clinical_trial	NCT02520427	A Phase 1 Study of AMG 330 in Subjects With Myeloid Malignancies	1-Jul-21	Recruiting	3P30CA016056-43S5
clinical_trial	NCT03915379	A Study of JNJ-67571244 in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)	8-Oct-21	Recruiting	1U01CA232486-01
clinical_trial	NCT03915379	A Study of JNJ-67571244 in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)	8-Oct-21	Recruiting	1U01CA232486-01
clinical_trial	NCT03516760	Dose-escalating Phase I Trial With GEM333 in Patients With Acute Myeloid Leukemia	9-Jul-20	"Active, not recruiting"	1U01CA232486-01
clinical_trial	NCT03516760	Dose-escalating Phase I Trial With GEM333 in Patients With Acute Myeloid Leukemia	9-Jul-20	"Active, not recruiting"	1U01CA232486-01
clinical_trial	NCT02623582	CD123 Redirected Autologous T Cells for AML	17-Oct-17	Terminated	1U01CA232486-01
clinical_trial	NCT02623582	CD123 Redirected Autologous T Cells for AML	17-Oct-17	Terminated	1U01CA232486-01
clinical_trial	NCT02623582	CD123 Redirected Autologous T Cells for AML	17-Oct-17	Terminated	1U01CA232486-01
clinical_trial	NCT03766126	Lentivirally Redirected CD123 Autologous T Cells in AML	17-Dec-20	"Active, not recruiting"	1U01CA232486-01
clinical_trial	NCT03766126	Lentivirally Redirected CD123 Autologous T Cells in AML	17-Dec-20	"Active, not recruiting"	1U01CA232486-01
clinical_trial	NCT03766126	Lentivirally Redirected CD123 Autologous T Cells in AML	17-Dec-20	"Active, not recruiting"	1U01CA232486-01
clinical_trial	NCT03766126	Lentivirally Redirected CD123 Autologous T Cells in AML	17-Dec-20	"Active, not recruiting"	1U01CA232486-01
clinical_trial	NCT02159495	Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm	27-Jan-21	Recruiting	1U01CA232486-01
clinical_trial	NCT02159495	Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm	27-Jan-21	Recruiting	1U01CA232486-01
clinical_trial	NCT02159495	Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm	27-Jan-21	Recruiting	1U01CA232486-01
clinical_trial	NCT01632852	A Study of CSL362 in Patients With CD123+ Acute Myeloid Leukemia Currently in Remission	9-Oct-15	Completed	1U01CA232486-01
clinical_trial	NCT01632852	A Study of CSL362 in Patients With CD123+ Acute Myeloid Leukemia Currently in Remission	9-Oct-15	Completed	1U01CA232486-01
clinical_trial	NCT02181699	Study of KHK2823 in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)	2-Aug-19	Terminated	1U01CA232486-01
clinical_trial	NCT02181699	Study of KHK2823 in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)	2-Aug-19	Terminated	1U01CA232486-01
clinical_trial	NCT02848248	A Safety Study of SGN-CD123A in Patients With Acute Myeloid Leukemia	14-May-18	Terminated	1U01CA232486-01
clinical_trial	NCT02848248	A Safety Study of SGN-CD123A in Patients With Acute Myeloid Leukemia	14-May-18	Terminated	1U01CA232486-01
clinical_trial	NCT02270463	SL-401 as Consolidation Therapy in Patients With Adverse Risk Acute Myeloid Leukemia in First Complete Remission	7-Apr-20	Completed	1U01CA232486-01
clinical_trial	NCT02270463	SL-401 as Consolidation Therapy in Patients With Adverse Risk Acute Myeloid Leukemia in First Complete Remission	7-Apr-20	Completed	1U01CA232486-01
clinical_trial	NCT02152956	Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML)	25-May-21	Recruiting	1U01CA232486-01
clinical_trial	NCT02152956	Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML)	25-May-21	Recruiting	1U01CA232486-01
clinical_trial	NCT02152956	Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML)	25-May-21	Recruiting	1U01CA232486-01
clinical_trial	NCT02152956	Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML)	25-May-21	Recruiting	3P30CA016056-43S5
clinical_trial	NCT02715011	"Dose Escalation Study of JNJ-63709178, a Humanized CD123 x CD3 DuoBody in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)"	31-Aug-21	Completed	1U01CA232486-01
clinical_trial	NCT02715011	"Dose Escalation Study of JNJ-63709178, a Humanized CD123 x CD3 DuoBody in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)"	31-Aug-21	Completed	1U01CA232486-01
clinical_trial	NCT02730312	PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies	22-Sep-21	Recruiting	1U01CA232486-01
clinical_trial	NCT02730312	PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies	22-Sep-21	Recruiting	1U01CA232486-01
clinical_trial	NCT02730312	PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies	22-Sep-21	Recruiting	3P30CA016056-43S5
clinical_trial	NCT03190278	Study Evaluating Safety and Efficacy of UCART123 in Patients With Relapsed/ Refractory Acute Myeloid Leukemia (AMELI-01)	22-Sep-21	Recruiting	1U01CA232486-01
clinical_trial	NCT03190278	Study Evaluating Safety and Efficacy of UCART123 in Patients With Relapsed/ Refractory Acute Myeloid Leukemia (AMELI-01)	22-Sep-21	Recruiting	1U01CA232486-01
clinical_trial	NCT03190278	Study Evaluating Safety and Efficacy of UCART123 in Patients With Relapsed/ Refractory Acute Myeloid Leukemia (AMELI-01)	22-Sep-21	Recruiting	1U01CA232486-01
clinical_trial	NCT03190278	Study Evaluating Safety and Efficacy of UCART123 in Patients With Relapsed/ Refractory Acute Myeloid Leukemia (AMELI-01)	22-Sep-21	Recruiting	3P30CA021765-41S3
clinical_trial	NCT03203369	Study to Evaluate the Safety and Clinical Activity of UCART123 in Patients With BPDCN (ABC123)	31-Jul-19	Terminated	1U01CA232486-01
clinical_trial	NCT03203369	Study to Evaluate the Safety and Clinical Activity of UCART123 in Patients With BPDCN (ABC123)	31-Jul-19	Terminated	1U01CA232486-01
clinical_trial	NCT01998793	N/A	N/A	N/A	1U01CA232486-01
clinical_trial	NCT01998793	N/A	N/A	N/A	1U01CA232486-01
clinical_trial	NCT01898793	Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)	21-May-21	Recruiting	1U01CA232486-01
clinical_trial	NCT01898793	Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)	21-May-21	Recruiting	1U01CA232486-01
clinical_trial	NCT01898793	Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)	21-May-21	Recruiting	1U01CA232488-01
clinical_trial	NCT03068819	Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML After Allogeneic Hematopoietic Cell Transplant	20-Sep-21	Recruiting	1U01CA232486-01
clinical_trial	NCT03068819	Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML After Allogeneic Hematopoietic Cell Transplant	20-Sep-21	Recruiting	1U01CA232486-01
clinical_trial	NCT03068819	Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML After Allogeneic Hematopoietic Cell Transplant	20-Sep-21	Recruiting	1U01CA232486-01
clinical_trial	NCT03326921	HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant	29-Sep-21	Recruiting	1U01CA232486-01
clinical_trial	NCT03326921	HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant	29-Sep-21	Recruiting	1U01CA232486-01
clinical_trial	NCT02828358	Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement	2-Aug-21	"Active, not recruiting"	1U01CA232486-01
clinical_trial	NCT02828358	Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement	2-Aug-21	"Active, not recruiting"	1U01CA232486-01
clinical_trial	NCT02828358	Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement	2-Aug-21	"Active, not recruiting"	1U01CA232486-01
clinical_trial	NCT02101853	Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia	25-Aug-21	"Active, not recruiting"	1U01CA232486-01
clinical_trial	NCT02101853	Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia	25-Aug-21	"Active, not recruiting"	1U01CA232486-01
clinical_trial	NCT02101853	Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia	25-Aug-21	"Active, not recruiting"	1U01CA232486-01
clinical_trial	NCT02642965	"Liposome-encapsulated Daunorubicin-Cytarabine, Fludarabine Phosphate, Cytarabine, and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia"	25-Jan-21	"Active, not recruiting"	1U01CA232486-01
clinical_trial	NCT02642965	"Liposome-encapsulated Daunorubicin-Cytarabine, Fludarabine Phosphate, Cytarabine, and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia"	25-Jan-21	"Active, not recruiting"	1U01CA232486-01
clinical_trial	NCT03739606	Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer	17-Dec-20	Withdrawn	1U01CA232486-01
clinical_trial	NCT03739606	Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer	17-Dec-20	Withdrawn	1U01CA232486-01
clinical_trial	NCT03739606	Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer	17-Dec-20	Withdrawn	1U01CA232486-01
clinical_trial	NCT02879695	Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia	9-Jun-21	Recruiting	1U01CA232486-01
clinical_trial	NCT02879695	Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia	9-Jun-21	Recruiting	1U01CA232486-01
clinical_trial	NCT03605589	Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or Lymphoma	1-Apr-21	Withdrawn	1U01CA232486-01
clinical_trial	NCT03605589	Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or Lymphoma	1-Apr-21	Withdrawn	1U01CA232486-01
clinical_trial	NCT03605589	Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or Lymphoma	1-Apr-21	Withdrawn	1U54CA232561-01A1
clinical_trial	NCT03825367	Nivolumab in Combination With 5-azacytidine in Childhood Relapsed/Refractory AML	5-Oct-21	Recruiting	1U01CA232486-01
clinical_trial	NCT03825367	Nivolumab in Combination With 5-azacytidine in Childhood Relapsed/Refractory AML	5-Oct-21	Recruiting	1U01CA232486-01
clinical_trial	NCT03384654	A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (&gt;=)1 and Less Than or Equal to (&lt;=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma	15-Oct-21	"Active, not recruiting"	1U01CA232486-01
clinical_trial	NCT02981628	Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia	19-Oct-21	Recruiting	1U01CA232486-01
clinical_trial	NCT03914625	A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia	12-Oct-21	Recruiting	1U01CA232486-01
clinical_trial	NCT03224819	Study of AMG 673 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia	27-Sep-21	"Active, not recruiting"	1U01CA232486-01
clinical_trial	NCT03541369	"Safety, Tolerability, PK, PD, and Efficacy of AMG 427 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (20170528)"	29-Jul-21	"Active, not recruiting"	1U01CA232486-01
clinical_trial	NCT02315612	Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies	18-Oct-21	Recruiting	1U01CA232486-01
clinical_trial	NCT02315612	Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies	18-Oct-21	Recruiting	1U01CA232488-01
clinical_trial	NCT02315612	Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies	18-Oct-21	Recruiting	1U54CA232561-01A1
clinical_trial	NCT02652548	N/A	N/A	N/A	1U01CA232486-01
clinical_trial	NCT03389035	Transposon-manipulated Allogeneic CARCIK-CD19 Cells in Pediatric and Adult Patients With r/r ALL Post HSCT (CARCIK)	5-Feb-20	Recruiting	1U01CA232486-01
clinical_trial	NCT03573700	Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia	12-Nov-20	Recruiting	1U01CA232486-01
clinical_trial	NCT03467256	CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL	8-Apr-21	"Active, not recruiting"	1U01CA232486-01
clinical_trial	NCT02808442	Study of UCART19 in Pediatric Patients With Relapsed/Refractory B Acute Lymphoblastic Leukemia (PALL)	8-Oct-21	Completed	1U01CA232486-01
clinical_trial	NCT02808442	Study of UCART19 in Pediatric Patients With Relapsed/Refractory B Acute Lymphoblastic Leukemia (PALL)	8-Oct-21	Completed	3P30CA021765-41S3
clinical_trial	NCT04049383	CAR-20/19-T Cells in Pediatric and Young Adult Patients With Relapsed/Refractory B Cell ALL (CAR-20/19-T)	2-Feb-21	Recruiting	1U01CA232486-01
clinical_trial	NCT03876769	Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients (CASSIOPEIA)	12-Oct-21	Recruiting	1U01CA232486-01
clinical_trial	NCT03792622	N/A	N/A	N/A	1U01CA232486-01
clinical_trial	NCT02772198	T-cells Expressing Anti-CD19 CAR in Pediatric and Young Adults With B-cell Malignancies	3-Nov-20	Recruiting	1U01CA232486-01
clinical_trial	NCT02772198	T-cells Expressing Anti-CD19 CAR in Pediatric and Young Adults With B-cell Malignancies	3-Nov-20	Recruiting	1U01CA232488-01
clinical_trial	NCT03373071	Anti-CD19 CAR T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and NHL	8-Jul-20	Recruiting	1U01CA232486-01
clinical_trial	NCT03373071	Anti-CD19 CAR T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and NHL	8-Jul-20	Recruiting	3P30CA016520-44S5
clinical_trial	NCT03373071	Anti-CD19 CAR T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and NHL	8-Jul-20	Recruiting	3P30CA016520-44S6
clinical_trial	NCT03938987	"Anti-CD19, Dual Co-stimulatory (4-1BB, CD3&#950;) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL) (ACIT001/EXC002)"	20-Jul-21	Recruiting	1U01CA232486-01
clinical_trial	NCT02650414	CD22 Redirected Autologous T Cells for ALL	4-Nov-20	Recruiting	1U01CA232486-01
clinical_trial	NCT03016377	Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL	15-Jul-21	Recruiting	1U01CA232486-01
clinical_trial	NCT03321123	MB-CART19.1 in Patients With R/R ALL	25-Oct-17	Unknown	1U01CA232486-01
clinical_trial	NCT02374333	Pilot Study of Redirected Autologous T Cells Engineered to Contain Humanized Anti-CD19 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma Previously Treated With Cell Therapy	23-Sep-21	Completed	1U01CA232486-01
clinical_trial	NCT03555941	N/A	N/A	N/A	1U01CA232486-01
clinical_trial	NCT03853616	MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM)	9-Jul-20	Recruiting	1U01CA232486-01
clinical_trial	NCT03676504	Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR	20-Nov-20	Recruiting	1U01CA232486-01
clinical_trial	NCT03601442	CTL019 Out of Specification MAP for ALL or DLBCL Patients	24-Jun-21	Available	1U01CA232486-01
clinical_trial	NCT02028455	A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia	29-Jan-21	"Active, not recruiting"	1U01CA232486-01
clinical_trial	NCT02028455	A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia	29-Jan-21	"Active, not recruiting"	1U54CA232561-01A1
clinical_trial	NCT02028455	A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia	29-Jan-21	"Active, not recruiting"	1U01CA247548-01
clinical_trial	NCT02028455	A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia	29-Jan-21	"Active, not recruiting"	3P30CA008748-54S3
clinical_trial	NCT03186118	Pilot Study of T-APCs Following CAR T Cell Immunotherapy for CD19+ Leukemia	25-Mar-21	Recruiting	1U01CA232486-01
clinical_trial	NCT03186118	Pilot Study of T-APCs Following CAR T Cell Immunotherapy for CD19+ Leukemia	25-Mar-21	Recruiting	1U54CA232561-01A1
clinical_trial	NCT03064269	CAR-T Therapy for Central Nervous System B-cell Acute Lymphocytic Leukemia	22-May-18	Unknown	1U01CA232486-01
clinical_trial	NCT03391739	CART-19 Cells For R/R B-ALL (CCFRRBA)	5-Jan-18	Unknown	1U01CA232486-01
clinical_trial	NCT03027739	CART-19 Cells For MRD Positive CD19+ ALL (CCFMPCA)	23-Jan-17	Unknown	1U01CA232486-01
clinical_trial	NCT03684889	CD19-specific CAR T Cells With a Fully Human Binding Domain for CD19+ Leukemia or Lymphoma	10-Feb-21	"Active, not recruiting"	1U01CA232486-01
clinical_trial	NCT03684889	CD19-specific CAR T Cells With a Fully Human Binding Domain for CD19+ Leukemia or Lymphoma	10-Feb-21	"Active, not recruiting"	1U01CA247548-01
clinical_trial	NCT03684889	CD19-specific CAR T Cells With a Fully Human Binding Domain for CD19+ Leukemia or Lymphoma	10-Feb-21	"Active, not recruiting"	3P30CA008748-54S3
clinical_trial	NCT02443831	CARPALL: Immunotherapy With CD19 CAR T-cells for CD19+ Haematological Malignancies	13-Nov-20	"Active, not recruiting"	1U01CA232486-01
clinical_trial	NCT03289455	CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell Acute Lymphoblastic Leukemia (ALL) (AMELIA)	1-Feb-21	Completed	1U01CA232486-01
clinical_trial	NCT03289455	CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell Acute Lymphoblastic Leukemia (ALL) (AMELIA)	1-Feb-21	Completed	1U54CA232568-01
clinical_trial	NCT03754764	A Feasibility and Safety Study of CD38 CAR-T Cell Immunotherapy for Relapsed B-cell Acute Lymphoblastic Leukemia After CD19 CAR-T Adoptive Cellular Immunotherapy	7-Dec-18	Recruiting	1U01CA232486-01
clinical_trial	NCT03142646	Safety and Efficacy Evaluation of IM19 CAR-T Cells (IM19CAR-T)	1-May-18	Unknown	1U01CA232486-01
clinical_trial	NCT03671460	CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL.	14-Sep-18	Unknown	1U01CA232486-01
clinical_trial	NCT03366324	Anti-CD19 CAR-T Therapy Combine With HSCT to Treat MRD+ B-cell Malignancies	20-Nov-18	Unknown	1U01CA232486-01
clinical_trial	NCT03574168	CD19-CAR-T Cells in Patients With R/R B-ALL	29-Jun-18	Unknown	1U01CA232486-01
clinical_trial	NCT03544021	CART-19 FOR Relapsed/Refractory Acute Lymphoblastic Leukemia &#65288;ALL&#65289;	4-Jun-18	Unknown	1U01CA232486-01
clinical_trial	NCT04036019	A Study of C-CAR066 in Subjects With r/r B Cell Lymphoma Who Received CD19 CAR-T Therapy	29-Jul-19	Unknown	1U01CA232486-01
clinical_trial	NCT02710149	A Clinical Research of CD20-Targeted CAR-T in B Cell Malignancies	25-Jun-19	Unknown	1U01CA232486-01
clinical_trial	NCT02935153	A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies	25-Jun-19	Unknown	1U01CA232486-01
clinical_trial	NCT04007978	Anti-CD22 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy for Relapsed Refractory B-cell Malignancies	7-Aug-19	Recruiting	1U01CA232486-01
clinical_trial	NCT03366350	Anti-CD19 CAR-T Therapy Bridging to HSCT for CD19+ B-Cell Malignancies	10-May-19	Unknown	1U01CA232486-01
clinical_trial	NCT03275493	Humanized CD19 CAR-T Cells With CRS Suppression Technology for r/r CD19+ Acute Lymphoblastic Leukemia	22-May-18	Unknown	1U01CA232486-01
clinical_trial	NCT03398967	A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and Lymphoma	16-Jan-18	Recruiting	1U01CA232486-01
clinical_trial	NCT03398967	A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and Lymphoma	16-Jan-18	Recruiting	3P30CA021765-41S3
clinical_trial	NCT03232619	CD19-CART Treatment for ALL	22-Sep-20	Completed	1U01CA232486-01
clinical_trial	NCT02965092	CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies	10-May-19	Recruiting	1U01CA232486-01
clinical_trial	NCT03241940	Phase I Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies	17-Aug-21	Recruiting	1U01CA232486-01
clinical_trial	NCT03241940	Phase I Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies	17-Aug-21	Recruiting	1U54CA232568-01
clinical_trial	NCT03937544	Intravenous Autologous CD19 CAR-T Cells for R/R B-ALL	6-May-19	Recruiting	1U01CA232486-01
clinical_trial	NCT03840317	Senl_1904A and Senl_1904B Chimeric Antigen Receptor &#65288;CAR&#65289; T-Cell in the Treatment of r/ r Acute B Lymphocytic Leukemia	20-Jan-21	"Active, not recruiting"	1U01CA232486-01
clinical_trial	NCT03685786	CART19 Cells Treatment of MRD of B Cell Malignancies and Then Auto-HSCT	7-Dec-18	Unknown	1U01CA232486-01
clinical_trial	NCT04016129	CAR-T Immunotherapy Targeting CD19- ALL	19-Sep-19	Recruiting	1U01CA232486-01
clinical_trial	NCT02537977	CD19-directed CAR T Cells Therapy in Relapsed/Refractory B Cell Malignancy	3-Dec-18	Unknown	1U01CA232486-01
clinical_trial	NCT03919240	CAR-T Cell Therapy Targeting to CD19 for R/R ALL	1-Jul-20	Recruiting	1U01CA232486-01
clinical_trial	NCT03068416	"CD19-targeting, 3rd Generation CAR T Cells for Refractory B Cells Malignancy"	20-Oct-21	Completed	1U01CA232486-01
clinical_trial	NCT03825718	A Study of GC007F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL	31-Jan-19	Unknown	1U01CA232486-01
clinical_trial	NCT04008251	Humanized CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies	7-Aug-19	Recruiting	1U01CA232486-01
clinical_trial	NCT02935257	"Immunotherapy for High Risk/Relapsed CD19+ Acute Lymphoblastic Leukaemia, B-cell Non-Hodgkin's Lymphoma (B-NHL) and Chronic Lymphocytic Leukaemia (CLL)/ Small Lymphocytic Lymphoma (SLL) Using CAR T-cells to Target CD19 (ALLCAR19)"	23-Nov-20	Recruiting	1U01CA232486-01
clinical_trial	NCT03825731	A Study of GC022 CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL	31-Jan-19	Unknown	1U01CA232486-01
clinical_trial	NCT03614858	CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia.	16-Jul-19	Unknown	1U01CA232486-01
clinical_trial	NCT04033302	Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies	19-Sep-19	Recruiting	1U01CA232486-01
clinical_trial	NCT02349698	A Clinical Research of CAR T Cells Targeting CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma	25-Jun-19	Recruiting	1U01CA232486-01
clinical_trial	NCT03642626	MT2017-45: CAR-T Cell Therapy for Heme Malignancies	25-May-21	Recruiting	1U01CA232486-01
clinical_trial	NCT03050190	A Phase I/II Multiple Center Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Malignancies	19-Sep-19	Unknown	1U01CA232486-01
clinical_trial	NCT03624686	Production of Clinical-grade Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory B-cell Malignancies	10-Aug-18	Unknown	1U01CA232486-01
clinical_trial	NCT03448393	CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies	5-Sep-21	Recruiting	1U01CA232486-01
clinical_trial	NCT03448393	CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies	5-Sep-21	Recruiting	1U54CA232568-01
clinical_trial	NCT03448393	CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies	5-Sep-21	Recruiting	1U54CA232561-01A1
clinical_trial	NCT03081910	Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen (MAGENTA)	5-Oct-21	Recruiting	1U01CA232486-01
clinical_trial	NCT03155191	Study of TBI-1501 for Relapsed or Refractory Acute Lymphoblastic Leukemia (TBI-1501)	28-Dec-20	Recruiting	1U01CA232486-01
clinical_trial	NCT01853631	"Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN) (SAGAN)"	11-Jan-21	Recruiting	1U01CA232486-01
clinical_trial	NCT03902197	CD19 hsCAR-T for Refractory/Relapsed CD19+ B-ALL Patients	8-Apr-19	Recruiting	1U01CA232486-01
clinical_trial	NCT03265106	A Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in Childhood R/R ALL and Lymphoma Subjects	4-Feb-21	"Active, not recruiting"	1U01CA232486-01
clinical_trial	NCT03229876	Safety and Efficacy Evaluation of CD19-UCART	27-May-21	Recruiting	1U01CA232486-01
clinical_trial	NCT03229876	Safety and Efficacy Evaluation of CD19-UCART	27-May-21	Recruiting	3P30CA021765-41S3
clinical_trial	NCT03910842	Treatment of Children CD19+ Leukemia and Non-Hodgkin Lymphoma With CD19-TriCAR-T/SILK Cell Therapy	6-Sep-19	Recruiting	1U01CA232486-01
clinical_trial	NCT03904069	"Study Evaluating the Safety, Tolerability, and Efficacy of FLT3 CAR-T AMG 553 in FLT3-positive Relapsed/Refractory AML"	24-Dec-20	Not yet recruiting	1U01CA232486-01
clinical_trial	NCT03971799	Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults With Relapsed/Refractory Acute Myeloid Leukemia	14-Oct-21	Recruiting	1U01CA232486-01
clinical_trial	NCT03971799	Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults With Relapsed/Refractory Acute Myeloid Leukemia	14-Oct-21	Recruiting	1U01CA232486-01
clinical_trial	NCT03722775	N/A	N/A	N/A	1U01CA232486-01
clinical_trial	NCT03631576	CD123/CLL1 CAR-T Cells for R/R AML (STPHI_0001)	2-Jan-20	Recruiting	1U01CA232486-01
clinical_trial	NCT03473457	CAR-T Cells Therapy in Relapsed/Refractory Acute Myeloid Leukemia (AML)	13-Sep-21	Terminated	1U01CA232486-01
clinical_trial	NCT04010877	Multiple CAR-T Cell Therapy Targeting AML	19-Sep-19	Recruiting	1U01CA232486-01
clinical_trial	NCT03585517	Safety and Efficacy Evaluation of IM23 CAR-T Cells (IM23CAR-T)	16-Jul-18	Unknown	1U01CA232486-01
clinical_trial	NCT03796390	Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With Acute Myelocytic Leukemia	11-Jan-19	Unknown	1U01CA232486-01
clinical_trial	NCT03556982	CART-123 FOR Relapsed/Refractory Acute Myelocytic Leukemia&#65288;AML&#65289;	14-Jun-18	Unknown	1U01CA232486-01
clinical_trial	NCT03330691	A Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia	24-May-21	Recruiting	1U01CA232486-01
clinical_trial	NCT03330691	A Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia	24-May-21	Recruiting	1U54CA232568-01
clinical_trial	NCT03330691	A Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia	24-May-21	Recruiting	1U54CA232561-01A1
clinical_trial	NCT03330691	A Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia	24-May-21	Recruiting	1U01CA247548-01
clinical_trial	NCT03330691	A Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia	24-May-21	Recruiting	3P30CA008748-54S3
clinical_trial	NCT03579927	"CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma"	29-Jan-20	Withdrawn	1U01CA232486-01
clinical_trial	NCT03579927	"CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma"	29-Jan-20	Withdrawn	1U01CA239258-01
clinical_trial	NCT04024761	A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation	20-Sep-21	Recruiting	1U01CA232486-01
clinical_trial	NCT02420717	Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia	26-Jan-21	Completed	1U01CA232486-01
clinical_trial	NCT02420717	Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia	26-Jan-21	Completed	1U01CA232486-01
clinical_trial	NCT02723994	A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia	22-Sep-21	Recruiting	1U01CA232486-01
clinical_trial	NCT02723994	A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia	22-Sep-21	Recruiting	1U01CA232486-01
clinical_trial	NCT03117751	Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma	27-Aug-21	Recruiting	1U01CA232486-01
clinical_trial	NCT03571321	Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia	16-Sep-21	Recruiting	1U01CA232486-01
clinical_trial	NCT01406756	Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations	8-Sep-21	"Active, not recruiting"	1U01CA232486-01
clinical_trial	NCT02343939	Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML) (ENTO in AML)	15-Nov-19	Terminated	1U01CA232486-01
clinical_trial	NCT02404220	Safety and Efficacy of Entospletinib With Vincristine and Dexamethasone in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)	2-Jan-20	Terminated	1U01CA232486-01
clinical_trial	NCT03135028	Entospletinib (ENTO) as Monotherapy and in Combination With Chemotherapy in Japanese Adults (Japanese AML)	6-Mar-20	Terminated	1U01CA232486-01
clinical_trial	NCT01141126	N/A	N/A	N/A	1U01CA232486-01
clinical_trial	NCT02141828	A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene	8-May-20	Completed	1U01CA232486-01
clinical_trial	NCT03705507	International Trial of Selumetinib in Combination With Dexamethasone for the Treatment of Acute Lymphoblastic Leukaemia (SeluDex)	19-Jan-21	Recruiting	1U01CA232486-01
clinical_trial	NCT00557193	Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia	25-Mar-21	"Active, not recruiting"	1U01CA232486-01
clinical_trial	NCT02883049	Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations	8-Sep-21	"Active, not recruiting"	1U01CA232486-01
clinical_trial	NCT02906371	Study of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release Syndrome	2-Jul-21	Completed	1U01CA232486-01
clinical_trial	NCT02716233	A French Protocol for the Treatment of Acute Lymphoblastic Leukemia (ALL) in Children and Adolescents (CAALL-F01)	19-Feb-19	Recruiting	1U01CA232486-01
clinical_trial	NCT01240538	Viral Therapy in Treating Young Patients With Relapsed or Refractory Solid Tumors	13-May-14	Completed	1U01CA232488-01
clinical_trial	NCT01048892	"Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features"	30-Jan-14	Completed	1U01CA232488-01
clinical_trial	NCT02457845	HSV G207 Alone or With a Single Radiation Dose in Children With Progressive or Recurrent Supratentorial Brain Tumors	8-Jul-21	"Active, not recruiting"	1U01CA232488-01
clinical_trial	NCT02457845	HSV G207 Alone or With a Single Radiation Dose in Children With Progressive or Recurrent Supratentorial Brain Tumors	8-Jul-21	"Active, not recruiting"	1U54CA232561-01A1
clinical_trial	NCT03043391	Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children	13-Jul-21	"Active, not recruiting"	1U01CA232488-01
clinical_trial	NCT03043391	Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children	13-Jul-21	"Active, not recruiting"	1U54CA232561-01A1
clinical_trial	NCT02756845	Study of Talimogene Laherparepvec In Children With Advanced Non CNS Tumors	19-Aug-21	Recruiting	1U01CA232488-01
clinical_trial	NCT00931931	HSV1716 in Patients With Non-Central Nervous System (Non-CNS) Solid Tumors	21-Mar-18	Completed	1U01CA232488-01
clinical_trial	NCT00931931	HSV1716 in Patients With Non-Central Nervous System (Non-CNS) Solid Tumors	21-Mar-18	Completed	1U54CA232561-01A1
clinical_trial	NCT01326104	Vaccine Immunotherapy for Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor (Re-MATCH)	24-Sep-21	"Active, not recruiting"	1U01CA232488-01
clinical_trial	NCT02932956	Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Patients With Pediatric Solid Tumors (GAP) (GAP)	8-Jan-21	Recruiting	1U01CA232488-01
clinical_trial	NCT02932956	Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Patients With Pediatric Solid Tumors (GAP) (GAP)	8-Jan-21	Recruiting	1U54CA232561-01A1
clinical_trial	NCT03500991	HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors	15-Mar-21	Recruiting	1U01CA232488-01
clinical_trial	NCT03500991	HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors	15-Mar-21	Recruiting	1U54CA232561-01A1
clinical_trial	NCT03638167	EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors	15-Mar-21	Recruiting	1U01CA232488-01
clinical_trial	NCT03638167	EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors	15-Mar-21	Recruiting	1U54CA232561-01A1
clinical_trial	NCT01555892	"Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE (GRALE)"	23-Dec-20	Recruiting	1U01CA232488-01
clinical_trial	NCT02892695	PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma	6-Dec-16	Unknown	1U01CA232488-01
clinical_trial	NCT02573896	Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells	20-Jan-21	Recruiting	1U01CA232488-01
clinical_trial	NCT02573896	Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells	20-Jan-21	Recruiting	1U01CA232491-01
clinical_trial	NCT02650648	Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma	1-Oct-21	"Active, not recruiting"	1U01CA232488-01
clinical_trial	NCT02650648	Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma	1-Oct-21	"Active, not recruiting"	1U01CA232491-01
clinical_trial	NCT03209869	Treatment of Relapsed or Refractory Neuroblastoma and Osteosarcoma With Expanded Haploidentical NK Cells and Hu14.18-IL2	5-Aug-21	Suspended	1U01CA232488-01
clinical_trial	NCT03420963	"Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors"	29-Apr-21	Recruiting	1U01CA232488-01
clinical_trial	NCT03420963	"Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors"	29-Apr-21	Recruiting	1U01CA232491-01
clinical_trial	NCT02100891	Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors (STIR)	24-Mar-21	"Active, not recruiting"	1U01CA232488-01
clinical_trial	NCT01823198	Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies	4-Dec-20	"Active, not recruiting"	1U01CA232488-01
clinical_trial	NCT01904136	"Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia"	10-Feb-21	"Active, not recruiting"	1U01CA232488-01
clinical_trial	NCT02809092	Interleukin-21 (IL-21)- Expanded Natural Killer Cells for Induction of Acute Myeloid Leukemia	15-Oct-19	Unknown	1U01CA232488-01
clinical_trial	NCT01619761	NK Cells in Cord Blood Transplantation	11-Feb-20	"Active, not recruiting"	1U01CA232488-01
clinical_trial	NCT03077477	Study of Orally-Administered AMXT 1501 Dicaprate in Normal Healthy Volunteers	14-Jun-18	Withdrawn	1U01CA232488-01
clinical_trial	NCT02484443	Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma	5-Aug-21	"Active, not recruiting"	1U01CA232491-01
clinical_trial	NCT02484443	Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma	5-Aug-21	"Active, not recruiting"	1U54CA232561-01A1
clinical_trial	NCT02484443	Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma	5-Aug-21	"Active, not recruiting"	3P30CA021765-41S3
clinical_trial	NCT01419834	Humanized 3F8 Monoclonal Antibody (Hu3F8) in Patients With High-Risk Neuroblastoma and GD2-Positive Tumors	25-Aug-21	"Active, not recruiting"	1U01CA232491-01
clinical_trial	NCT01662804	Humanized 3F8 Monoclonal Antibody (Hu3F8) When Combined With Interleukin-2 in Patients With High-Risk Neuroblastoma and GD2-positive Solid Tumors	27-May-21	Completed	1U01CA232491-01
clinical_trial	NCT02159443	Pretreatment Anti-Therapeutic Antibodies (PATA) in Patients Treated With hu14.18K322A Antibody	5-Nov-20	Completed	1U01CA232491-01
clinical_trial	NCT00743496	"A Phase I Trial Of The Humanized Anti-GD2 Antibody In Children And Adolescents With Neuroblastoma, Osteosarcoma, Ewing Sarcoma and Melanoma"	17-Aug-17	Completed	1U01CA232491-01
clinical_trial	NCT00743496	"A Phase I Trial Of The Humanized Anti-GD2 Antibody In Children And Adolescents With Neuroblastoma, Osteosarcoma, Ewing Sarcoma and Melanoma"	17-Aug-17	Completed	3P30CA021765-41S3
clinical_trial	NCT02982941	Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors	30-Jan-20	Completed	1U01CA232491-01
clinical_trial	NCT00582608	Tumor Detection Using Iodine-131-Labeled Monoclonal Antibody 8H9	1-Mar-17	Terminated	1U01CA232491-01
clinical_trial	NCT02173093	Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma	29-Jan-19	Unknown	1U01CA232491-01
clinical_trial	NCT03860207	"Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers"	25-May-21	Recruiting	1U01CA232491-01
clinical_trial	NCT03985852	"Broadening the Reach, Impact, and Delivery of Genetic Services (BRIDGE)"	27-Aug-21	Enrolling by invitation	1U01CA232826-01
clinical_trial	NCT00058474	Radiation Therapy and Either Capecitabine or Fluorouracil With or Without Oxaliplatin Before Surgery in Treating Patients With Resectable Rectal Cancer	23-Mar-16	Unknown	1U01CA232859-01
clinical_trial	NCT00058474	Radiation Therapy and Either Capecitabine or Fluorouracil With or Without Oxaliplatin Before Surgery in Treating Patients With Resectable Rectal Cancer	23-Mar-16	Unknown	1U01CA232859-01
clinical_trial	NCT01522443	Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer (COMET-2)	23-May-18	Terminated	1U01CA233046-01
clinical_trial	NCT02060188	"An Investigational Immuno-therapy Study of Nivolumab, and Nivolumab in Combination With Other Anti-cancer Drugs, in Colon Cancer That Has Come Back or Has Spread (CheckMate142)"	18-Oct-21	"Active, not recruiting"	1U01CA233056-01
clinical_trial	NCT02460198	Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Previously-Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer (MK-3475-164/KEYNOTE-164)	22-Mar-21	Completed	1U01CA233056-01
clinical_trial	NCT03631641	Nivolumab in Preventing Colon Adenomas in Participants With Lynch Syndrome and a History of Partial Colectomy	15-May-20	"Active, not recruiting"	1U01CA233056-01
clinical_trial	NCT01461148	Vaccination Against MSI Colorectal Cancer	23-Jun-15	Completed	1U01CA233056-01
clinical_trial	NCT01461148	Vaccination Against MSI Colorectal Cancer	23-Jun-15	Completed	1U01CA233056-01
clinical_trial	NCT01461148	Vaccination Against MSI Colorectal Cancer	23-Jun-15	Completed	1U01CA233097-01
clinical_trial	NCT01885702	Dendritic Cell Vaccination in Patients With Lynch Syndrome or Colorectal Cancer With MSI	22-Sep-21	"Active, not recruiting"	1U01CA233056-01
clinical_trial	NCT04131413	HPV DNA Vaccine Via Electroporation for HPV16 Positive Cervical Neoplasia	6-Jul-21	Recruiting	1U01CA233056-01
clinical_trial	NCT04131413	HPV DNA Vaccine Via Electroporation for HPV16 Positive Cervical Neoplasia	6-Jul-21	Recruiting	1U01CA233097-01
clinical_trial	NCT02950766	NeoVax Plus Ipilimumab in Renal Cell Carcinoma	3-Mar-21	Recruiting	1U01CA233100-01
clinical_trial	NCT03422094	"Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma"	23-Apr-21	Terminated	1U01CA233100-01
clinical_trial	NCT03361852	Personalized Neoantigen Cancer Vaccine + Pembrolizumab After Rituximab for Follicular Lymphoma	19-Oct-21	Not yet recruiting	1U01CA233100-01
clinical_trial	NCT03219450	"A Personalized Neoantigen Cancer Vaccine in Treatment Na&#239;ve, Asymptomatic Patients With IGHV Unmutated CLL."	21-Sep-21	Recruiting	1U01CA233100-01
clinical_trial	NCT02614456	Combination of Interferon-gamma and Nivolumab for Advanced Solid Tumors	29-Nov-19	Completed	1U01CA233100-01
clinical_trial	NCT02646748	Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors	4-Dec-20	"Active, not recruiting"	1U01CA233100-01
clinical_trial	NCT03012230	Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast Cancer	25-May-21	Recruiting	1U01CA233100-01
clinical_trial	NCT03425006	Pembrolizumab and Itacitinib (INCB039110) for NSCLC	16-Sep-21	"Active, not recruiting"	1U01CA233100-01
clinical_trial	NCT03147287	Palbociclib After CDK and Endocrine Therapy (PACE)	23-Aug-21	Recruiting	1U01CA233100-01
clinical_trial	NCT03573648	"Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer (ImmunoADAPT)"	2-Jun-21	Recruiting	1U01CA233100-01
clinical_trial	NCT03294694	Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer	29-Dec-20	"Active, not recruiting"	1U01CA233100-01
clinical_trial	NCT02779751	A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer	4-Mar-21	"Active, not recruiting"	1U01CA233100-01
clinical_trial	NCT02947165	Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.	8-Jul-21	Completed	1U01CA233100-01
clinical_trial	NCT02517398	MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors	22-Mar-21	"Active, not recruiting"	1U01CA233100-01
clinical_trial	NCT03620201	M7824 in Treating Patients With Stage II-III HER2 Positive Breast Cancer	14-Oct-21	Recruiting	1U01CA233100-01
clinical_trial	NCT03631706	M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC)	20-Oct-20	"Active, not recruiting"	1U01CA233100-01
clinical_trial	NCT00064129	Ipilimumab and Sargramostim in Treating Patients With Metastatic Prostate Cancer	30-Jul-20	Completed	1U01CA233100-01
clinical_trial	NCT01363206	Granulocyte Macrophage-Colony Stimulating Factor and Ipilimumab as Therapy in Melanoma (GIPI)	19-Mar-20	Completed	1U01CA233100-01
clinical_trial	NCT02451423	Neoadjuvant Atezolizumab in Localized Bladder Cancer	30-Mar-20	Recruiting	1U01CA233100-01
clinical_trial	NCT02451423	Neoadjuvant Atezolizumab in Localized Bladder Cancer	30-Mar-20	Recruiting	1U01CA244452-01
clinical_trial	NCT01693562	A Phase 1/2 Study to Evaluate MEDI4736	13-May-21	Completed	1U01CA233100-01
clinical_trial	NCT01942837	Phase II Trial of Enzalutamide for CRPC With Correlative Assessment of Androgen Receptor Signaling	12-Jan-21	"Active, not recruiting"	1U01CA233100-01
clinical_trial	NCT02703623	"Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer"	1-Oct-21	"Active, not recruiting"	1U01CA233100-01
clinical_trial	NCT02703623	"Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer"	1-Oct-21	"Active, not recruiting"	1U01CA244452-01
clinical_trial	NCT01688492	Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-na&#239;ve Patients With Progressive Metastatic Castration-resistant Prostate Cancer	10-Sep-21	"Active, not recruiting"	1U01CA233100-01
clinical_trial	NCT01688492	Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-na&#239;ve Patients With Progressive Metastatic Castration-resistant Prostate Cancer	10-Sep-21	"Active, not recruiting"	1U01CA244452-01
clinical_trial	NCT04388852	"DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers"	8-Oct-21	Recruiting	1U01CA233100-01
clinical_trial	NCT04388852	"DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers"	8-Oct-21	Recruiting	1U01CA244452-01
clinical_trial	NCT02787005	Study of Pembrolizumab (MK-3475) in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)(MK-3475-199/KEYNOTE-199)	23-Aug-21	"Active, not recruiting"	1U01CA233100-01
clinical_trial	NCT02787005	Study of Pembrolizumab (MK-3475) in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)(MK-3475-199/KEYNOTE-199)	23-Aug-21	"Active, not recruiting"	1U01CA244452-01
clinical_trial	NCT03834493	Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)	11-Oct-21	Recruiting	1U01CA233100-01
clinical_trial	NCT03834493	Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)	11-Oct-21	Recruiting	1U01CA244452-01
clinical_trial	NCT02312557	Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide	17-May-21	"Active, not recruiting"	1U01CA233100-01
clinical_trial	NCT02312557	Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide	17-May-21	"Active, not recruiting"	1U01CA244452-01
clinical_trial	NCT03770455	Avelumab Plus 2nd-generation ADT in African American Subjects With mCRPC	19-Oct-20	"Active, not recruiting"	1U01CA233100-01
clinical_trial	NCT03770455	Avelumab Plus 2nd-generation ADT in African American Subjects With mCRPC	19-Oct-20	"Active, not recruiting"	1U01CA244452-01
clinical_trial	NCT03338790	"An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CheckMate 9KD)"	30-Aug-21	"Active, not recruiting"	1U01CA233100-01
clinical_trial	NCT03338790	"An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CheckMate 9KD)"	30-Aug-21	"Active, not recruiting"	1U01CA244452-01
clinical_trial	NCT02861573	Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)	8-Oct-21	Recruiting	1U01CA233100-01
clinical_trial	NCT02861573	Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)	8-Oct-21	Recruiting	1U01CA244452-01
clinical_trial	NCT03658447	PRINCE (PSMA-lutetium Radionuclide Therapy and ImmuNotherapy in Prostate CancEr) (PRINCE)	23-Dec-20	"Active, not recruiting"	1U01CA233100-01
clinical_trial	NCT03658447	PRINCE (PSMA-lutetium Radionuclide Therapy and ImmuNotherapy in Prostate CancEr) (PRINCE)	23-Dec-20	"Active, not recruiting"	1U01CA244452-01
clinical_trial	NCT03093428	Study Evaluating the Addition of Pembrolizumab to Radium-223 in mCRPC	28-Jul-21	"Active, not recruiting"	1U01CA233100-01
clinical_trial	NCT03093428	Study Evaluating the Addition of Pembrolizumab to Radium-223 in mCRPC	28-Jul-21	"Active, not recruiting"	1U01CA244452-01
clinical_trial	NCT03834506	Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-na&#239;ve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)	9-Jun-21	"Active, not recruiting"	1U01CA233100-01
clinical_trial	NCT03834506	Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-na&#239;ve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)	9-Jun-21	"Active, not recruiting"	1U01CA244452-01
clinical_trial	NCT03248570	Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects	26-May-21	Recruiting	1U01CA233100-01
clinical_trial	NCT03248570	Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects	26-May-21	Recruiting	1U01CA244452-01
clinical_trial	NCT02998567	Combination Study of Guadecitabine and Pembrolizumab. (HyPeR)	17-Nov-20	"Active, not recruiting"	1U01CA233100-01
clinical_trial	NCT02998567	Combination Study of Guadecitabine and Pembrolizumab. (HyPeR)	17-Nov-20	"Active, not recruiting"	1U01CA244452-01
clinical_trial	NCT03572478	Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer	9-Mar-21	Terminated	1U01CA233100-01
clinical_trial	NCT03572478	Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer	9-Mar-21	Terminated	1U01CA244452-01
clinical_trial	NCT03834519	Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010) (KEYLYNK-010)	16-Sep-21	"Active, not recruiting"	1U01CA233100-01
clinical_trial	NCT03834519	Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010) (KEYLYNK-010)	16-Sep-21	"Active, not recruiting"	1U01CA244452-01
clinical_trial	NCT02484404	"Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can..."	5-Oct-21	Recruiting	1U01CA233100-01
clinical_trial	NCT02484404	"Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can..."	5-Oct-21	Recruiting	1U01CA244452-01
clinical_trial	NCT03330405	Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors	24-Sep-21	"Active, not recruiting"	1U01CA233100-01
clinical_trial	NCT03330405	Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors	24-Sep-21	"Active, not recruiting"	1U01CA244452-01
clinical_trial	NCT04446117	Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC (CONTACT-02)	17-Sep-21	Recruiting	1U01CA233100-01
clinical_trial	NCT04446117	Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC (CONTACT-02)	17-Sep-21	Recruiting	1U01CA244452-01
clinical_trial	NCT03849469	A Study of XmAb&#174;22841 Monotherapy &amp; in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors (DUET-4)	18-Aug-21	Recruiting	1U01CA233100-01
clinical_trial	NCT03849469	A Study of XmAb&#174;22841 Monotherapy &amp; in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors (DUET-4)	18-Aug-21	Recruiting	1U01CA244452-01
clinical_trial	NCT03406858	Pembrolizumab and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer	1-Mar-21	Recruiting	1U01CA233100-01
clinical_trial	NCT03406858	Pembrolizumab and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer	1-Mar-21	Recruiting	1U01CA244452-01
clinical_trial	NCT03217747	"Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies"	30-Oct-20	Recruiting	1U01CA233100-01
clinical_trial	NCT03217747	"Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies"	30-Oct-20	Recruiting	1U01CA244452-01
clinical_trial	NCT03821246	Atezolizumab With or Without Tocilizumab in Treating Men With Prostate Cancer Before Radical Prostatectomy	12-Nov-20	Recruiting	1U01CA233100-01
clinical_trial	NCT03821246	Atezolizumab With or Without Tocilizumab in Treating Men With Prostate Cancer Before Radical Prostatectomy	12-Nov-20	Recruiting	1U01CA244452-01
clinical_trial	NCT03473925	Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034)	2-Jul-21	Completed	1U01CA233100-01
clinical_trial	NCT03473925	Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034)	2-Jul-21	Completed	1U01CA244452-01
clinical_trial	NCT04020094	Perioperative Atezolizumab With MVA-BN-Brachyury and PROSTVAC For Intermediate-Risk And High-Risk Localized Prostate Cancer (AtezoVax)	22-Sep-21	Withdrawn	1U01CA233100-01
clinical_trial	NCT04020094	Perioperative Atezolizumab With MVA-BN-Brachyury and PROSTVAC For Intermediate-Risk And High-Risk Localized Prostate Cancer (AtezoVax)	22-Sep-21	Withdrawn	1U01CA244452-01
clinical_trial	NCT03835533	Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations (PORTER)	3-Aug-21	Recruiting	1U01CA233100-01
clinical_trial	NCT03835533	Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations (PORTER)	3-Aug-21	Recruiting	1U01CA244452-01
clinical_trial	NCT04090775	A Phase 2 Trial for Men With Metastatic Prostatic Adenocarcinoma	11-Oct-19	Recruiting	1U01CA233100-01
clinical_trial	NCT04090775	A Phase 2 Trial for Men With Metastatic Prostatic Adenocarcinoma	11-Oct-19	Recruiting	1U01CA244452-01
clinical_trial	NCT03518606	Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumours (MOVIE)	16-Sep-21	"Active, not recruiting"	1U01CA233100-01
clinical_trial	NCT03518606	Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumours (MOVIE)	16-Sep-21	"Active, not recruiting"	1U01CA244452-01
clinical_trial	NCT03532217	Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer	17-Sep-21	"Active, not recruiting"	1U01CA233100-01
clinical_trial	NCT03532217	Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer	17-Sep-21	"Active, not recruiting"	1U01CA244452-01
clinical_trial	NCT03204812	Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate Cancer	15-Apr-21	Completed	1U01CA233100-01
clinical_trial	NCT03204812	Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate Cancer	15-Apr-21	Completed	1U01CA244452-01
clinical_trial	NCT02985957	"Study of Nivolumab Plus Ipilimumab, Ipilimumab or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650)"	18-Oct-21	"Active, not recruiting"	1U01CA233100-01
clinical_trial	NCT02985957	"Study of Nivolumab Plus Ipilimumab, Ipilimumab or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650)"	18-Oct-21	"Active, not recruiting"	1U01CA244452-01
clinical_trial	NCT03879122	A Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancer	22-Sep-21	"Active, not recruiting"	1U01CA233100-01
clinical_trial	NCT03879122	A Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancer	22-Sep-21	"Active, not recruiting"	1U01CA244452-01
clinical_trial	NCT03866382	Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors	20-Oct-21	Recruiting	1U01CA233100-01
clinical_trial	NCT03866382	Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors	20-Oct-21	Recruiting	1U01CA244452-01
clinical_trial	NCT03454451	CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers	27-Jul-21	Recruiting	1U01CA233100-01
clinical_trial	NCT03454451	CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers	27-Jul-21	Recruiting	1U01CA244452-01
clinical_trial	NCT02655822	Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers	30-Aug-21	Completed	1U01CA233100-01
clinical_trial	NCT02655822	Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers	30-Aug-21	Completed	1U01CA244452-01
clinical_trial	NCT04089553	"An Open-label, Phase II Study of AZD4635 in Patients With Prostate Cancer"	3-Aug-21	"Active, not recruiting"	1U01CA233100-01
clinical_trial	NCT04089553	"An Open-label, Phase II Study of AZD4635 in Patients With Prostate Cancer"	3-Aug-21	"Active, not recruiting"	1U01CA244452-01
clinical_trial	NCT02740985	A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies	30-Jul-21	"Active, not recruiting"	1U01CA233100-01
clinical_trial	NCT02740985	A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies	30-Jul-21	"Active, not recruiting"	1U01CA244452-01
clinical_trial	NCT04381832	Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer (ARC-6)	7-Oct-21	Recruiting	1U01CA233100-01
clinical_trial	NCT04381832	Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer (ARC-6)	7-Oct-21	Recruiting	1U01CA244452-01
clinical_trial	NCT03792841	"Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPC"	4-Oct-21	Recruiting	1U01CA233100-01
clinical_trial	NCT03792841	"Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPC"	4-Oct-21	Recruiting	1U01CA244452-01
clinical_trial	NCT04631601	Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)	7-Oct-21	Recruiting	1U01CA233100-01
clinical_trial	NCT04631601	Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)	7-Oct-21	Recruiting	1U01CA244452-01
clinical_trial	NCT03972657	Study of REGN5678 (Anti-PSMAxCD28) With Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-resistant Prostate Cancer	12-Jul-21	Recruiting	1U01CA233100-01
clinical_trial	NCT03972657	Study of REGN5678 (Anti-PSMAxCD28) With Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-resistant Prostate Cancer	12-Jul-21	Recruiting	1U01CA244452-01
clinical_trial	NCT04702737	A Study of AMG 757 in Participants With Neuroendocrine Prostate Cancer	15-Oct-21	Recruiting	1U01CA233100-01
clinical_trial	NCT04702737	A Study of AMG 757 in Participants With Neuroendocrine Prostate Cancer	15-Oct-21	Recruiting	1U01CA244452-01
clinical_trial	NCT04221542	Study of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer	2-Sep-21	Recruiting	1U01CA233100-01
clinical_trial	NCT04221542	Study of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer	2-Sep-21	Recruiting	1U01CA244452-01
clinical_trial	NCT03577028	Study of HPN424 in Patients With Advanced Prostate Cancer	5-Oct-20	Recruiting	1U01CA233100-01
clinical_trial	NCT03577028	Study of HPN424 in Patients With Advanced Prostate Cancer	5-Oct-20	Recruiting	1U01CA244452-01
clinical_trial	NCT04397276	A Study of JNJ-70218902 in Participants With Advanced Stage Solid Tumors	8-Oct-21	Recruiting	1U01CA233100-01
clinical_trial	NCT04397276	A Study of JNJ-70218902 in Participants With Advanced Stage Solid Tumors	8-Oct-21	Recruiting	1U01CA244452-01
clinical_trial	NCT03873805	PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer	10-Mar-21	Recruiting	1U01CA233100-01
clinical_trial	NCT03873805	PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer	10-Mar-21	Recruiting	1U01CA244452-01
clinical_trial	NCT03873805	PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer	10-Mar-21	Recruiting	3P30CA013696-45S1
clinical_trial	NCT03753243	Neoadjuvant Pembrolizumab Plus Androgen Axis Blockade Prior to Prostatectomy for High Risk Localized Prostate Cancer	23-Sep-20	Recruiting	1U01CA233100-01
clinical_trial	NCT03753243	Neoadjuvant Pembrolizumab Plus Androgen Axis Blockade Prior to Prostatectomy for High Risk Localized Prostate Cancer	23-Sep-20	Recruiting	1U01CA244452-01
clinical_trial	NCT03810105	A Study of Olaparib and Durvalumab in Prostate Cancer	16-Sep-21	Recruiting	1U01CA233100-01
clinical_trial	NCT03810105	A Study of Olaparib and Durvalumab in Prostate Cancer	16-Sep-21	Recruiting	1U01CA244452-01
clinical_trial	NCT03016312	"A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen (IMbassador250)"	19-Aug-21	"Active, not recruiting"	1U01CA233100-01
clinical_trial	NCT03016312	"A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen (IMbassador250)"	19-Aug-21	"Active, not recruiting"	1U01CA244452-01
clinical_trial	NCT01804465	Sipuleucel-T With Immediate vs. Delayed Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Blockade for Prostate Cancer	18-Aug-21	Completed	1U01CA233100-01
clinical_trial	NCT01804465	Sipuleucel-T With Immediate vs. Delayed Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Blockade for Prostate Cancer	18-Aug-21	Completed	1U01CA244452-01
clinical_trial	NCT03958383	"IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma"	8-Oct-21	Recruiting	1U01CA233102-01
clinical_trial	NCT03958383	"IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma"	8-Oct-21	Recruiting	1U01CA233102-01
clinical_trial	NCT03958383	"IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma"	8-Oct-21	Recruiting	1U54CA232568-01
clinical_trial	NCT02504372	Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091) (PEARLS)	17-Jul-20	"Active, not recruiting"	1U01CA233102-01
clinical_trial	NCT02998528	A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC) (CheckMate 816)	26-Aug-20	"Active, not recruiting"	1U01CA233102-01
clinical_trial	NCT04025879	"A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer"	21-Sep-21	Recruiting	1U01CA233102-01
clinical_trial	NCT04214262	Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer	20-Oct-21	Recruiting	1U01CA233102-01
clinical_trial	NCT02306954	Study of High Dose Interleukin-2 (IL-2) and Stereotactic Body Radiation (SBRT) in Patients With Metastatic Renal Cancer	3-Mar-20	Recruiting	1U01CA233102-01
clinical_trial	NCT02306954	Study of High Dose Interleukin-2 (IL-2) and Stereotactic Body Radiation (SBRT) in Patients With Metastatic Renal Cancer	3-Mar-20	Recruiting	1U54CA232568-01
clinical_trial	NCT03294954	GD2 Specific CAR and Interleukin-15 Expressing Autologous NKT Cells to Treat Children With Neuroblastoma (GINAKIT2)	15-Jan-21	Recruiting	1U01CA239258-01
clinical_trial	NCT03294954	GD2 Specific CAR and Interleukin-15 Expressing Autologous NKT Cells to Treat Children With Neuroblastoma (GINAKIT2)	15-Jan-21	Recruiting	3P30CA021765-41S3
clinical_trial	NCT03545815	Study of CRISPR-Cas9 Mediated PD-1 and TCR Gene-knocked Out Mesothelin-directed CAR-T Cells in Patients With Mesothelin Positive Multiple Solid Tumors.	10-Aug-20	Recruiting	1U01CA239258-01
clinical_trial	NCT03545815	Study of CRISPR-Cas9 Mediated PD-1 and TCR Gene-knocked Out Mesothelin-directed CAR-T Cells in Patients With Mesothelin Positive Multiple Solid Tumors.	10-Aug-20	Recruiting	3P30CA021765-41S3
clinical_trial	NCT02414269	Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin	1-Apr-21	Recruiting	1U01CA239258-01
clinical_trial	NCT04003649	IL13Ralpha2-Targeted Chimeric Antigen Receptor (CAR) T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With Recurrent or Refractory Glioblastoma	9-Dec-20	Recruiting	1U01CA239258-01
clinical_trial	NCT02498912	Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors	8-Feb-21	"Active, not recruiting"	1U01CA239258-01
clinical_trial	NCT04093648	T Cells co- Expressing a Second Generation Glypican 3-specific Chimeric Antigen Receptor With Cytokines Interleukin-21 and 15 as Immunotherapy for Patients With Liver Cancer (TEGAR)	20-May-20	Withdrawn	1U01CA239258-01
clinical_trial	NCT03721068	Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma	7-Jul-21	Recruiting	1U01CA239258-01
clinical_trial	NCT03412877	Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer	29-Jan-21	Suspended	1U01DE028227-01
clinical_trial	NCT03937141	Efficacy and Safety Trial of ADU-S100 and Pembrolizumab in Head and Neck Cancer	10-Mar-21	"Active, not recruiting"	1U01DE028227-01
clinical_trial	NCT02014909	A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors	24-Jul-17	Completed	1U01DE028227-01
clinical_trial	NCT03254927	A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma	28-Apr-21	Completed	1U01DE028227-01
clinical_trial	NCT03637491	"A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors"	23-Jul-21	Terminated	1U01DE028233-01
clinical_trial	NCT03598270	Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer (ANITA)	13-Aug-21	Recruiting	1U01DE028233-01
clinical_trial	NCT01069081	Docetaxel and Cisplatin Chemotherapy With or Without High Dose Proton Pump Inhibitor in Metastatic Breast Cancer	6-Mar-15	Completed	1U01DE028233-01
clinical_trial	NCT02595372	Inhibiting Fatty Acid Synthase to Improve Efficacy of Neoadjuvant Chemotherapy	8-Apr-21	Completed	1U01DE028233-01
clinical_trial	NCT04317092	Tocilizumab in COVID-19 Pneumonia (TOCIVID-19) (TOCIVID-19)	3-Mar-21	"Active, not recruiting"	1U24CA233032-01
clinical_trial	NCT04315298	Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19	23-Sep-21	Completed	1U24CA233032-01
clinical_trial	NCT02639546	Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors (iMATRIXcobi)	30-Sep-21	"Active, not recruiting"	1U2CCA233262-01
clinical_trial	NCT03095248	Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors (SEL-TH-1601)	23-Jul-21	Recruiting	1U2CCA233262-01
clinical_trial	NCT02523014	"Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas"	12-Oct-21	Recruiting	1U2CCA233262-01
clinical_trial	NCT02831257	AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas	22-Dec-20	Completed	1U2CCA233262-01
clinical_trial	NCT03071874	Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas	20-Jan-21	"Active, not recruiting"	1U2CCA233262-01
clinical_trial	NCT02457910	Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer	23-Feb-21	"Active, not recruiting"	1U2CCA233280-01
clinical_trial	NCT02456857	"Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative"	13-Apr-21	"Active, not recruiting"	1U2CCA233280-01
clinical_trial	NCT03805399	FUSCC Refractory TNBC Umbrella (FUTURE) (FUTURE)	5-Feb-20	Recruiting	1U2CCA233280-01
clinical_trial	NCT03487666	OXEL: Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for TNBC With Residual Disease	16-Sep-21	"Active, not recruiting"	1U2CCA233280-01
clinical_trial	NCT01042379	I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (I-SPY)	27-Aug-21	Recruiting	1U2CCA233280-01
clinical_trial	NCT01042379	I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (I-SPY)	27-Aug-21	Recruiting	3P30CA016058-44S3
clinical_trial	NCT03801369	Olaparib and Durvalumab in Treating Patients With Metastatic Triple Negative Breast Cancer	11-Jun-21	Recruiting	1U2CCA233280-01
clinical_trial	NCT02884102	MMRF Molecular Profiling Protocol	19-Mar-19	Recruiting	1U2CCA233303-01
clinical_trial	NCT03600649	Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas	30-Sep-21	Recruiting	1U54CA231641-01
clinical_trial	NCT03600649	Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas	30-Sep-21	Recruiting	3R01CA204915-02S1
clinical_trial	NCT01023386	A Clinical Pharmacological Study of YM155 After Intravenous Infusion in Patients With Advanced Cancer	13-Apr-10	Completed	1U54CA231652-01
clinical_trial	NCT00818480	An Extension Study Administering YM155 to Subjects Previously Enrolled in Another Protocol Administering YM155	4-Sep-15	Completed	1U54CA231652-01
clinical_trial	NCT01007292	A Study of YM155 Plus Rituximab in Subjects With Non-Hodgkin's Lymphoma Who Have Received Prior Treatment	19-Oct-15	Completed	1U54CA231652-01
clinical_trial	NCT01009775	A Study of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma	4-Sep-15	Completed	1U54CA231652-01
clinical_trial	NCT01038804	A Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer	18-Sep-13	Completed	1U54CA231652-01
clinical_trial	NCT00498914	Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects	4-Sep-15	Terminated	1U54CA231652-01
clinical_trial	NCT01100931	"A Phase I/II Study of Paclitaxel, Carboplatin and YM155 (Survivin Suppressor) in Subjects With Solid Tumors (Phase I) and Advanced Non-Small Cell Lung Carcinoma (Phase II)"	19-Oct-15	Completed	1U54CA231652-01
clinical_trial	NCT00514267	An Open-Label Study of YM155 + Docetaxel in Subjects With Advanced Hormone Refractory Prostate Cancer and Other Solid Tumors	13-Aug-15	Completed	1U54CA231652-01
clinical_trial	NCT00281541	A Study for the Treatment of Unresectable Stage III or Metastatic Stage IV Melanoma	7-Jun-12	Completed	1U54CA231652-01
clinical_trial	NCT00328588	LUCY: A Study for the Treatment of Non-Small Cell Lung Cancer (NSCLC) in Patients Previously Treated With Chemotherapy	2-Jan-08	Completed	1U54CA231652-01
clinical_trial	NCT00257478	A Study for the Treatment of Hormone Refractory Prostate Cancer (HRPC) in Patients Previously Treated With Chemotherapy	7-Jun-12	Completed	1U54CA231652-01
clinical_trial	NCT00902044	Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma	24-Aug-21	"Active, not recruiting"	1U54CA232568-01
clinical_trial	NCT00902044	Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma	24-Aug-21	"Active, not recruiting"	1U54CA232561-01A1
clinical_trial	NCT02453594	Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-087/KEYNOTE-087)	19-Apr-21	"Active, not recruiting"	1U54CA232568-01
clinical_trial	NCT02992964	Pilot Study of Nivolumab in Pediatric Patients With Hypermutant Cancers	15-Feb-21	"Active, not recruiting"	1U54CA232568-01
clinical_trial	NCT02311621	Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01	27-Apr-21	Recruiting	1U54CA232568-01
clinical_trial	NCT02311621	Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01	27-Apr-21	Recruiting	1U54CA232561-01A1
clinical_trial	NCT03233854	CD19/CD22 Chimeric Antigen Receptor(CAR) T Cells in Adults With Recurrent/Refractory B Cell Malignancies	17-Aug-21	Recruiting	1U54CA232568-01
clinical_trial	NCT03233854	CD19/CD22 Chimeric Antigen Receptor(CAR) T Cells in Adults With Recurrent/Refractory B Cell Malignancies	17-Aug-21	Recruiting	3P30CA016520-44S5
clinical_trial	NCT03233854	CD19/CD22 Chimeric Antigen Receptor(CAR) T Cells in Adults With Recurrent/Refractory B Cell Malignancies	17-Aug-21	Recruiting	3P30CA016520-44S6
clinical_trial	NCT04088890	Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies	3-Aug-21	Recruiting	1U54CA232568-01
clinical_trial	NCT01850628	NSABP Biospecimen Discovery Project	5-Oct-21	"Active, not recruiting"	1U54CA233223-01
clinical_trial	NCT04410302	Patient-Derived Xenografts to Reduce Cancer Health Disparities	13-Jul-21	Recruiting	1U54CA233306-01
clinical_trial	NCT02569723	Oxaliplatin Microdosing Assay in Predicting Exposure and Sensitivity to Oxaliplatin-Based Chemotherapy	30-Mar-21	Completed	1U54CA233306-01
clinical_trial	NCT02807805	"Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer"	19-Mar-21	Recruiting	1U54CA233306-01
clinical_trial	NCT04514341	Implementing a Multilevel Intervention to Accelerate Colorectal Cancer Screening and Follow-up	14-Aug-20	Not yet recruiting	1UG3CA233229-01
clinical_trial	NCT04514341	Implementing a Multilevel Intervention to Accelerate Colorectal Cancer Screening and Follow-up	14-Aug-20	Not yet recruiting	1UG3CA233229-01
clinical_trial	NCT04406714	"Scaling CRC Screening Through Outreach, Referral, and Engagement (SCORE) (SCORE)"	12-May-21	Recruiting	1UG3CA233251-01
clinical_trial	NCT04427527	Accelerating Colorectal Cancer Screening Through Implementation Science in Appalachia (ACCSIS)	3-May-21	Recruiting	1UG3CA233282-01
clinical_trial	NCT04427527	Accelerating Colorectal Cancer Screening Through Implementation Science in Appalachia (ACCSIS)	3-May-21	Recruiting	3P30CA016058-44S3
clinical_trial	NCT04427527	Accelerating Colorectal Cancer Screening Through Implementation Science in Appalachia (ACCSIS)	3-May-21	Recruiting	3P30CA177558-08S2
clinical_trial	NCT03892967	"Enhanced, EHR-facilitated Cancer Symptom Control (E2C2) Pragmatic Clinical Trial (E2C2)"	13-Aug-21	Recruiting	1UM1CA233033-01
clinical_trial	NCT03988543	"Bilingual Electronic Symptom Management Program Across Multi-site, Comprehensive Cancer Center (NU IMPACT)"	3-Mar-21	Recruiting	1UM1CA233035-01
clinical_trial	NCT03850912	Symptom Management Implementation of Patient Reported Outcomes in Oncology (SIMPRO)	16-Sep-20	Recruiting	1UM1CA233080-01
clinical_trial	NCT04199026	Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma	14-Oct-21	Not yet recruiting	3R01CA180279-05S1
clinical_trial	NCT01231906	Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma	6-May-21	"Active, not recruiting"	3R01CA204915-02S1
clinical_trial	NCT02579226	"A Phase I Study of Safety, Tolerability, and PK of AZD2811 in Patients With Advanced Solid Tumors."	1-May-20	Completed	3R01CA204915-02S1
clinical_trial	NCT02657005	TK216 in Patients With Relapsed or Refractory Ewing Sarcoma	23-Aug-21	Recruiting	3R01CA204915-02S1
clinical_trial	NCT00070109	Trabectedin in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of Tumors	14-Sep-18	Completed	3R01CA204915-02S1
clinical_trial	NCT01610570	Mithramycin for Children and Adults With Solid Tumors or Ewing Sarcoma	2-Mar-18	Terminated	3R01CA204915-02S1
clinical_trial	NCT01610570	Mithramycin for Children and Adults With Solid Tumors or Ewing Sarcoma	2-Mar-18	Terminated	3P30CA177558-08S2
clinical_trial	NCT03456700	Auranofin and Sirolimus in Treating Participants With Ovarian Cancer	16-Mar-21	"Active, not recruiting"	3U54CA224065-01S1
clinical_trial	NCT03414034	Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer	23-Mar-21	Recruiting	3U54CA224065-01S1
clinical_trial	NCT03303339	Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML)	27-May-21	"Active, not recruiting"	3U54CA224065-01S1
clinical_trial	NCT02864992	Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)	22-Sep-21	"Active, not recruiting"	3U54CA224065-01S1
clinical_trial	NCT03066206	Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC	9-Sep-21	Recruiting	3U54CA224065-01S1
clinical_trial	NCT00983424	Cyclosporine A in Combination With Nab-Paclitaxel in Patients With Metastatic Breast Cancer	16-Sep-13	Completed	3U54CA224065-01S1
clinical_trial	NCT02188264	Selumetinib and Cyclosporine in Treating Patients With Advanced Solid Tumors or Advanced or Metastatic Colorectal Cancer	2-Apr-21	"Active, not recruiting"	3U54CA224065-01S1
clinical_trial	NCT00003950	"Irinotecan and Cyclosporine in Treating Patients With Metastatic, Advanced or Locally Recurrent Colorectal Cancer"	7-Mar-14	Completed	3U54CA224065-01S1
clinical_trial	NCT03538938	Improving Quitline Support Study (IQS)	12-Oct-21	Enrolling by invitation	5R01CA218156-02
clinical_trial	NCT02936609	Assessing Community Cancer Care After Insurance ExpanSionS (ACCESS)	30-Aug-21	Completed	1P50CA244289-01
clinical_trial	NCT03545763	Evaluating Control of Hypertension - Effect of Social Determinants (ECHOES)	23-Mar-21	"Active, not recruiting"	1P50CA244289-01
clinical_trial	NCT03607617	ASCEND: ApproacheS to CHC ImplEmeNtation of SDH Data Collection and Action (ASCEND)	15-Jun-21	"Active, not recruiting"	1P50CA244289-01
clinical_trial	NCT04314284	Patient-Centered Intervention to Reduce Cancer Patients' Financial Toxicity	14-Jan-21	Recruiting	1P50CA244431-01
clinical_trial	NCT12345678	N/A	N/A	N/A	1P50CA244431-01
clinical_trial	NCT03799432	Collaborative Organizational Approach to Selecting and Tailoring Implementation Strategies (COAST-IS)	8-Jan-21	"Active, not recruiting"	1P50CA244431-01
clinical_trial	NCT04585919	Paired Promotion of Colorectal Cancer and Social Determinants of Health Screening	1-Apr-21	Enrolling by invitation	1P50CA244433-01
clinical_trial	NCT04302675	Adapting Motivational Interviewing for Maternal Immunizations (MI4MI) (MI4MI)	26-Jul-21	"Active, not recruiting"	1P50CA244688-01
clinical_trial	NCT05021133	Tele-Navigation of Lung Cancer Screening (Tele-Navi LCS)	31-Aug-21	Not yet recruiting	1P50CA244693-01
clinical_trial	NCT04337203	Shared Healthcare Actions and Reflections Electronic Systems in Survivorship	18-Jun-21	Recruiting	1P50CA244693-01
clinical_trial	NCT04746794	Early Detection of GEnetic Risk (EDGE)	10-Feb-21	Recruiting	1U01CA232795-01A1
clinical_trial	NCT04323774	Intervention For AYAS With Cancer Risk Syndromes (AYA-RISE)	13-Apr-21	Recruiting	1U01CA243688-01
clinical_trial	NCT00480363	QUIREDEX: Revlimid (Lenalidomide) and Dexamethasone (ReDex) Treatment Versus Observation in Patients With Smoldering Multiple Myeloma With High Risk of Progression (QUIREDEX)	31-Jul-13	Completed	1U01CA244291-01
clinical_trial	NCT01169337	Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma	18-May-21	"Active, not recruiting"	1U01CA244291-01
clinical_trial	NCT02681302	Check Point Inhibition After Autologous Stem Cell Transplantation in Patients at High Risk of Post Transplant Recurrence (CPIT001)	4-May-21	"Active, not recruiting"	1U01CA244291-01
clinical_trial	NCT02654132	An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)	14-Jul-20	"Active, not recruiting"	1U01CA244291-01
clinical_trial	NCT02289222	1454GCC: Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple Myeloma	5-Nov-19	Terminated	1U01CA244291-01
clinical_trial	NCT02036502	A Study of Pembrolizumab (MK-3475) in Combination With Standard of Care Treatments in Participants With Multiple Myeloma (MK-3475-023/KEYNOTE-023)	8-Apr-21	Terminated	1U01CA244291-01
clinical_trial	NCT02726581	"An Investigational Immuno-therapy Study of Nivolumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple Myeloma (CheckMate 602)"	6-Aug-21	"Active, not recruiting"	1U01CA244291-01
clinical_trial	NCT02431208	A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)	2-Apr-21	Completed	1U01CA244291-01
clinical_trial	NCT01592370	An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma	18-Jun-21	"Active, not recruiting"	1U01CA244291-01
clinical_trial	NCT03357952	"A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma"	15-Oct-21	"Active, not recruiting"	1U01CA244291-01
clinical_trial	NCT03015922	Viral Immunotherapy in Relapsed/Refractory Multiple Myeloma (MUKeleven)	22-Jan-20	"Active, not recruiting"	1U01CA244291-01
clinical_trial	NCT02514382	"Wild-Type Reovirus, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma"	3-May-19	Unknown	1U01CA244291-01
clinical_trial	NCT02101944	Wild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma	13-Aug-21	Recruiting	1U01CA244291-01
clinical_trial	NCT02192775	UARK 2014-21 A Phase II Trial of Oncolytic Virotherapy by Systemic Administration of Edmonston Strain of Measles Virus	19-Oct-20	Completed	1U01CA244291-01
clinical_trial	NCT03017820	"VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia, or T-cell Lymphoma"	27-Sep-21	Recruiting	1U01CA244291-01
clinical_trial	NCT01858558	Tadalafil and Lenalidomide Maintenance With or Without Activated Marrow Infiltrating Lymphocytes (MILs) in High Risk Myeloma	29-Jun-20	Completed	1U01CA244291-01
clinical_trial	NCT03672318	Study of ATLCAR.CD138 Cells for Relapsed/Refractory Multiple Myeloma	30-Jun-21	Recruiting	1U01CA244291-01
clinical_trial	NCT03958656	T-cells Expressing an Anti-SLAMF7 CAR for Treating Multiple Myeloma	9-Sep-21	Completed	1U01CA244291-01
clinical_trial	NCT02181413	A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant	9-Mar-21	"Active, not recruiting"	1U01CA244291-01
clinical_trial	NCT00114101	Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant	23-Jun-21	"Active, not recruiting"	1U01CA244291-01
clinical_trial	NCT04939597	A Study to See if Memantine Protects the Brain During Radiation Therapy Treatment for a Brain Tumor	25-Jun-21	Not yet recruiting	1U01CA246568-01
clinical_trial	NCT04789720	Using Information Technology to Improve Outcomes for Children Living With Cancer (SyMon-SAYS)	18-Jun-21	Recruiting	1U01CA246612-01
clinical_trial	NCT04089358	"Mobile Health and Social Media Physical Activity Intervention Among Adolescent and Young Adult Childhood Cancer Survivors, the StepByStep Study"	19-Oct-21	Recruiting	1U01CA246665-01
clinical_trial	NCT02369874	Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer (EAGLE)	10-Feb-21	Completed	1U01DE029188-01
clinical_trial	NCT00404339	Vaccine Therapy in Treating Patients With Head and Neck Cancer	18-Apr-16	Completed	1U01DE029188-01
clinical_trial	NCT00257738	0804 GCC: MAGE-A3/HPV 16 Vaccine for Squamous Cell Carcinoma of the Head and Neck	17-Oct-19	Completed	1U01DE029188-01
clinical_trial	NCT02426892	Nivolumab and HPV-16 Vaccination in Patients With HPV-16 Positive Incurable Solid Tumors	17-Feb-20	"Active, not recruiting"	1U01DE029188-01
clinical_trial	NCT01147991	Vaccine Therapy in Treating Patients With Epstein-Barr Virus-Related Cancer	28-Feb-12	Completed	1U01DE029188-01
clinical_trial	NCT03821272	A Phase I/II Clinical Trial of PepCan in Head and Neck Cancer Patients	13-May-21	Recruiting	1U01DE029188-01
clinical_trial	NCT02002182	"ADXS 11-001 Vaccination Prior to Robotic Surgery, HPV-Positive Oropharyngeal Cancer"	2-Jul-21	"Active, not recruiting"	1U01DE029188-01
clinical_trial	NCT02865135	"Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer"	9-Sep-21	"Active, not recruiting"	1U01DE029188-01
clinical_trial	NCT03260023	Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers	29-Jun-21	Recruiting	1U01DE029188-01
clinical_trial	NCT03418480	HPV Anti-CD40 RNA Vaccine (HARE-40)	6-May-21	"Active, not recruiting"	1U01DE029188-01
clinical_trial	NCT04369937	HPV-16 Vaccination and Pembrolizumab Plus Cisplatin for &quot;Intermediate Risk&quot; HPV-16-associated Head and Neck Squamous Cell Carcinoma	20-Sep-21	Recruiting	1U01DE029188-01
clinical_trial	NCT02544880	PDE5 Inhibition Via Tadalafil to Enhance Anti-Tumor Mucin 1 (MUC1) Vaccine Efficacy in Patients With HNSCC	15-Jun-21	Completed	1U01DE029188-01
clinical_trial	NCT04247282	Anti-PD-L1/TGF-beta Trap (M7824) Alone and in Combination With TriAd Vaccine and N-803 for Resectable Head and Neck Squamous Cell Carcinoma Not Associated With Human Papillomavirus Infection	9-Jun-21	Suspended	1U01DE029188-01
clinical_trial	NCT02999646	Personalized and Cell-based Antitumor Immunization MVX-ONCO-1 in Advanced HNSCC	22-Sep-21	Recruiting	1U01DE029188-01
clinical_trial	NCT03568058	Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers	9-Dec-20	"Active, not recruiting"	1U01DE029188-01
clinical_trial	NCT04266730	Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab (PANDA-VAC)	8-Jul-21	Not yet recruiting	1U01DE029188-01
clinical_trial	NCT03689192	Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors	12-Feb-20	Recruiting	1U01DE029188-01
clinical_trial	NCT00019110	Vaccine Therapy in Treating Patients With Advanced or Recurrent Cancer	29-Apr-15	Completed	1U01DE029188-01
clinical_trial	NCT00019331	Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors	20-Jun-13	Completed	1U01DE029188-01
clinical_trial	NCT00021424	Vaccine Therapy in Treating Patients With Stage IV Head and Neck Cancer	30-Apr-15	Completed	1U01DE029188-01
clinical_trial	NCT00027534	Vaccine Therapy in Treating Patients With Advanced or Metastatic Cancer	8-Sep-14	Completed	1U01DE029188-01
clinical_trial	NCT01462838	Immune Therapy of HPV-induced Cancers	23-Jun-15	Completed	1U01DE029188-01
clinical_trial	NCT01998542	Safety and Tolerability Study of AlloVax(TM) in Patients With Metastatic or Recurrent Cancer of the Head and Neck (HNC)	23-Jan-20	Completed	1U01DE029188-01
clinical_trial	NCT02163057	Study of HPV Specific Immunotherapy in Participants With HPV Associated Head and Neck Squamous Cell Carcinoma	22-Jan-21	Completed	1U01DE029188-01
clinical_trial	NCT02291055	Phase 1-2 Study of ADXS11-001 or MEDI4736 Alone or Combo In Cervical or HPV+ Head &amp; Neck Cancer	19-Feb-20	"Active, not recruiting"	1U01DE029188-01
clinical_trial	NCT02526316	Cisplatin-based Chemotherapy Combined With P16_37-63 Peptide Vaccination in Patients With HPV-positive Cancers (VICORYX-2)	2-Jul-17	Completed	1U01DE029188-01
clinical_trial	NCT03162224	Safety and Efficacy of MEDI0457 and Durvalumab in Patients With HPV Associated Recurrent/Metastatic Head and Neck Cancer	27-Apr-21	Completed	1U01DE029188-01
clinical_trial	NCT03019003	Oral Decitabine (ASTX727) and Durvalumab in Recurrent and/or Metastatic Head and Neck Cancer Patients	1-Dec-20	Recruiting	1U01DE029188-01
clinical_trial	NCT03525795	ORIOn-E: A Study Evaluating CPI-1205 in Patients With Advanced Solid Tumors	11-Jan-21	Completed	1U01DE029188-01
clinical_trial	NCT03854474	Tazemetostat and Pembrolizumab in Treating Patients With Locally Advanced or Metastatic Urothelial Carcinoma	15-Oct-21	Recruiting	1U01DE029188-01
clinical_trial	NCT03635164	Radiotherapy With Durvalumab Prior to Surgical Resection for HPV Negative Squamous Cell Carcinoma	20-May-21	"Active, not recruiting"	1U01DE029255-01
clinical_trial	NCT01120288	"A Pilot Study of EZN-2968, an Antisense Oligonucleotide Inhibitor of HIF-1alpha, in Adults With Advanced Solid Tumors With Liver Metastases"	5-Jul-18	Completed	1U01DE029255-01
clinical_trial	NCT00466583	Phase 1 Study of EZN-2968 Weekly in Adult Patients With Advanced Solid Tumors or Lymphoma	7-Jul-11	Completed	1U01DE029255-01
clinical_trial	NCT01750580	Safety Study of BMS-986015 (Anti-KIR) in Combination With Ipilimumab in Subjects With Selected Advanced Tumor	22-Jul-15	Completed	1U54CA232561-01A1
clinical_trial	NCT02331875	Efficacy Study of Pre-operative IPH2201 in Patients With Squamous Cell Carcinoma of the Oral Cavity	4-Jan-17	Terminated	1U54CA232561-01A1
clinical_trial	NCT02141451	ADAM17 Inhibitor/ Rituximab After Auto HCT for DLBCL	19-Feb-20	Completed	1U54CA232561-01A1
clinical_trial	NCT02393859	Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)	8-Dec-20	"Active, not recruiting"	1U54CA232561-01A1
clinical_trial	NCT02559778	Pediatric Precision Laboratory Advanced Neuroblastoma Therapy (PEDS-PLAN)	11-Oct-21	Recruiting	1U54CA232561-01A1
clinical_trial	NCT03837899	Durvalumab and Tremelimumab for Pediatric Malignancies	22-Sep-21	Recruiting	1U54CA232561-01A1
clinical_trial	NCT04044378	Famitinib Plus Camrelizumab &amp; Famitinib Alone &amp; Famitinib Plus Ifosfamide in Advanced Osteosarcoma	19-May-20	Withdrawn	1U54CA232561-01A1
clinical_trial	NCT03130959	An Investigational Immuno-therapy Study of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Patients With High Grade Primary CNS Malignancies (CheckMate 908)	1-Apr-21	"Active, not recruiting"	1U54CA232561-01A1
clinical_trial	NCT03618381	EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults	19-Apr-21	Recruiting	1U54CA232561-01A1
clinical_trial	NCT03334305	Adoptive Cellular Therapy in Pediatric Patients With High-grade Gliomas (ACTION)	12-Aug-21	Recruiting	1U54CA232561-01A1
clinical_trial	NCT01192555	Allogeneic Tumor Cell Vaccination With Oral Metronomic Cytoxan in Patients With High-Risk Neuroblastoma (ATOMIC)	10-Mar-21	"Active, not recruiting"	1U54CA232561-01A1
clinical_trial	NCT03703050	"Nivolumab for Pediatric and Adult Relapsing/Refractory ALK+, for Evaluation of Response in Patients With Progressive Disease (Cohort 1) or as Consolidative Immunotherapy in Patients in Complete Remission After Relapse (Cohort 2) (NIVO-ALCL)"	7-Jul-21	Recruiting	1U54CA232561-01A1
clinical_trial	NCT03907488	Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma	20-Oct-21	Recruiting	1U54CA232561-01A1
clinical_trial	NCT02789228	Research Study Utilizing Expanded Multi-antigen Specific Lymphocytes for the Treatment of Solid Tumors (REST)	25-Feb-21	Recruiting	1U54CA232561-01A1
clinical_trial	NCT03396575	Brain Stem Gliomas Treated With Adoptive Cellular Therapy During Focal Radiotherapy Recovery Alone or With Dose-intensified Temozolomide (Phase I) (BRAVO)	13-Jul-21	Recruiting	1U54CA232561-01A1
clinical_trial	NCT03911388	HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors	8-Jul-21	Recruiting	1U54CA232561-01A1
clinical_trial	NCT03178032	"Oncolytic Adenovirus, DNX-2401, for Naive Diffuse Intrinsic Pontine Gliomas"	16-Jul-20	"Active, not recruiting"	1U54CA232561-01A1
clinical_trial	NCT02962167	Modified Measles Virus (MV-NIS) for Children and Young Adults With Recurrent Medulloblastoma or Recurrent ATRT	30-Jun-21	Recruiting	1U54CA232561-01A1
clinical_trial	NCT02444546	Wild-Type Reovirus in Combination With Sargramostim in Treating Younger Patients With High-Grade Relapsed or Refractory Brain Tumors	18-Aug-21	"Active, not recruiting"	1U54CA232561-01A1
clinical_trial	NCT03495921	Vigil + Irinotecan and Temozolomide in Ewing's Sarcoma (VITA)	18-Oct-21	"Active, not recruiting"	1U54CA232561-01A1
clinical_trial	NCT00790413	Haploidentical Stem Cell Transplantation in Neuroblastoma	21-Feb-21	"Active, not recruiting"	1U54CA232561-01A1
clinical_trial	NCT02793466	Durvalumab in Pediatric and Adolescent Patients	30-Jan-19	Unknown	1U54CA232561-01A1
clinical_trial	NCT01860937	T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia	6-Jul-21	"Active, not recruiting"	1U54CA232561-01A1
clinical_trial	NCT03006848	A Phase II Trial of Avelumab in Patients With Recurrent or Progressive Osteosarcoma	16-Sep-21	"Active, not recruiting"	1U54CA232561-01A1
clinical_trial	NCT00634231	A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors	27-Jan-21	"Active, not recruiting"	1U54CA232561-01A1
clinical_trial	NCT02511132	A Two-part Phase IIb Trial of Vigil in Ewing's Sarcoma	4-Feb-21	Completed	1U54CA232561-01A1
clinical_trial	NCT03299309	PEP-CMV in Recurrent MEdulloblastoma/Malignant Glioma (PRiME)	25-May-21	Suspended	1U54CA232561-01A1
clinical_trial	NCT03643276	Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017	7-Jul-21	Recruiting	1U54CA232561-01A1
clinical_trial	NCT03244306	A Phase 1 Study of CD22-CAR TCell Immunotherapy for CD22+ Leukemia and Lymphoma (PLAT-04)	19-Jan-21	"Active, not recruiting"	1U54CA232561-01A1
clinical_trial	NCT03244306	A Phase 1 Study of CD22-CAR TCell Immunotherapy for CD22+ Leukemia and Lymphoma (PLAT-04)	19-Jan-21	"Active, not recruiting"	1U01CA247548-01
clinical_trial	NCT03244306	A Phase 1 Study of CD22-CAR TCell Immunotherapy for CD22+ Leukemia and Lymphoma (PLAT-04)	19-Jan-21	"Active, not recruiting"	3P30CA008748-54S3
clinical_trial	NCT03769467	Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)	24-Sep-21	Completed	1U54CA232561-01A1
clinical_trial	NCT02960230	H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas	25-Aug-21	Recruiting	1U54CA232561-01A1
clinical_trial	NCT01700946	Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma	24-Aug-21	Completed	1U54CA232561-01A1
clinical_trial	NCT01169584	Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients	21-Jan-16	Completed	1U54CA232561-01A1
clinical_trial	NCT03359018	Apatinib Plus Anti-PD1 Therapy for Advanced Osteosarcoma (APFAO)	19-May-20	Completed	1U54CA232561-01A1
clinical_trial	NCT02403778	Ipilimumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma	29-Sep-21	"Active, not recruiting"	1U54CA232561-01A1
clinical_trial	NCT03225105	M3541 in Combination With Radiotherapy in Subjects With Solid Tumors	14-Sep-20	Completed	1U54CA244719-01
clinical_trial	NCT02588105	Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer (AToM)	18-Aug-21	"Active, not recruiting"	1U54CA244719-01
clinical_trial	NCT02494583	Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062)	10-Mar-21	"Active, not recruiting"	1U54CA244719-01
clinical_trial	NCT03189719	First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590/KEYNOTE-590)	20-Sep-21	"Active, not recruiting"	1U54CA244719-01
clinical_trial	NCT04941300	ColoRectal Cancer Screening for Southern California Community Health Centers	19-Jul-21	Enrolling by invitation	1UG3CA233314-01A1
clinical_trial	NCT04890054	"Screening More Patients for Colorectal Cancer Through Adapting and Refining Targeted Evidence-Based Interventions in Rural Settings, SMARTER CRC (SMARTER CRC)"	15-Jul-21	Recruiting	1UG3CA244298-01
clinical_trial	NCT01924689	Safety Study of Intratumoral Injection of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Standard Therapies	9-Sep-19	Completed	1UG3CA244687-01
clinical_trial	NCT04745754	The Engaging Primary Care in Cancer Survivorship (EPICS) Study (EPICS)	4-Aug-21	Not yet recruiting	1R01CA249419-01
clinical_trial	NCT04358276	"Technology-Enabled Activation of Skin Cancer Screening for Stem Cell Transplant Survivors and Their Primary Care Providers, TEACH Study"	16-Feb-21	Recruiting	1R01CA249460-01
clinical_trial	NCT05006482	Geriatric Evaluation and Management With Survivorship Health Education (GEMS) for Older Survivors of Cancer	31-Aug-21	Not yet recruiting	1R01CA249467-01
clinical_trial	NCT04428905	Self-Management Survivorship Care in Stage I-III Non-small Cell Lung Cancer or Colorectal Cancer	16-Feb-21	Recruiting	1R01CA249501-01
clinical_trial	NCT04494945	Identifying and Caring for Individuals With Inherited Cancer Syndrome	27-Sep-21	Recruiting	1U01CA232819-01A1
clinical_trial	NCT01865617	"Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia"	20-Jul-21	Completed	1U01CA247548-01
clinical_trial	NCT01865617	"Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia"	20-Jul-21	Completed	3P30CA008748-54S3
clinical_trial	NCT02706392	Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies	20-Oct-21	Recruiting	1U01CA247548-01
clinical_trial	NCT02706392	Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies	20-Oct-21	Recruiting	3P30CA008748-54S3
clinical_trial	NCT03103971	huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia	10-Sep-21	Recruiting	1U01CA247548-01
clinical_trial	NCT03103971	huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia	10-Sep-21	Recruiting	3P30CA008748-54S3
clinical_trial	NCT02631044	Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)	21-Jun-21	Recruiting	1U01CA247548-01
clinical_trial	NCT02631044	Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)	21-Jun-21	Recruiting	3P30CA008748-54S3
clinical_trial	NCT03277729	A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas	13-Jul-21	Recruiting	1U01CA247548-01
clinical_trial	NCT03277729	A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas	13-Jul-21	Recruiting	3P30CA008748-54S3
clinical_trial	NCT03105336	A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (ZUMA-5)	5-Aug-21	"Active, not recruiting"	1U01CA247548-01
clinical_trial	NCT03105336	A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (ZUMA-5)	5-Aug-21	"Active, not recruiting"	3P30CA008748-54S3
clinical_trial	NCT02614066	A Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-3) (ZUMA-3)	28-Jun-21	"Active, not recruiting"	1U01CA247548-01
clinical_trial	NCT02614066	A Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-3) (ZUMA-3)	28-Jun-21	"Active, not recruiting"	3P30CA008748-54S3
clinical_trial	NCT03331198	Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)	7-May-21	Recruiting	1U01CA247548-01
clinical_trial	NCT03331198	Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)	7-May-21	Recruiting	3P30CA008748-54S3
clinical_trial	NCT03575351	"A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas (TRANSFORM)"	10-Jun-21	"Active, not recruiting"	1U01CA247548-01
clinical_trial	NCT03575351	"A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas (TRANSFORM)"	10-Jun-21	"Active, not recruiting"	3P30CA008748-54S3
clinical_trial	NCT04365257	Prazosin to Prevent COVID-19 (PREVENT-COVID Trial) (PREVENT)	9-Jun-21	Recruiting	1U01CA247576-01
clinical_trial	NCT01684150	"A Phase 1, Open-Label, Dose-Escalation &amp; Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK &amp; PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving"	4-Aug-16	Completed	5R01CA176745-09
clinical_trial	NCT03701295	"Pinometostat and Azacitidine in Treating Patients With Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia With 11q23 Rearrangement"	9-Sep-21	Completed	5R01CA176745-09
clinical_trial	NCT03724084	Pinometostat With Standard Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and MLL Gene Rearrangement	8-Sep-21	"Active, not recruiting"	5R01CA176745-09
clinical_trial	NCT04065399	A Study of SNDX-5613 in R/R Leukemias Including Those With an MLLr/KMT2A Gene Rearrangement or NPM1 Mutation (AUGMENT-101)	6-May-21	Recruiting	5R01CA176745-09
clinical_trial	NCT04067336	First in Human Study of KO-539 in Relapsed or Refractory Acute Myeloid Leukemia	15-Oct-21	Recruiting	5R01CA176745-09
clinical_trial	NCT02698176	A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Advanced Solid Tumors (MK-8628-006)	27-Jan-21	Terminated	5R01CA176745-09
clinical_trial	NCT02259114	"A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003)"	26-Jan-21	Completed	5R01CA176745-09
clinical_trial	NCT02296476	A Dose-finding Study of Birabresib (MK-8628) in Participants With Recurrent Glioblastoma Multiforme (MK-8628-002)	26-Jan-21	Terminated	5R01CA176745-09
clinical_trial	NCT03068351	Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma	7-Feb-20	Completed	5R01CA176745-09
clinical_trial	NCT01987362	A Two Part Study of RO6870810. Dose-Escalation Study in Participants With Advanced Solid Tumors and Expansion Study in Participants With Selected Malignancies	5-Jan-18	Completed	5R01CA176745-09
clinical_trial	NCT03292172	"A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer"	6-Nov-20	Terminated	5R01CA176745-09
clinical_trial	NCT03255096	"A Study to Evaluate Safety, Pharmacokinetics, and Clinical Activity of Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory DLBCL and/or High-Grade B-Cell Lymphoma and/or High Grade B-Cell Lymphoma With MYC and/or BCL2 and/or BCL6"	28-Jan-21	Completed	5R01CA176745-09
clinical_trial	NCT04597359	To Evaluate if Green Tea Can be Effective in Reducing the Progression of Prostate Cancer in Men on Close Monitoring	18-Oct-21	Recruiting	3UG1CA189828-07S1
clinical_trial	NCT04467021	"Cancer and Blood Pressure Management, CARISMA Study"	5-Mar-21	Recruiting	3UG1CA189828-07S1
clinical_trial	NCT04438382	Infliximab and Intravenous Immunoglobulin Therapy in Treating Patients With Steroid-Refractory Pneumonitis	20-Aug-21	Recruiting	3UG1CA189828-07S1
clinical_trial	NCT04239573	Comparing Two Methods to Follow Patients With Pancreatic Cysts	6-Aug-21	Recruiting	3UG1CA189828-07S1
clinical_trial	NCT04001829	Docetaxel or Paclitaxel in Reducing Chemotherapy-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer	18-Oct-21	Recruiting	3UG1CA189828-07S1
clinical_trial	NCT03804255	Assessment of Current Biomarker Testing Practices for Common Solid Cancers in Precision Oncology in the Community Setting	3-Nov-20	"Active, not recruiting"	3UG1CA189828-07S1
clinical_trial	NCT02352883	MRI and Gene Expression in Diagnosing Patients With Ductal Breast Cancer In Situ	26-Oct-20	"Active, not recruiting"	3UG1CA189828-07S1
clinical_trial	NCT03253848	Simplified Patient Care Strategy in Decreasing Early Death in Patients With Acute Promyelocytic Leukemia	9-Mar-21	Recruiting	3UG1CA189828-07S1
clinical_trial	NCT02933489	Abbreviated Breast MRI and Digital Tomosynthesis Mammography in Screening Women With Dense Breasts	5-Feb-21	"Active, not recruiting"	3UG1CA189828-07S1
clinical_trial	NCT04321616	The Efficacy of Different Anti-viral Drugs in COVID 19 Infected Patients	14-Apr-20	Recruiting	3UG1CA189828-07S1
clinical_trial	NCT04321616	The Efficacy of Different Anti-viral Drugs in COVID 19 Infected Patients	14-Apr-20	Recruiting	3P30CA054174-25S2
clinical_trial	NCT04321616	The Efficacy of Different Anti-viral Drugs in COVID 19 Infected Patients	14-Apr-20	Recruiting	3P30CA013696-45S1
clinical_trial	NCT04321616	The Efficacy of Different Anti-viral Drugs in COVID 19 Infected Patients	14-Apr-20	Recruiting	3P30CA054174-25S1
clinical_trial	NCT04381936	Randomised Evaluation of COVID-19 Therapy (RECOVERY)	20-Oct-21	Recruiting	3UG1CA189828-07S1
clinical_trial	NCT04381936	Randomised Evaluation of COVID-19 Therapy (RECOVERY)	20-Oct-21	Recruiting	3P30CA054174-25S2
clinical_trial	NCT04381936	Randomised Evaluation of COVID-19 Therapy (RECOVERY)	20-Oct-21	Recruiting	3P30CA013696-45S1
clinical_trial	NCT04381936	Randomised Evaluation of COVID-19 Therapy (RECOVERY)	20-Oct-21	Recruiting	3P30CA054174-25S1
clinical_trial	NCT04381936	Randomised Evaluation of COVID-19 Therapy (RECOVERY)	20-Oct-21	Recruiting	3P30CA006516-55S9
clinical_trial	NCT04356937	Efficacy of Tocilizumab on Patients With COVID-19	27-Jul-21	Completed	3UG1CA189828-07S1
clinical_trial	NCT04356937	Efficacy of Tocilizumab on Patients With COVID-19	27-Jul-21	Completed	3P30CA054174-25S2
clinical_trial	NCT04356937	Efficacy of Tocilizumab on Patients With COVID-19	27-Jul-21	Completed	3P30CA013696-45S1
clinical_trial	NCT04356937	Efficacy of Tocilizumab on Patients With COVID-19	27-Jul-21	Completed	3P30CA054174-25S1
clinical_trial	NCT04372186	A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia (EMPACTA)	27-Sep-21	"Active, not recruiting"	3UG1CA189828-07S1
clinical_trial	NCT04372186	A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia (EMPACTA)	27-Sep-21	"Active, not recruiting"	3P30CA054174-25S2
clinical_trial	NCT04372186	A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia (EMPACTA)	27-Sep-21	"Active, not recruiting"	3P30CA013696-45S1
clinical_trial	NCT04372186	A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia (EMPACTA)	27-Sep-21	"Active, not recruiting"	3P30CA054174-25S1
clinical_trial	NCT04370834	Tocilizumab for Patients With Cancer and COVID-19 Disease	20-Jul-21	Terminated	3UG1CA189828-07S1
clinical_trial	NCT04370834	Tocilizumab for Patients With Cancer and COVID-19 Disease	20-Jul-21	Terminated	3P30CA054174-25S2
clinical_trial	NCT04370834	Tocilizumab for Patients With Cancer and COVID-19 Disease	20-Jul-21	Terminated	3P30CA013696-45S1
clinical_trial	NCT04370834	Tocilizumab for Patients With Cancer and COVID-19 Disease	20-Jul-21	Terminated	3P30CA054174-25S1
clinical_trial	NCT04354701	COVID-19 and Cancer Consortium Registry (CCC19)	9-Sep-21	Recruiting	3UG1CA189828-07S1
clinical_trial	NCT04354701	COVID-19 and Cancer Consortium Registry (CCC19)	9-Sep-21	Recruiting	3P30CA168524-09S3
clinical_trial	NCT04354701	COVID-19 and Cancer Consortium Registry (CCC19)	9-Sep-21	Recruiting	3P30CA054174-25S2
clinical_trial	NCT04354701	COVID-19 and Cancer Consortium Registry (CCC19)	9-Sep-21	Recruiting	3P30CA054174-25S2
clinical_trial	NCT04354701	COVID-19 and Cancer Consortium Registry (CCC19)	9-Sep-21	Recruiting	3P30CA046592-31S8
clinical_trial	NCT04354701	COVID-19 and Cancer Consortium Registry (CCC19)	9-Sep-21	Recruiting	3P30CA016058-44S3
clinical_trial	NCT04354701	COVID-19 and Cancer Consortium Registry (CCC19)	9-Sep-21	Recruiting	3P30CA046592-31S4
clinical_trial	NCT04354701	COVID-19 and Cancer Consortium Registry (CCC19)	9-Sep-21	Recruiting	3P30CA013696-45S1
clinical_trial	NCT04354701	COVID-19 and Cancer Consortium Registry (CCC19)	9-Sep-21	Recruiting	3P30CA013696-45S1
clinical_trial	NCT04354701	COVID-19 and Cancer Consortium Registry (CCC19)	9-Sep-21	Recruiting	3P30CA054174-25S1
clinical_trial	NCT04354701	COVID-19 and Cancer Consortium Registry (CCC19)	9-Sep-21	Recruiting	3P30CA054174-25S1
clinical_trial	NCT04354701	COVID-19 and Cancer Consortium Registry (CCC19)	9-Sep-21	Recruiting	3P30CA177558-08S2
clinical_trial	NCT04354701	COVID-19 and Cancer Consortium Registry (CCC19)	9-Sep-21	Recruiting	3P30CA177558-08S2
clinical_trial	NCT01642251	Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer	5-Feb-19	Completed	3UG1CA189828-07S1
clinical_trial	NCT02289690	Dose Escalation and Double-blind Study of Veliparib in Combination With Carboplatin and Etoposide in Treatment-naive Extensive Stage Disease Small Cell Lung Cancer	14-May-20	Completed	3UG1CA189828-07S1
clinical_trial	NCT00088907	Phase III Trial Of Docetaxel Versus Docetaxel Plus ZD1839 In Head And Neck Cancer	6-May-15	Terminated	3UG1CA189828-07S1
clinical_trial	NCT03904862	Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery	22-Sep-21	Recruiting	2UM1CA081457-21
clinical_trial	NCT03033992	Feasibility Trial of Optune for Children With Recurrent or Progressive Supratentorial High-Grade Glioma and Ependymoma	16-Sep-21	Recruiting	2UM1CA081457-21
clinical_trial	NCT01836549	Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors	20-Jul-18	Terminated	2UM1CA081457-21
clinical_trial	NCT00503724	Enzastaurin in Treating Young Patients With Refractory Primary CNS Tumors	6-Mar-12	Completed	2UM1CA081457-21
clinical_trial	NCT00357253	"Capecitabine and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Nonmetastatic Brain Stem Glioma or High-Grade Glioma"	10-Jan-13	Completed	2UM1CA081457-21
clinical_trial	NCT00112619	"Topotecan in Treating Young Patients With Neoplastic Meningitis Due to Leukemia, Lymphoma, or Solid Tumors"	30-Jun-11	Terminated	2UM1CA081457-21
clinical_trial	NCT01158300	PTC299 in Treating Young Patients With Refractory or Recurrent Primary Central Nervous System Tumors	4-May-15	Completed	2UM1CA081457-21
clinical_trial	NCT00572182	MK0752 in Treating Young Patients With Recurrent or Refractory CNS Cancer	6-Mar-12	Terminated	2UM1CA081457-21
clinical_trial	NCT00021229	Imatinib Mesylate With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed or Recurrent Glioma	31-Jul-14	Terminated	2UM1CA081457-21
clinical_trial	NCT01514201	"Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas"	13-Aug-19	Completed	2UM1CA081457-21
clinical_trial	NCT00770471	"ABT-888, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme"	27-Jun-18	Completed	2UM1CA081457-21
clinical_trial	NCT05071209	Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors	8-Oct-21	Not yet recruiting	5UM1CA228823-03
clinical_trial	NCT04870944	"CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma"	26-Aug-21	Not yet recruiting	5UM1CA228823-03
clinical_trial	NCT04851119	"Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors"	5-Sep-21	Not yet recruiting	5UM1CA228823-03
clinical_trial	NCT04158739	Flotetuzumab for the Treatment of Pediatric Recurrent or Refractory Acute Myeloid Leukemia	9-Sep-21	"Active, not recruiting"	5UM1CA228823-03
clinical_trial	NCT03316274	Intra-lesional Nivolumab Therapy for Limited Cutaneous Kaposi Sarcoma	15-Oct-21	Completed	3P30CA082103-21S9
clinical_trial	NCT03316274	Intra-lesional Nivolumab Therapy for Limited Cutaneous Kaposi Sarcoma	15-Oct-21	Completed	3P30CA082103-21S6
clinical_trial	NCT04335136	Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19 (APN01-COVID-19)	2-Aug-21	Completed	3P30CA082103-21S9
clinical_trial	NCT04335136	Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19 (APN01-COVID-19)	2-Aug-21	Completed	3P30CA082103-21S6
clinical_trial	NCT02073994	"Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation"	18-Aug-21	"Active, not recruiting"	3P30CA082103-21S9
clinical_trial	NCT02073994	"Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation"	18-Aug-21	"Active, not recruiting"	3P30CA082103-21S6
clinical_trial	NCT03343197	Study of AG-120 and AG-881 in Subjects With Low Grade Glioma	24-Aug-21	"Active, not recruiting"	3P30CA082103-21S9
clinical_trial	NCT03343197	Study of AG-120 and AG-881 in Subjects With Low Grade Glioma	24-Aug-21	"Active, not recruiting"	3P30CA082103-21S6
clinical_trial	NCT02481154	"Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Mutation"	24-Aug-21	"Active, not recruiting"	3P30CA082103-21S9
clinical_trial	NCT02481154	"Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Mutation"	24-Aug-21	"Active, not recruiting"	3P30CA082103-21S6
clinical_trial	NCT04164901	Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)	25-Jun-21	Recruiting	3P30CA082103-21S9
clinical_trial	NCT04164901	Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)	25-Jun-21	Recruiting	3P30CA082103-21S6
clinical_trial	NCT02746081	Phase I Study of BAY1436032 in IDH1-mutant Advanced Solid Tumors	23-Sep-21	"Active, not recruiting"	3P30CA082103-21S9
clinical_trial	NCT02746081	Phase I Study of BAY1436032 in IDH1-mutant Advanced Solid Tumors	23-Sep-21	"Active, not recruiting"	3P30CA082103-21S6
clinical_trial	NCT02273739	"Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation"	23-Feb-21	Completed	3P30CA082103-21S9
clinical_trial	NCT02273739	"Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation"	23-Feb-21	Completed	3P30CA082103-21S6
clinical_trial	NCT03684811	A Study of FT 2102 in Participants With Advanced Solid Tumors and Gliomas With an IDH1 Mutation	29-Mar-21	"Active, not recruiting"	3P30CA082103-21S9
clinical_trial	NCT03684811	A Study of FT 2102 in Participants With Advanced Solid Tumors and Gliomas With an IDH1 Mutation	29-Mar-21	"Active, not recruiting"	3P30CA082103-21S6
clinical_trial	NCT04106219	A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma	5-Oct-21	Recruiting	3P30CA082103-21S9
clinical_trial	NCT04106219	A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma	5-Oct-21	Recruiting	3P30CA125123-14S6
clinical_trial	NCT04106219	A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma	5-Oct-21	Recruiting	3P30CA082103-21S6
clinical_trial	NCT02926053	TIL Therapy for Metastatic Renal Cell Carcinoma	23-Dec-19	Recruiting	3P30CA168524-09S3
clinical_trial	NCT03158896	Evaluation of Umbilical Cord-Derived Wharton's Jelly Stem Cells for the Treatment of Acute Graft Versus Host Disease	19-Apr-21	Recruiting	3P30CA168524-09S3
clinical_trial	NCT03348514	"Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients With Advanced Solid Tumors"	1-Sep-20	Recruiting	3P30CA168524-09S3
clinical_trial	NCT04608045	"Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients With Advanced Solid Tumors"	20-Oct-21	Recruiting	3P30CA168524-09S3
clinical_trial	NCT04525131	"Safety, Dose Tolerance, Pharmacokinetics, Pharmacodynamics of CPX-POM in Patients With Newly Diagnosed or Recurrent Bladder Tumors"	19-Dec-20	Recruiting	3P30CA168524-09S3
clinical_trial	NCT02186821	Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE) (SIGNATURE)	8-Apr-21	Terminated	3P30CA168524-09S3
clinical_trial	NCT02963740	Feasibility of High Levels of Energy Expenditure From Physical Activity for Breast Cancer Survivors	6-Feb-19	Completed	3P30CA168524-09S3
clinical_trial	NCT03720111	N/A	N/A	N/A	3P30CA168524-09S3
clinical_trial	NCT01031953	Fosaprepitant Dimeglumine in Treating Patients With Nausea and Vomiting Caused By Chemotherapy	9-May-17	Terminated	3P30CA069533-22S5
clinical_trial	NCT01913015	Dietary Fat Levels and Abiraterone Acetate Uptake in Patients With Metastatic Hormone-Resistant Prostate Cancer	28-Apr-17	Terminated	3P30CA069533-22S5
clinical_trial	NCT01649505	Fibrin Sealant in Preventing Fluid Build Up During Surgery in Patients Undergoing Breast Reconstruction	15-Mar-13	Terminated	3P30CA069533-22S5
clinical_trial	NCT01005914	Pegaspargase and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia	4-Mar-15	Terminated	3P30CA069533-22S5
clinical_trial	NCT00900302	OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer	10-Feb-16	Completed	3P30CA069533-22S5
clinical_trial	NCT00899795	"Evaluating Cell Damage in Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, or Fanconi Anemia; in Patients Who Were Exposed to Alkylating Agents; and in Healthy Volunteers"	4-Dec-17	Completed	3P30CA069533-22S5
clinical_trial	NCT03677531	Video Distraction to Decrease Use of Sedation in Pediatric Participants During Radiation Therapy	4-May-20	Completed	3P30CA069533-22S5
clinical_trial	NCT03479268	Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma	7-Jul-21	Recruiting	3P30CA069533-22S5
clinical_trial	NCT03261180	Nestle Impact Advanced Recovery in Improving Surgery Recovery in Patients With Head and Neck Cancer	25-Feb-20	Withdrawn	3P30CA069533-22S5
clinical_trial	NCT00482274	Docetaxel in Treating Patients With Relapsed Prostate Cancer	28-Apr-17	Terminated	3P30CA069533-22S5
clinical_trial	NCT03406013	Internet-Based Exercise and Diet Support in Prostate Cancer Survivors	29-Jul-20	Completed	3P30CA069533-22S5
clinical_trial	NCT03406013	Internet-Based Exercise and Diet Support in Prostate Cancer Survivors	29-Jul-20	Completed	3P30CA069533-22S5
clinical_trial	NCT03630354	EXERCISING TOGETHER for Couples Coping With Cancer	24-Sep-21	Recruiting	3P30CA069533-22S5
clinical_trial	NCT04053673	"RBN-2397, an Oral PARP7 Inhibitor, in Patients With Solid Tumors , FIH, MAD Study"	26-Aug-21	Recruiting	3P30CA069533-22S5
clinical_trial	NCT01858922	"Chemotherapy With or Without Radiation, Low and Intermediate Risk Hodgkins Lymphoma, TXCH-HD-12A (TXCH-HD-12A)"	7-Jan-21	"Active, not recruiting"	3P30CA125123-14S6
clinical_trial	NCT03740256	"Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors (VISTA)"	23-Jul-21	Recruiting	3P30CA125123-14S6
clinical_trial	NCT00265759	"Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer"	12-Feb-20	Completed	3P30CA125123-14S6
clinical_trial	NCT01059071	Safety Study for Refractory or Relapsed Neuroblastoma With DFMO Alone and in Combination With Etoposide	18-Nov-20	Completed	3P30CA125123-14S6
clinical_trial	NCT02395666	Preventative Trial of Difluoromethylornithine (DFMO) in High Risk Patients With Neuroblastoma That is in Remission	18-Nov-20	"Active, not recruiting"	3P30CA125123-14S6
clinical_trial	NCT03536728	Oral AMXT 1501 Dicaprate in Combination With DFMO	20-Oct-21	Recruiting	3P30CA125123-14S6
clinical_trial	NCT00567229	Lenalidomide and Rituximab in Treating Patients With Recurrent and/or Refractory Multiple Myeloma	20-Nov-15	Terminated	3P30CA008748-54S3
clinical_trial	NCT00550628	Fludeoxyglucose F 18 PET Imaging in Determining Protein and Gene Expression Signatures in Patients With Premalignant Polyps or Colon Cancer	23-Dec-15	Completed	3P30CA008748-54S3
clinical_trial	NCT00541034	"Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia"	11-Aug-17	Completed	3P30CA008748-54S3
clinical_trial	NCT00519974	Factors Affecting Decisions About Breast Reconstruction After Mastectomy in Black and Latina Women	1-Oct-15	Completed	3P30CA008748-54S3
clinical_trial	NCT00514254	Risk Factors for Endometrial Cancer in Black Women	10-Aug-21	"Active, not recruiting"	3P30CA008748-54S3
clinical_trial	NCT00483678	Couples Therapy to Enhance Intimacy Between Patients With Advanced or Recurrent Prostate Cancer and Their Partners	6-Mar-18	Completed	3P30CA008748-54S3
clinical_trial	NCT00471679	Ethanol-Lock Treatment in Preventing Central Venous Catheter Infections in Patients With High-Risk Neuroblastoma	5-Mar-13	Completed	3P30CA008748-54S3
clinical_trial	NCT00471601	Development of a Questionnaire to Evaluate Patient Expectations for Breast Reconstruction in Women With Breast Cancer or Other Conditions	4-Oct-21	"Active, not recruiting"	3P30CA008748-54S3
clinical_trial	NCT00470574	Vaccine Therapy and QS21 in Treating Patients With Metastatic Breast Cancer	18-Nov-20	Completed	3P30CA008748-54S3
clinical_trial	NCT00462982	Sunitinib in Treating Patients With Brain Metastases Caused by Kidney Cancer or Melanoma	30-Dec-15	Completed	3P30CA008748-54S3
clinical_trial	NCT03617003	Treatment of Tumors in the Urinary Collecting System of the Kidney or Ureter Using a Light Activated Drug (WST11)	22-Apr-21	"Active, not recruiting"	3P30CA008748-54S3
clinical_trial	NCT03451383	Older Breast Cancer Patients: Risk for Cognitive Decline (TLC)	30-Jul-21	Recruiting	3P30CA008748-54S3
clinical_trial	NCT03451383	Older Breast Cancer Patients: Risk for Cognitive Decline (TLC)	30-Jul-21	Recruiting	3P30CA008748-54S3
clinical_trial	NCT02684032	A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer	27-Sep-21	"Active, not recruiting"	3P30CA008748-54S3
clinical_trial	NCT03535701	Ketogenic Diet and Chemotherapy in Affecting Recurrence in Patients With Stage IV Breast Cancer (KETO-CARE)	8-Sep-21	Completed	3P30CA008748-54S3
clinical_trial	NCT02399085	A Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCL (L-MIND)	29-Sep-21	"Active, not recruiting"	3P30CA008748-54S3
clinical_trial	NCT04150328	Lenalidomide Monotherapy in R/R DLBCL (RE-MIND)	16-Sep-20	Completed	3P30CA008748-54S3
clinical_trial	NCT04697160	Observational Retrospective Cohort Study of Systemic Therapies for R/R DLBCL (RE-MIND2)	20-Oct-21	Completed	3P30CA008748-54S3
clinical_trial	NCT02763319	A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) (B-MIND)	10-Jun-21	"Active, not recruiting"	3P30CA008748-54S3
clinical_trial	NCT03013491	PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas	5-Aug-21	"Active, not recruiting"	3P30CA008748-54S3
clinical_trial	NCT03013491	PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas	5-Aug-21	"Active, not recruiting"	3P30CA008748-54S3
clinical_trial	NCT03371420	PET Imaging of Subjects Using 124I-PU-AD	11-Jun-19	Completed	3P30CA008748-54S3
clinical_trial	NCT03935568	A Single and Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of PU-AD in Healthy Subjects	26-Dec-19	Completed	3P30CA008748-54S3
clinical_trial	NCT04311515	"To Evaluate Safety, Tolerability and Pharmacological Effects of PU AD in Subjects With Mild AD Dementia"	12-Oct-20	"Active, not recruiting"	3P30CA008748-54S3
clinical_trial	NCT04505358	Evaluate PU-AD in Subjects With Amyotrophic Lateral Sclerosis (ALS)	22-Sep-21	Not yet recruiting	3P30CA008748-54S3
clinical_trial	NCT04782609	Study of Icapamespib (PU-AD) in Patients With Recurrent Malignant Glioma (Glio)	22-Sep-21	Not yet recruiting	3P30CA008748-54S3
clinical_trial	NCT01269593	PET Imaging of Cancer Patients Using 124I-PUH71: A Pilot Study	20-Nov-20	"Active, not recruiting"	3P30CA008748-54S3
clinical_trial	NCT01888601	TRAcking Non-small Cell Lung Cancer Evolution Through Therapy (Rx) (TRACERx)	27-Jan-20	Recruiting	3P30CA008748-54S3
clinical_trial	NCT02201992	Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)	21-May-20	Recruiting	3P30CA008748-54S3
clinical_trial	NCT02193282	Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)	28-Sep-21	"Active, not recruiting"	3P30CA008748-54S3
clinical_trial	NCT03456076	A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer	18-Oct-21	Recruiting	3P30CA008748-54S3
clinical_trial	NCT04385368	Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC) (MERMAID-1)	20-Oct-21	Recruiting	3P30CA008748-54S3
clinical_trial	NCT04642469	Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy. (MERMAID-2)	20-Oct-21	Recruiting	3P30CA008748-54S3
clinical_trial	NCT04351555	A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer (NeoADAURA)	7-Oct-21	Recruiting	3P30CA008748-54S3
clinical_trial	NCT04712877	Testing Tumor Tissue and Blood to Help Select Personalized Treatments for Patients With Suspected Lung Cancers	4-Mar-21	Not yet recruiting	3P30CA008748-54S3
clinical_trial	NCT02194738	Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)	19-Oct-21	Recruiting	3P30CA008748-54S3
clinical_trial	NCT01865747	A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma (METEOR)	27-Apr-21	Completed	3P30CA008748-54S3
clinical_trial	NCT00562640	"Autologous T Cells With or Without Cyclophosphamide and Fludarabine in Treating Patients With Recurrent or Persistent Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer (Fludarabine Treatment Closed as of 12/01/2009)"	6-Aug-21	Completed	3P30CA008748-54S3
clinical_trial	NCT02550535	A Phase I/II Study of Gene-modified WT1 TCR Therapy in MDS &amp; AML Patients	2-Oct-18	Completed	3P30CA008748-54S3
clinical_trial	NCT02408016	Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma	13-Sep-21	Terminated	3P30CA008748-54S3
clinical_trial	NCT03130569	Skin Health Online for Melanoma: Better Risk Assessment (SOMBRA)	6-Oct-17	Completed	3P30CA008748-54S3
clinical_trial	NCT01458548	Sequential Treatment of CD20-positive Posttransplant Lymphoproliferative Disorder (PTLD)	25-Oct-11	Terminated	3P30CA008748-54S3
clinical_trial	NCT00066469	"Cyclophosphamide, Rituximab, and Either Prednisone or Methylprednisolone in Treating Patients With Lymphoproliferative Disease After Solid Organ Transplantation"	6-Aug-19	Completed	3P30CA008748-54S3
clinical_trial	NCT01058239	Bortezomib Plus Rituximab for EBV+ PTLD	15-Feb-18	Completed	3P30CA008748-54S3
clinical_trial	NCT02753062	Bendamustine Plus Subcutaneous Rituximab in Patients With Diffuse Large B-cell Lymphoma (PTLD)	27-Apr-16	Recruiting	3P30CA008748-54S3
clinical_trial	NCT02973113	"Nivolumab With Epstein Barr Virus Specific T Cells (EBVSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE) (PREVALE)"	21-Jul-21	Completed	3P30CA008748-54S3
clinical_trial	NCT01805037	Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas	1-Sep-21	Terminated	3P30CA008748-54S3
clinical_trial	NCT01075321	Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma	22-Oct-20	Completed	3P30CA008748-54S3
clinical_trial	NCT00918333	"Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma"	10-Mar-20	Completed	3P30CA008748-54S3
clinical_trial	NCT03397706	Dose Escalation &amp; Expansion Study of Oral VRx-3996 &amp; Valganciclovir in Subjects With EBV-Associated Lymphoid Malignancies	28-Jul-21	Recruiting	3P30CA008748-54S3
clinical_trial	NCT03397706	Dose Escalation &amp; Expansion Study of Oral VRx-3996 &amp; Valganciclovir in Subjects With EBV-Associated Lymphoid Malignancies	28-Jul-21	Recruiting	3P30CA016520-44S5
clinical_trial	NCT03397706	Dose Escalation &amp; Expansion Study of Oral VRx-3996 &amp; Valganciclovir in Subjects With EBV-Associated Lymphoid Malignancies	28-Jul-21	Recruiting	3P30CA016520-44S6
clinical_trial	NCT01261247	Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma	20-Oct-20	"Active, not recruiting"	3P30CA008748-54S3
clinical_trial	NCT03394365	Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy (ALLELE)	27-Sep-21	Recruiting	3P30CA008748-54S3
clinical_trial	NCT03394365	Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy (ALLELE)	27-Sep-21	Recruiting	3P30CA016520-44S5
clinical_trial	NCT03394365	Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy (ALLELE)	27-Sep-21	Recruiting	3P30CA016520-44S6
clinical_trial	NCT03131934	Immunotherapy With Tacrolimus Resistant EBV CTL for Lymphoproliferative Disease After Solid Organ Transplant (ITREC)	31-Mar-20	Recruiting	3P30CA008748-54S3
clinical_trial	NCT02779439	Partially HLA-matched Third Party Antigen Specific T-cells for Infection Post-stem Cell or Solid Organ Transplantation (R3ACT)	21-Jul-16	Unknown	3P30CA008748-54S3
clinical_trial	NCT02900976	"Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder"	30-Apr-21	"Active, not recruiting"	3P30CA008748-54S3
clinical_trial	NCT02822495	Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies	30-Sep-20	Available	3P30CA008748-54S3
clinical_trial	NCT01774071	Study of 89Zr-DFO-MSTP2109A in Patients With Prostate Cancer	4-Feb-21	"Active, not recruiting"	3P30CA008748-54S3
clinical_trial	NCT00933517	Assessment of the Efficacy of the Neoadjuvant Combination: &quot;Chemotherapy-Targeted Therapy&quot; in Breast Cancer. (TVA)	21-Mar-14	Completed	3P30CA008748-54S3
clinical_trial	NCT00600249	Assessment of the Efficacy of a Neoadjuvant Combination: &quot;Chemotherapy-targeted Therapy&quot; in Breast Cancer.	20-Mar-14	Completed	3P30CA008748-54S3
clinical_trial	NCT04258280	Improving Genetic Counseling for BRCA+ Mothers (PCS IV)	28-Oct-20	Recruiting	3P30CA008748-54S3
clinical_trial	NCT04248257	Peer Support For Young Adult Women With High Breast Cancer Risk	17-Aug-21	Recruiting	3P30CA008748-54S3
clinical_trial	NCT02494206	Immunotherapy for the Treatment of Breast Cancer Related Upper Extremity Lymphedema (BCRL)	8-Nov-18	Completed	3P30CA008748-54S3
clinical_trial	NCT02851407	Study Comparing Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients	22-Oct-20	Completed	3P30CA008748-54S3
clinical_trial	NCT03339297	An Open-Label Study of Defibrotide for the Prevention of Acute Graft-versus-Host-Disease (AGvHD)	18-Aug-21	Completed	3P30CA008748-54S3
clinical_trial	NCT03954106	A Safety and Efficacy Study of Defibrotide in the Prevention of Chimeric Antigen Receptor-T-cell-associated Neurotoxicity	27-May-21	Terminated	3P30CA008748-54S3
clinical_trial	NCT03805581	Defibrotide in Sickle Cell Disease-Related Acute Chest Syndrome	21-Feb-21	"Active, not recruiting"	3P30CA008748-54S3
clinical_trial	NCT03597581	A Study of RGX-202-01 as a Single Agent and as Combination Therapy in Patients With Advanced Gastrointestinal Malignancies	16-Sep-21	Recruiting	3P30CA008748-54S3
clinical_trial	NCT01418495	Pharmacokinetics of Ch14.18 in Younger Patients With High-Risk Neuroblastoma	1-Oct-19	Completed	3P30CA016520-44S5
clinical_trial	NCT01418495	Pharmacokinetics of Ch14.18 in Younger Patients With High-Risk Neuroblastoma	1-Oct-19	Completed	3P30CA016520-44S6
clinical_trial	NCT00679094	Bowman-Birk Inhibitor Concentrate in Healthy Men	29-Dec-16	Completed	3P30CA016520-44S5
clinical_trial	NCT00679094	Bowman-Birk Inhibitor Concentrate in Healthy Men	29-Dec-16	Completed	3P30CA016520-44S6
clinical_trial	NCT04464759	A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma (LIMIT)	16-Sep-21	Recruiting	3P30CA016520-44S5
clinical_trial	NCT04058470	Toripalimab in Combination With R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma	15-Mar-21	Recruiting	3P30CA016520-44S5
clinical_trial	NCT04058470	Toripalimab in Combination With R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma	15-Mar-21	Recruiting	3P30CA016520-44S6
clinical_trial	NCT04181489	"Sintilimab in Combination With R-CHOP in Patients With Treatment-naive EBV-positive DLBCL, NOS"	29-Nov-19	Recruiting	3P30CA016520-44S5
clinical_trial	NCT04181489	"Sintilimab in Combination With R-CHOP in Patients With Treatment-naive EBV-positive DLBCL, NOS"	29-Nov-19	Recruiting	3P30CA016520-44S6
clinical_trial	NCT04084626	PD1 Antibody and Lenalidomide as a Treatment for EBV-HLH or CAEBV	30-Jun-21	Recruiting	3P30CA016520-44S5
clinical_trial	NCT04084626	PD1 Antibody and Lenalidomide as a Treatment for EBV-HLH or CAEBV	30-Jun-21	Recruiting	3P30CA016520-44S6
clinical_trial	NCT03586024	"Pembrolizumab in Relapsed or Refractory Extranodal NK/T- Cell Lymphoma, Nasal Type and EBV-associated Diffuse Large B Cell Lymphomas"	7-May-21	Withdrawn	3P30CA016520-44S5
clinical_trial	NCT03586024	"Pembrolizumab in Relapsed or Refractory Extranodal NK/T- Cell Lymphoma, Nasal Type and EBV-associated Diffuse Large B Cell Lymphomas"	7-May-21	Withdrawn	3P30CA016520-44S6
clinical_trial	NCT03258567	Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas	22-Sep-21	Recruiting	3P30CA016520-44S5
clinical_trial	NCT03258567	Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas	22-Sep-21	Recruiting	3P30CA016520-44S6
clinical_trial	NCT03038672	Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas	17-Sep-21	Recruiting	3P30CA016520-44S5
clinical_trial	NCT03038672	Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas	17-Sep-21	Recruiting	3P30CA016520-44S6
clinical_trial	NCT04156217	EBV-TCR-T Cells for EB Virus Infection After HSCT	13-Aug-20	Recruiting	3P30CA016520-44S5
clinical_trial	NCT04156217	EBV-TCR-T Cells for EB Virus Infection After HSCT	13-Aug-20	Recruiting	3P30CA016520-44S6
clinical_trial	NCT03789617	Clinical Trial to Evaluate the Efficacy and Safety of Epstein-Barr Virus Induced Natural T Lymphocyte(EBViNT) Cell in Patients With Progressive EBV Positive Extranodal NK/T-cell Lymphoma Where Standard Treatments Have Failed	18-May-21	Recruiting	3P30CA016520-44S5
clinical_trial	NCT03789617	Clinical Trial to Evaluate the Efficacy and Safety of Epstein-Barr Virus Induced Natural T Lymphocyte(EBViNT) Cell in Patients With Progressive EBV Positive Extranodal NK/T-cell Lymphoma Where Standard Treatments Have Failed	18-May-21	Recruiting	3P30CA016520-44S6
clinical_trial	NCT03671850	VT-EBV-N for Treatment of Severe in EBV Positive Extranodal NK/T Cell Lymphoma Patients	6-Nov-19	Recruiting	3P30CA016520-44S5
clinical_trial	NCT03671850	VT-EBV-N for Treatment of Severe in EBV Positive Extranodal NK/T Cell Lymphoma Patients	6-Nov-19	Recruiting	3P30CA016520-44S6
clinical_trial	NCT03392142	Tabelecleucel for Allogeneic Hematopoietic Cell Transplant Subjects With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab (MATCH)	26-Mar-21	Completed	3P30CA016520-44S5
clinical_trial	NCT03392142	Tabelecleucel for Allogeneic Hematopoietic Cell Transplant Subjects With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab (MATCH)	26-Mar-21	Completed	3P30CA016520-44S6
clinical_trial	NCT03044743	PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated Malignancies	2-May-17	Recruiting	3P30CA016520-44S5
clinical_trial	NCT03044743	PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated Malignancies	2-May-17	Recruiting	3P30CA016520-44S6
clinical_trial	NCT01956084	Cytotoxic T Cells to Treat Relapsed EBV-positive Lymphoma (ALCI2)	24-Feb-21	"Active, not recruiting"	3P30CA016520-44S5
clinical_trial	NCT01956084	Cytotoxic T Cells to Treat Relapsed EBV-positive Lymphoma (ALCI2)	24-Feb-21	"Active, not recruiting"	3P30CA016520-44S6
clinical_trial	NCT02924402	Study to Evaluate Safety and Tolerability of XmAb13676 in Patients With CD20-expressing Hematologic Malignancies	25-Mar-21	Recruiting	3P30CA016520-44S5
clinical_trial	NCT02924402	Study to Evaluate Safety and Tolerability of XmAb13676 in Patients With CD20-expressing Hematologic Malignancies	25-Mar-21	Recruiting	3P30CA016520-44S6
clinical_trial	NCT02670616	Study of Ibrutinib in Combination With Rituximab-CHOP in Epstein-Barr Virus-positive Diffuse Large B-cell Lymphoma	22-Oct-20	Completed	3P30CA016520-44S5
clinical_trial	NCT02670616	Study of Ibrutinib in Combination With Rituximab-CHOP in Epstein-Barr Virus-positive Diffuse Large B-cell Lymphoma	22-Oct-20	Completed	3P30CA016520-44S6
clinical_trial	NCT03083288	Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Breast Cancer	14-May-21	"Active, not recruiting"	3P30CA016520-44S5
clinical_trial	NCT03083288	Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Breast Cancer	14-May-21	"Active, not recruiting"	3P30CA016520-44S6
clinical_trial	NCT03846167	Imaging of Primary or Recurrent Breast Cancer With 18F-FluorThanatrace PET/CT (FTT 2)	6-Aug-21	Recruiting	3P30CA016520-44S5
clinical_trial	NCT03846167	Imaging of Primary or Recurrent Breast Cancer With 18F-FluorThanatrace PET/CT (FTT 2)	6-Aug-21	Recruiting	3P30CA016520-44S6
clinical_trial	NCT02651246	Optional Sub-study to Intraoperative Imaging With ICG Registry	24-Jun-21	Completed	3P30CA016520-44S5
clinical_trial	NCT02651246	Optional Sub-study to Intraoperative Imaging With ICG Registry	24-Jun-21	Completed	3P30CA016520-44S6
clinical_trial	NCT01873833	"Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer"	26-Aug-21	Terminated	3P30CA014089-45S6
clinical_trial	NCT04981834	Robot-Assisted Radical Prostatectomy With or Without Vesicopexy in Patients With Prostate Cancer	18-Oct-21	Not yet recruiting	3P30CA014089-45S6
clinical_trial	NCT04941430	7T MRI Scan for the Early Detection of Melanoma Brain Metastases	18-Oct-21	Recruiting	3P30CA014089-45S6
clinical_trial	NCT04927559	Health Literacy in Understanding Radiation Therapy Information in Patients Undergoing Definitive Radiation Therapy	16-Jun-21	Recruiting	3P30CA014089-45S6
clinical_trial	NCT04832763	Medical and Psychosocial Issues in Adolescents and Young Adults With Colorectal Cancer	6-Apr-21	Recruiting	3P30CA014089-45S6
clinical_trial	NCT04830735	Dasatinib for the Treatment of Moderate and Severe COVID-19	18-Oct-21	Not yet recruiting	3P30CA014089-45S6
clinical_trial	NCT04752267	18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases	17-Mar-21	Recruiting	3P30CA014089-45S6
clinical_trial	NCT04387084	Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy	5-Apr-21	Recruiting	3P30CA014089-45S6
clinical_trial	NCT04387071	CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma	18-Oct-21	Recruiting	3P30CA014089-45S6
clinical_trial	NCT04373044	"Baricitinib, Placebo and Antiviral Therapy for the Treatment of Patients With Moderate and Severe COVID-19"	26-May-21	Terminated	3P30CA014089-45S6
clinical_trial	NCT02217709	Phenelzine Sulfate in Treating Patients With Non-metastatic Recurrent Prostate Cancer	5-Apr-21	"Active, not recruiting"	3P30CA014089-45S6
clinical_trial	NCT01658878	"An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer (CheckMate040)"	19-Jul-21	"Active, not recruiting"	3P30CA014089-45S6
clinical_trial	NCT04513951	AVELUMAB and CETUXIMAB and mFOLFOXIRI as Initial Therapy for Unresectable Metastatic Colorectal Cancer Patients (AVETRIC)	16-Sep-20	Recruiting	3P30CA014089-45S6
clinical_trial	NCT03874026	Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients (CIFRA)	2-Sep-21	Recruiting	3P30CA014089-45S6
clinical_trial	NCT00433927	"5-FU, Folinic Acid and Irinotecan (FOLFIRI) Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment Colorectal Cancer (CRC)"	14-Mar-14	Unknown	3P30CA014089-45S6
clinical_trial	NCT00433927	"5-FU, Folinic Acid and Irinotecan (FOLFIRI) Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment Colorectal Cancer (CRC)"	14-Mar-14	Unknown	3P30CA014089-45S6
clinical_trial	NCT00719797	Combination Chemotherapy and Bevacizumab as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer (TRIBE)	11-Mar-15	Completed	3P30CA014089-45S6
clinical_trial	NCT00719797	Combination Chemotherapy and Bevacizumab as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer (TRIBE)	11-Mar-15	Completed	3P30CA014089-45S6
clinical_trial	NCT00719797	Combination Chemotherapy and Bevacizumab as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer (TRIBE)	11-Mar-15	Completed	3P30CA014089-45S6
clinical_trial	NCT01374425	Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer (mCRC) (MAVERICC)	11-Aug-16	Completed	3P30CA014089-45S6
clinical_trial	NCT02189486	Prostate Cancer Upgrading Reference Set	30-Jun-21	Recruiting	3P30CA054174-25S2
clinical_trial	NCT02189486	Prostate Cancer Upgrading Reference Set	30-Jun-21	Recruiting	3P30CA054174-25S1
clinical_trial	NCT00055822	Combination Chemotherapy and Oblimersen in Treating Patients With Advanced Colorectal Cancer	4-Jul-12	Completed	3P30CA054174-25S2
clinical_trial	NCT00055822	Combination Chemotherapy and Oblimersen in Treating Patients With Advanced Colorectal Cancer	4-Jul-12	Completed	3P30CA054174-25S1
clinical_trial	NCT00003709	Chemotherapy in Treating Patients With Advanced Solid Tumors	9-Aug-12	Completed	3P30CA054174-25S2
clinical_trial	NCT00003709	Chemotherapy in Treating Patients With Advanced Solid Tumors	9-Aug-12	Completed	3P30CA054174-25S1
clinical_trial	NCT00003760	Irofulvene in Treating Patients With Stage III or Stage IV Pancreatic Cancer	9-Aug-12	Completed	3P30CA054174-25S2
clinical_trial	NCT00003760	Irofulvene in Treating Patients With Stage III or Stage IV Pancreatic Cancer	9-Aug-12	Completed	3P30CA054174-25S1
clinical_trial	NCT00003708	Chemotherapy in Treating Patients With Advanced Solid Tumors	9-Aug-12	Completed	3P30CA054174-25S2
clinical_trial	NCT00003708	Chemotherapy in Treating Patients With Advanced Solid Tumors	9-Aug-12	Completed	3P30CA054174-25S1
clinical_trial	NCT00003710	Irinotecan Plus Mitomycin in Treating Patients With Advanced Solid Tumors	9-Aug-12	Completed	3P30CA054174-25S2
clinical_trial	NCT00003710	Irinotecan Plus Mitomycin in Treating Patients With Advanced Solid Tumors	9-Aug-12	Completed	3P30CA054174-25S1
clinical_trial	NCT00003706	LY231514 in Treating Patients With Locally Advanced or Metastatic Solid Tumors and Varying Degrees of Kidney Function	28-Jun-12	Completed	3P30CA054174-25S2
clinical_trial	NCT00003706	LY231514 in Treating Patients With Locally Advanced or Metastatic Solid Tumors and Varying Degrees of Kidney Function	28-Jun-12	Completed	3P30CA054174-25S1
clinical_trial	NCT00003712	CCI-779 in Treating Patients With Advanced Solid Tumors	9-Aug-12	Completed	3P30CA054174-25S2
clinical_trial	NCT00003712	CCI-779 in Treating Patients With Advanced Solid Tumors	9-Aug-12	Completed	3P30CA054174-25S1
clinical_trial	NCT00003707	Combination Chemotherapy in Treating Patients With Advanced Cancer	28-Jun-12	Completed	3P30CA054174-25S2
clinical_trial	NCT00003707	Combination Chemotherapy in Treating Patients With Advanced Cancer	28-Jun-12	Completed	3P30CA054174-25S1
clinical_trial	NCT00003721	Chemotherapy in Treating Patients With Advanced Solid Tumors	29-Jun-12	Completed	3P30CA054174-25S2
clinical_trial	NCT00003721	Chemotherapy in Treating Patients With Advanced Solid Tumors	29-Jun-12	Completed	3P30CA054174-25S1
clinical_trial	NCT01434316	Veliparib and Dinaciclib in Treating Patients With Advanced Solid Tumors	20-Jul-21	Recruiting	3P30CA054174-25S2
clinical_trial	NCT01434316	Veliparib and Dinaciclib in Treating Patients With Advanced Solid Tumors	20-Jul-21	Recruiting	3P30CA054174-25S1
clinical_trial	NCT02753309	A Study of Rapamycin Combined With Intravesical BCG in Patients With Non-muscle Invasive Bladder Cancer	19-Mar-21	Completed	3P30CA054174-25S2
clinical_trial	NCT02753309	A Study of Rapamycin Combined With Intravesical BCG in Patients With Non-muscle Invasive Bladder Cancer	19-Mar-21	Completed	3P30CA054174-25S1
clinical_trial	NCT04375813	Trial of Encapsulated Rapamycin (eRapa) for Bladder Cancer Prevention	21-Jul-21	Recruiting	3P30CA054174-25S2
clinical_trial	NCT04375813	Trial of Encapsulated Rapamycin (eRapa) for Bladder Cancer Prevention	21-Jul-21	Recruiting	3P30CA054174-25S1
clinical_trial	NCT02342379	TH-302 in Combination With Bevacizumab for Glioblastoma	10-Apr-20	Completed	3P30CA054174-25S2
clinical_trial	NCT02342379	TH-302 in Combination With Bevacizumab for Glioblastoma	10-Apr-20	Completed	3P30CA054174-25S1
clinical_trial	NCT04444674	COVID-19 Vaccine (ChAdOx1 nCoV-19) Trial in South African Adults With and Without HIV-infection	27-Nov-20	"Active, not recruiting"	3P30CA054174-25S2
clinical_trial	NCT04444674	COVID-19 Vaccine (ChAdOx1 nCoV-19) Trial in South African Adults With and Without HIV-infection	27-Nov-20	"Active, not recruiting"	3P30CA046592-31S8
clinical_trial	NCT04444674	COVID-19 Vaccine (ChAdOx1 nCoV-19) Trial in South African Adults With and Without HIV-infection	27-Nov-20	"Active, not recruiting"	3P30CA046592-31S4
clinical_trial	NCT04444674	COVID-19 Vaccine (ChAdOx1 nCoV-19) Trial in South African Adults With and Without HIV-infection	27-Nov-20	"Active, not recruiting"	3P30CA054174-25S1
clinical_trial	NCT01971515	First-in-Human Dose Escalation Trial in Subjects With Advanced Malignancies	19-Sep-18	Completed	3P30CA054174-25S2
clinical_trial	NCT01971515	First-in-Human Dose Escalation Trial in Subjects With Advanced Malignancies	19-Sep-18	Completed	3P30CA054174-25S1
clinical_trial	NCT00064272	UMCCOP 02-01 Ginger in Treating Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer (IRB 2003-551)	21-Oct-16	Completed	3P30CA046592-31S8
clinical_trial	NCT00064272	UMCCOP 02-01 Ginger in Treating Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer (IRB 2003-551)	21-Oct-16	Completed	3P30CA046592-31S4
clinical_trial	NCT00098969	UMCC 2003-064 Resveratrol in Preventing Cancer in Healthy Participants (IRB 2004-535)	17-Dec-12	Completed	3P30CA046592-31S8
clinical_trial	NCT00098969	UMCC 2003-064 Resveratrol in Preventing Cancer in Healthy Participants (IRB 2004-535)	17-Dec-12	Completed	3P30CA046592-31S4
clinical_trial	NCT00967824	Tamoxifen Citrate Decision Aids for Women at Increased Risk of Breast Cancer	24-Mar-11	Completed	3P30CA046592-31S8
clinical_trial	NCT00967824	Tamoxifen Citrate Decision Aids for Women at Increased Risk of Breast Cancer	24-Mar-11	Completed	3P30CA046592-31S4
clinical_trial	NCT00955188	Computer-Based Tailored or Standard Information for Colorectal Cancer Screening	21-Dec-12	Completed	3P30CA046592-31S8
clinical_trial	NCT00955188	Computer-Based Tailored or Standard Information for Colorectal Cancer Screening	21-Dec-12	Completed	3P30CA046592-31S4
clinical_trial	NCT00003076	Eflornithine to Prevent Cancer in Patients With Barrett's Esophagus	19-Dec-12	Completed	3P30CA046592-31S8
clinical_trial	NCT00003076	Eflornithine to Prevent Cancer in Patients With Barrett's Esophagus	19-Dec-12	Completed	3P30CA046592-31S4
clinical_trial	NCT00900094	UMCC 003 Cancer-Related Protein Biomarkers in Blood and Tumor Tissue of Patients With Cancer (IRB 2000-294)	7-Feb-12	Completed	3P30CA046592-31S8
clinical_trial	NCT00900094	UMCC 003 Cancer-Related Protein Biomarkers in Blood and Tumor Tissue of Patients With Cancer (IRB 2000-294)	7-Feb-12	Completed	3P30CA046592-31S4
clinical_trial	NCT00005598	Azacitidine Plus Amifostine in Treating Patients With Myelodysplastic Syndrome	21-Dec-12	Completed	3P30CA046592-31S8
clinical_trial	NCT00005598	Azacitidine Plus Amifostine in Treating Patients With Myelodysplastic Syndrome	21-Dec-12	Completed	3P30CA046592-31S4
clinical_trial	NCT00003598	UMCC 9609 Tretinoin in Preventing Cancer of the Cervix in Patients With Cervical Neoplasia (IRB 1996-0189)	22-Sep-10	Completed	3P30CA046592-31S8
clinical_trial	NCT00003598	UMCC 9609 Tretinoin in Preventing Cancer of the Cervix in Patients With Cervical Neoplasia (IRB 1996-0189)	22-Sep-10	Completed	3P30CA046592-31S4
clinical_trial	NCT00027495	Curcumin for the Prevention of Colon Cancer	21-Dec-12	Completed	3P30CA046592-31S8
clinical_trial	NCT00027495	Curcumin for the Prevention of Colon Cancer	21-Dec-12	Completed	3P30CA046592-31S4
clinical_trial	NCT02007200	Soy Isoflavones in Preventing Head and Neck Cancer Recurrence in Patients With Stage I-IV Head and Neck Cancer Undergoing Surgery	24-Oct-16	Completed	3P30CA046592-31S8
clinical_trial	NCT02007200	Soy Isoflavones in Preventing Head and Neck Cancer Recurrence in Patients With Stage I-IV Head and Neck Cancer Undergoing Surgery	24-Oct-16	Completed	3P30CA046592-31S4
clinical_trial	NCT03888612	Trial of ARV-110 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)	25-Jun-21	Recruiting	3P30CA046592-31S8
clinical_trial	NCT03888612	Trial of ARV-110 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)	25-Jun-21	Recruiting	3P30CA046592-31S4
clinical_trial	NCT04456049	Randomized Open Label Phase II Study to Evaluate the Efficacy of Enzalutamide in High Risk Male Outpatients With COVID-19	2-Jul-20	Not yet recruiting	3P30CA046592-31S8
clinical_trial	NCT04456049	Randomized Open Label Phase II Study to Evaluate the Efficacy of Enzalutamide in High Risk Male Outpatients With COVID-19	2-Jul-20	Not yet recruiting	3P30CA046592-31S4
clinical_trial	NCT04475601	Enzalutamide Treatment in COVID-19 (COVIDENZA)	26-Aug-21	Terminated	3P30CA046592-31S8
clinical_trial	NCT04475601	Enzalutamide Treatment in COVID-19 (COVIDENZA)	26-Aug-21	Terminated	3P30CA046592-31S4
clinical_trial	NCT04509999	Bicalutamide to Block TMPRSS2 in Males With COVID-19 Infection	1-Jul-21	Withdrawn	3P30CA046592-31S8
clinical_trial	NCT04509999	Bicalutamide to Block TMPRSS2 in Males With COVID-19 Infection	1-Jul-21	Withdrawn	3P30CA046592-31S4
clinical_trial	NCT04374279	Trial to Promote Recovery From COVID-19 With Endocrine Therapy (RECOVER)	5-Mar-21	Withdrawn	3P30CA046592-31S8
clinical_trial	NCT04374279	Trial to Promote Recovery From COVID-19 With Endocrine Therapy (RECOVER)	5-Mar-21	Withdrawn	3P30CA046592-31S4
clinical_trial	NCT04397718	Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization (HITCH)	2-Jul-21	Completed	3P30CA046592-31S8
clinical_trial	NCT04397718	Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization (HITCH)	2-Jul-21	Completed	3P30CA046592-31S4
clinical_trial	NCT04446429	Anti-Androgen Treatment for COVID-19	16-Jun-21	Completed	3P30CA046592-31S8
clinical_trial	NCT04446429	Anti-Androgen Treatment for COVID-19	16-Jun-21	Completed	3P30CA046592-31S4
clinical_trial	NCT04353284	Camostat Mesylate in COVID-19 Outpatients	8-Oct-21	Completed	3P30CA046592-31S8
clinical_trial	NCT04353284	Camostat Mesylate in COVID-19 Outpatients	8-Oct-21	Completed	3P30CA046592-31S4
clinical_trial	NCT04524663	Oral Camostat Compared With Standard Supportive Care in Mild-Moderate COVID-19 Patients (COPS-2003)	11-Jun-21	Completed	3P30CA046592-31S8
clinical_trial	NCT04524663	Oral Camostat Compared With Standard Supportive Care in Mild-Moderate COVID-19 Patients (COPS-2003)	11-Jun-21	Completed	3P30CA046592-31S4
clinical_trial	NCT04470544	Camostat Mesilate Treating Patients With Hospitalized Patients With COVID-19 (RECOVER)	11-Jan-21	Recruiting	3P30CA046592-31S8
clinical_trial	NCT04470544	Camostat Mesilate Treating Patients With Hospitalized Patients With COVID-19 (RECOVER)	11-Jan-21	Recruiting	3P30CA046592-31S4
clinical_trial	NCT04352400	Efficacy of Nafamostat in Covid-19 Patients (RACONA Study) (RACONA)	9-Jun-21	Recruiting	3P30CA046592-31S8
clinical_trial	NCT04352400	Efficacy of Nafamostat in Covid-19 Patients (RACONA Study) (RACONA)	9-Jun-21	Recruiting	3P30CA046592-31S4
clinical_trial	NCT04418128	Clinical Efficacy of Nafamostat Mesylate for COVID-19 Pneumonia	9-Jun-20	Not yet recruiting	3P30CA046592-31S8
clinical_trial	NCT04418128	Clinical Efficacy of Nafamostat Mesylate for COVID-19 Pneumonia	9-Jun-20	Not yet recruiting	3P30CA046592-31S4
clinical_trial	NCT04390594	Efficacy and Safety Evaluation of Treatment Regimens in Adult COVID-19 Patients in Senegal (SEN-CoV-Fadj)	7-Sep-20	Recruiting	3P30CA046592-31S8
clinical_trial	NCT04390594	Efficacy and Safety Evaluation of Treatment Regimens in Adult COVID-19 Patients in Senegal (SEN-CoV-Fadj)	7-Sep-20	Recruiting	3P30CA046592-31S4
clinical_trial	NCT04473053	DEFINE - Evaluating Therapies for COVID-19 (DEFINE)	16-Sep-21	"Active, not recruiting"	3P30CA046592-31S8
clinical_trial	NCT04473053	DEFINE - Evaluating Therapies for COVID-19 (DEFINE)	16-Sep-21	"Active, not recruiting"	3P30CA046592-31S4
clinical_trial	NCT04424134	BromhexIne And Spironolactone For Coron&#1072;VirUs Infection Requiring HospiTalization (BISCUIT)	9-Jun-20	Recruiting	3P30CA046592-31S8
clinical_trial	NCT04424134	BromhexIne And Spironolactone For Coron&#1072;VirUs Infection Requiring HospiTalization (BISCUIT)	9-Jun-20	Recruiting	3P30CA046592-31S4
clinical_trial	NCT04355026	Use of Bromhexine and Hydroxychloroquine for Treatment of COVID-19 Pneumonia	21-Apr-20	Recruiting	3P30CA046592-31S8
clinical_trial	NCT04355026	Use of Bromhexine and Hydroxychloroquine for Treatment of COVID-19 Pneumonia	21-Apr-20	Recruiting	3P30CA046592-31S4
clinical_trial	NCT04273763	Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19)	1-May-20	"Active, not recruiting"	3P30CA046592-31S8
clinical_trial	NCT04273763	Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19)	1-May-20	"Active, not recruiting"	3P30CA046592-31S4
clinical_trial	NCT04340349	Low-dose Hydroxychloroquine and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals (ELEVATE)	29-Jun-21	Enrolling by invitation	3P30CA046592-31S8
clinical_trial	NCT04340349	Low-dose Hydroxychloroquine and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals (ELEVATE)	29-Jun-21	Enrolling by invitation	3P30CA046592-31S4
clinical_trial	NCT04405999	Prevention of Infection and Incidence of COVID-19 in Medical Personnel Assisting Patients With New Coronavirus Disease	3-Sep-20	Completed	3P30CA046592-31S8
clinical_trial	NCT04405999	Prevention of Infection and Incidence of COVID-19 in Medical Personnel Assisting Patients With New Coronavirus Disease	3-Sep-20	Completed	3P30CA046592-31S4
clinical_trial	NCT04426695	"Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for Hospitalized Adult Patients With COVID-19"	26-Aug-21	Completed	3P30CA046592-31S8
clinical_trial	NCT04426695	"Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for Hospitalized Adult Patients With COVID-19"	26-Aug-21	Completed	3P30CA046592-31S4
clinical_trial	NCT04425629	"Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult and Pediatric Patients With COVID-19"	8-Oct-21	Recruiting	3P30CA046592-31S8
clinical_trial	NCT04425629	"Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult and Pediatric Patients With COVID-19"	8-Oct-21	Recruiting	3P30CA046592-31S4
clinical_trial	NCT04592549	Study of Monoclonal Antibody Cocktail Being Tested for the Prevention of COVID-19	24-Sep-21	Recruiting	3P30CA046592-31S8
clinical_trial	NCT04592549	Study of Monoclonal Antibody Cocktail Being Tested for the Prevention of COVID-19	24-Sep-21	Recruiting	3P30CA046592-31S4
clinical_trial	NCT00603057	Using Imaging and Molecular Markers to Predict Tumor Response and Lung Toxicity in Lung Cancer	14-Oct-19	Completed	3P30CA046592-31S8
clinical_trial	NCT00603057	Using Imaging and Molecular Markers to Predict Tumor Response and Lung Toxicity in Lung Cancer	14-Oct-19	Completed	3P30CA046592-31S4
clinical_trial	NCT02333890	"A Phase 2 Randomized, Double-blind Trial Evaluating the Effects of Chloroquine in Breast Cancer (CUBiC)"	18-Nov-16	Unknown	3P30CA046592-31S8
clinical_trial	NCT02333890	"A Phase 2 Randomized, Double-blind Trial Evaluating the Effects of Chloroquine in Breast Cancer (CUBiC)"	18-Nov-16	Unknown	3P30CA046592-31S4
clinical_trial	NCT02378532	The Addition of Chloroquine to Chemoradiation for Glioblastoma (CHLOROBRAIN)	23-Jan-20	Completed	3P30CA046592-31S8
clinical_trial	NCT02378532	The Addition of Chloroquine to Chemoradiation for Glioblastoma (CHLOROBRAIN)	23-Jan-20	Completed	3P30CA046592-31S4
clinical_trial	NCT03400865	Cabergoline Combined Hydroxychloroquine/Chloroquine to Treat Resistant Prolactinomas	16-Oct-18	Unknown	3P30CA046592-31S8
clinical_trial	NCT03400865	Cabergoline Combined Hydroxychloroquine/Chloroquine to Treat Resistant Prolactinomas	16-Oct-18	Unknown	3P30CA046592-31S4
clinical_trial	NCT01700959	Melatonin Intervention For Neurocognitive Deficits in the St. Jude Lifetime Cohort	28-Jun-18	Completed	3P30CA021765-41S3
clinical_trial	NCT00004006	"Combination Chemotherapy, Radiation Therapy, and Bone Marrow Transplantation in Treating Patients With Retinoblastoma"	4-Oct-11	Completed	3P30CA021765-41S3
clinical_trial	NCT00004005	"Irinotecan Followed By Fluorouracil and Leucovorin in Treating Patients With Stage III or Stage IV Colorectal Carcinoma (Cancer), Other Refractory Carcinoma, or Metastatic Adenoma (Cancer) of Unknown Primary Origin"	26-Apr-17	Completed	3P30CA021765-41S3
clinical_trial	NCT00137111	Therapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia	11-Sep-20	Completed	3P30CA021765-41S3
clinical_trial	NCT00576472	Learning Impairments Among Survivors of Childhood Cancer	30-May-17	Completed	3P30CA021765-41S3
clinical_trial	NCT00002794	Carboplatin Plus Vincristine in Treating Children With Retinoblastoma	4-Oct-11	Completed	3P30CA021765-41S3
clinical_trial	NCT00004068	Irinotecan Followed by Radiation Therapy and Temozolomide in Treating Children With Newly Diagnosed Brain Tumor	4-Oct-11	Completed	3P30CA021765-41S3
clinical_trial	NCT00002748	Gene Therapy in Treating Children With Refractory or Recurrent Neuroblastoma	4-Oct-11	Completed	3P30CA021765-41S3
clinical_trial	NCT00101205	"Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma"	24-Feb-14	Terminated	3P30CA021765-41S3
clinical_trial	NCT02502786	Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent Osteosarcoma	4-Jun-21	Recruiting	3P30CA021765-41S3
clinical_trial	NCT03686783	N/A	N/A	N/A	3P30CA021765-41S3
clinical_trial	NCT00669305	Bone Marrow for Hemoglobinopathy Research	25-Feb-20	Completed	3P30CA021765-41S3
clinical_trial	NCT02729298	First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors	25-Jan-21	"Active, not recruiting"	3P30CA021765-41S3
clinical_trial	NCT03572634	Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL	2-Feb-21	Terminated	3P30CA021765-41S3
clinical_trial	NCT04244656	A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma	8-Oct-21	Recruiting	3P30CA021765-41S3
clinical_trial	NCT04264078	Anti-CD7 U-CAR-T Cell Therapy for T/NK Cell Hematologic Malignancies	28-Jun-21	Recruiting	3P30CA021765-41S3
clinical_trial	NCT03939026	Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma (ALPHA)	14-Oct-21	"Active, not recruiting"	3P30CA021765-41S3
clinical_trial	NCT04416984	Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma (ALPHA-2) (ALPHA-2)	14-Oct-21	"Active, not recruiting"	3P30CA021765-41S3
clinical_trial	NCT04173988	Study of alloCART-19 Cell Therapy in Pediatric Patients With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia	30-Nov-20	Recruiting	3P30CA021765-41S3
clinical_trial	NCT03166878	A Study Evaluating UCART019 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma	23-Jun-17	Recruiting	3P30CA021765-41S3
clinical_trial	NCT04035434	A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)	6-Oct-21	Recruiting	3P30CA021765-41S3
clinical_trial	NCT04384393	Safety and Efficacy of ThisCART19 in Patients With Refractory or Relapsed B Cell Malignancies	1-Dec-20	Recruiting	3P30CA021765-41S3
clinical_trial	NCT04264039	Anti-CD19 U-CAR-T Cell Therapy for B Cell Hematologic Malignancies	11-Feb-20	Not yet recruiting	3P30CA021765-41S3
clinical_trial	NCT04227015	A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy	28-Dec-20	Recruiting	3P30CA021765-41S3
clinical_trial	NCT03666000	Dose-escalation Study of Safety of PBCAR0191 in Patients With r/r NHL and r/r B-cell ALL	16-Sep-21	Recruiting	3P30CA021765-41S3
clinical_trial	NCT04166838	The Clinical Study of CD19 UCAR-T Cells in Patients With B-cell Acute Lymphoblastic Leukemia (B-ALL)	18-Nov-19	Recruiting	3P30CA021765-41S3
clinical_trial	NCT04176913	Study of LUCAR-20S in Patients With R/R NHL	25-Aug-21	Recruiting	3P30CA021765-41S3
clinical_trial	NCT04030195	Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL	29-Apr-21	Recruiting	3P30CA021765-41S3
clinical_trial	NCT04150497	Phase 1 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)	22-Sep-21	Recruiting	3P30CA021765-41S3
clinical_trial	NCT04502446	A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM)	15-Jul-21	Recruiting	3P30CA021765-41S3
clinical_trial	NCT04438083	A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory Renal Cell Carcinoma (COBALT-RCC)	14-May-21	Recruiting	3P30CA021765-41S3
clinical_trial	NCT04142619	Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myeloma (MELANI-01)	23-Sep-21	Recruiting	3P30CA021765-41S3
clinical_trial	NCT03692429	alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells (alloSHRINK)	20-Nov-20	Recruiting	3P30CA021765-41S3
clinical_trial	NCT01430390	In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies	5-Aug-21	Recruiting	3P30CA021765-41S3
clinical_trial	NCT04288726	Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas	1-Apr-21	Recruiting	3P30CA021765-41S3
clinical_trial	NCT04107142	Haplo / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted &#947;&#948; T Cells for Relapsed or Refractory Solid Tumour	27-Sep-19	Unknown	3P30CA021765-41S3
clinical_trial	NCT03774654	CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR)	16-Aug-21	Recruiting	3P30CA021765-41S3
clinical_trial	NCT04245722	FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies	10-Aug-21	Recruiting	3P30CA021765-41S3
clinical_trial	NCT03389230	Memory-Enriched T Cells in Treating Patients With Recurrent or Refractory Grade III-IV Glioma	12-Aug-21	Recruiting	3P30CA021765-41S3
clinical_trial	NCT02146924	Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia	30-Mar-21	Recruiting	3P30CA021765-41S3
clinical_trial	NCT02051257	Memory Enriched T Cells Following Stem Cell Transplant in Treating Patients With Recurrent B-Cell Non-Hodgkin Lymphoma	15-Jun-21	"Active, not recruiting"	3P30CA021765-41S3
clinical_trial	NCT02746952	Dose Escalation Study of UCART19 in Adult Patients With Relapsed / Refractory B-cell Acute Lymphoblastic Leukaemia (CALM)	1-Oct-21	Completed	3P30CA021765-41S3
clinical_trial	NCT03383978	Intracranial Injection of NK-92/5.28.z Cells in Patients With Recurrent HER2-positive Glioblastoma (CAR2BRAIN)	25-Sep-20	Recruiting	3P30CA021765-41S3
clinical_trial	NCT03841110	FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors	2-Nov-20	Recruiting	3P30CA021765-41S3
clinical_trial	NCT00760656	Establishment of a Lifetime of Cohort of Adults Surviving Childhood Cancer (SJLIFE)	2-Aug-21	Recruiting	3P30CA021765-41S3
clinical_trial	NCT03655678	A Safety and Efficacy Study Evaluating CTX001 in Subjects With Transfusion-Dependent &#946;-Thalassemia	16-Feb-21	Recruiting	3P30CA021765-41S3
clinical_trial	NCT03745287	A Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Cell Disease	22-Jan-21	Recruiting	3P30CA021765-41S3
clinical_trial	NCT03712358	PVSRIPO for Patients With Unresectable Melanoma	14-Jan-21	"Active, not recruiting"	3P30CA021765-41S3
clinical_trial	NCT02848001	A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes	22-Jul-21	Recruiting	3P30CA021765-41S3
clinical_trial	NCT04341311	Phase I Study of Marizomib + Panobinostat for Children With DIPG (DIPG)	11-May-21	"Active, not recruiting"	3P30CA021765-41S3
clinical_trial	NCT01922076	Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas	17-May-21	"Active, not recruiting"	3P30CA021765-41S3
clinical_trial	NCT02193724	Feasibility of Generating Pluripotent Stem Cells From Patients With Familial Retinoblastoma	23-Oct-20	Completed	3P30CA021765-41S3
clinical_trial	NCT00549848	Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia	19-Mar-21	"Active, not recruiting"	3P30CA021765-41S3
clinical_trial	NCT02261480	A New Reagent Assay Examining Natural Parvovirus B19 Infection in Sickle Cell Disease	19-Sep-16	Completed	3P30CA021765-41S3
clinical_trial	NCT01050296	Molecular Analysis Of Solid Tumors (MAST)	26-Aug-21	Recruiting	3P30CA021765-41S3
clinical_trial	NCT00124657	Erlotinib and Radiation Therapy in Treating Young Patients With Newly Diagnosed Glioma	4-Dec-15	Completed	3P30CA021765-41S3
clinical_trial	NCT04662645	Embedded Palliative Care in Managing Symptoms in Participants With Recurrent Stage III-IV Thoracic Malignancies and Their Caregivers	10-Dec-20	Recruiting	3P30CA016058-44S3
clinical_trial	NCT04602026	"Re-Defining Frailty and Improving Outcomes Through Prehabilitation in Patients With Pancreatic, Liver, or Gastric Cancer, The RIOT Trial (RIOT)"	27-Oct-20	Recruiting	3P30CA016058-44S3
clinical_trial	NCT04329962	Metabolism and Absorption of Anthocyanins From Extract and Whole Blueberry Powder Confections in Healthy Adults	24-Sep-21	"Active, not recruiting"	3P30CA016058-44S3
clinical_trial	NCT04269837	Sexual Health Counseling Intervention During Radiation Therapy in Improving Quality of Life for Women With Gynecologic Cancer	8-Dec-20	Recruiting	3P30CA016058-44S3
clinical_trial	NCT04229381	Resiliency Among Older Adults Receiving Lung Cancer Treatment (ROAR-LCT)	18-Jan-20	Recruiting	3P30CA016058-44S3
clinical_trial	NCT04220684	Off-the-shelf Third Party Expanded NK Cells in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome	4-Jun-20	Recruiting	3P30CA016058-44S3
clinical_trial	NCT04205071	Lorcaserin in Treating Chemotherapy-Induced Peripheral Neuropathy in Patients With Stage I-IV Gastrointestinal or Breast Cancer	19-Jan-21	Withdrawn	3P30CA016058-44S3
clinical_trial	NCT04164069	Dasatinib in Preventing Oxaliplatin-Induced Peripheral Neuropathy in Patients With Colorectal Cancer Receiving FOLFOX and Bevacizumab	8-Jul-21	Recruiting	3P30CA016058-44S3
clinical_trial	NCT04120454	Ramucirumab and Pembrolizumab for the Treatment of EGFR Mutant Recurrent or Metastatic Non-small Cell Lung Cancer	9-Oct-20	Recruiting	3P30CA016058-44S3
clinical_trial	NCT04115163	Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer	17-Sep-20	Recruiting	3P30CA016058-44S3
clinical_trial	NCT02445391	Platinum Based Chemotherapy or Capecitabine in Treating Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy	21-May-20	Recruiting	3P30CA016058-44S3
clinical_trial	NCT01771107	Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma	2-Aug-21	"Active, not recruiting"	3P30CA016058-44S3
clinical_trial	NCT04166318	"Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study"	10-Sep-21	Recruiting	3P30CA016058-44S3
clinical_trial	NCT04166318	"Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study"	10-Sep-21	Recruiting	3P30CA016058-44S3
clinical_trial	NCT01611623	Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Solid Tumor Malignancies	2-Apr-13	Completed	3P30CA016058-44S3
clinical_trial	NCT01635712	Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Hematological Malignancies	26-Apr-17	Completed	3P30CA016058-44S3
clinical_trial	NCT02973399	Efficacy and Safety of SNX-5422 Added to an Established Dose of Ibrutinib in CLL	22-Feb-19	Terminated	3P30CA016058-44S3
clinical_trial	NCT02914327	Safety and Activity of SNX-5422 Plus Ibrutinib in CLL	30-Jul-18	Withdrawn	3P30CA016058-44S3
clinical_trial	NCT02717611	A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy	5-Sep-21	"Active, not recruiting"	3P30CA016058-44S3
clinical_trial	NCT02477696	Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Subjects With High Risk CLL	30-Aug-21	"Active, not recruiting"	3P30CA016058-44S3
clinical_trial	NCT01408225	Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource (B-SCR-MM)	13-Jan-20	Recruiting	3P30CA016058-44S3
clinical_trial	NCT00385723	"Fish Oil (Omega 3), Immune Function, and Mood"	20-Nov-12	Completed	3P30CA016058-44S3
clinical_trial	NCT03824327	Papaverine and Stereotactic Body Radiotherapy (SBRT) for Non Small Cell Lung Cancer (NSCLC) or Lung Metastases	9-Feb-21	Recruiting	3P30CA016058-44S3
clinical_trial	NCT03018418	Proton Therapy in Reducing Toxicity in Anal Cancer	1-Jul-21	"Active, not recruiting"	3P30CA016058-44S3
clinical_trial	NCT03690921	LET-IMPT and Standard Chemotherapy in Treating Patients With Newly Diagnosed Stage I-III Anal Canal Squamous Cell Cancer	30-Jan-20	Recruiting	3P30CA016058-44S3
clinical_trial	NCT03117920	"A Phase II, International Open Label Trial of Minnelide&#8482; in Patients With Refractory Pancreatic Cancer (MinPAC)"	2-Sep-20	Completed	3P30CA016058-44S3
clinical_trial	NCT03886831	A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies	30-Jul-21	Recruiting	3P30CA016058-44S3
clinical_trial	NCT03573310	"A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS"	8-Oct-21	"Active, not recruiting"	3P30CA016058-44S3
clinical_trial	NCT02783300	"An Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma (Meteor 1)"	17-May-21	Recruiting	3P30CA016058-44S3
clinical_trial	NCT01738438	Cabozantinib for Metastatic Triple Negative BrCa	6-Dec-16	Completed	3P30CA016058-44S3
clinical_trial	NCT00048958	Cytogenetic Studies in Acute Leukemia and Multiple Myeloma	17-Aug-21	"Active, not recruiting"	3P30CA016058-44S3
clinical_trial	NCT00900224	Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia	12-Oct-20	"Active, not recruiting"	3P30CA016058-44S3
clinical_trial	NCT00003190	Combination Chemotherapy With or Without Valspodar in Treating Patients With Previously Untreated Acute Myeloid Leukemia	4-Jun-13	Completed	3P30CA016058-44S3
clinical_trial	NCT00085124	"Daunorubicin Hydrochloride, Cytarabine and Oblimersen Sodium in Treating Patients With Previously Untreated Acute Myeloid Leukemia"	5-Jun-13	Completed	3P30CA016058-44S3
clinical_trial	NCT00742625	"Bortezomib, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia"	12-Sep-14	Completed	3P30CA016058-44S3
clinical_trial	NCT01420926	Decitabine With or Without Bortezomib in Treating Older Patients With Acute Myeloid Leukemia	28-Sep-21	"Active, not recruiting"	3P30CA016058-44S3
clinical_trial	NCT00039377	"Chemotherapy, Imatinib Mesylate, and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia"	24-Nov-14	Completed	3P30CA016058-44S3
clinical_trial	NCT01253070	Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia	16-Sep-21	"Active, not recruiting"	3P30CA016058-44S3
clinical_trial	NCT04317040	CD24Fc (MK-7110) as a Non-antiviral Immunomodulator in COVID-19 Treatment (MK-7110-007) (SAC-COVID)	15-Oct-21	Completed	3P30CA016058-44S3
clinical_trial	NCT04315948	Trial of Treatments for COVID-19 in Hospitalized Adults (DisCoVeRy)	11-Oct-21	Recruiting	3P30CA016058-44S3
clinical_trial	NCT04162873	Celecoxib Through Surgery and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer	8-Sep-21	Recruiting	3P30CA042014-31S5
clinical_trial	NCT04106856	Losartan and Hypofractionated Rx After Chemo for Tx of Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer (SHAPER) (SHAPER)	16-Jul-21	Recruiting	3P30CA042014-31S5
clinical_trial	NCT03987217	Resistance Training +/- Creatine for Metastatic Prostate Cancer Patients	13-Jan-21	Recruiting	3P30CA042014-31S5
clinical_trial	NCT03972943	CPAP in Treating Obstructive Sleep Apnea in Patients With Polycythemia Vera or Essential Thrombocythemia	22-Apr-21	Recruiting	3P30CA042014-31S5
clinical_trial	NCT00335491	Exercise in Improving Mobility and Reducing Fatigue and/or Weakness in Older Cancer Survivors	30-Sep-11	Completed	3P30CA042014-31S5
clinical_trial	NCT05067777	"Massage for Prostate Cancer-Related Fatigue, mPROSTATE Study (mPROSTATE)"	5-Oct-21	Not yet recruiting	3P30CA042014-31S5
clinical_trial	NCT00026468	Exisulind in Preventing Polyps in Patients With Familial Adenomatous Polyposis	24-Jul-13	Withdrawn	3P30CA042014-31S5
clinical_trial	NCT02337517	Vismodegib in Treating Patients With Steroid-Refractory Chronic Graft-Versus-Host Disease	19-Jul-21	Terminated	3P30CA042014-31S5
clinical_trial	NCT04357613	IMATINIB IN COVID-19 DISEASE IN AGED PATIENTS. (IMAGE-19)	7-Aug-20	Not yet recruiting	3P30CA042014-31S5
clinical_trial	NCT04394416	Trial of Imatinib for Hospitalized Adults With COVID-19	12-Aug-21	Recruiting	3P30CA042014-31S5
clinical_trial	NCT02821013	Duration of Anti-PD-1 Therapy in Metastatic Melanoma (STOP-GAP)	14-Sep-21	Recruiting	3P30CA042014-31S5
clinical_trial	NCT03553836	Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)	24-Aug-21	"Active, not recruiting"	3P30CA042014-31S5
clinical_trial	NCT02328677	ColoCare Study - Colorectal Cancer Cohort	19-Oct-20	Recruiting	3P30CA042014-31S5
clinical_trial	NCT02328677	ColoCare Study - Colorectal Cancer Cohort	19-Oct-20	Recruiting	3P30CA042014-31S5
clinical_trial	NCT04874831	Domatinostat in Combination With Avelumab in Patients With Treatment-na&#239;ve Metastatic Merkel Cell Carcinoma (MERKLIN 1)	6-Jul-21	Not yet recruiting	3P30CA042014-31S5
clinical_trial	NCT04393753	Domatinostat in Combination With Avelumab in Patients With Advanced Merkel Cell Carcinoma Progressing on Anti-PD-(L)1 (MERKLIN2)	20-Oct-21	Recruiting	3P30CA042014-31S5
clinical_trial	NCT04871594	Checkpoint Inhibition With or Without Domatinostat in Urothelial Cancer (TURANDOT)	1-Sep-21	Recruiting	3P30CA042014-31S5
clinical_trial	NCT04133948	"Multicenter Phase 1b Trial Testing the Neoadjuvant Combination of Domatinostat, Nivolumab and Ipilimumab in IFN-gamma Signature-low and IFN-gamma Signature-high RECIST 1.1-measurable Stage III Cutaneous or Unknown Primary Melanoma (DONIMI)"	1-Jun-20	Recruiting	3P30CA042014-31S5
clinical_trial	NCT03812796	Epigenetic Modulation of the immunE Response in GastrointEstinal Cancers (EMERGE) (EMERGE)	5-Feb-19	Recruiting	3P30CA042014-31S5
clinical_trial	NCT01091974	Cognitive Behavioral Therapy +/- Armodafinil for Insomnia and Fatigue Following Chemotherapy	9-Feb-17	Completed	3P30CA042014-31S5
clinical_trial	NCT02159755	Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell Lymphoma	19-Oct-21	"Active, not recruiting"	3P30CA013696-45S1
clinical_trial	NCT00233935	Defined Green Tea Catechin Extract in Preventing Esophageal Cancer in Patients With Barrett's Esophagus	11-Sep-14	Completed	3P30CA013696-45S1
clinical_trial	NCT02755597	A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy (Bellini)	20-Jul-21	Suspended	3P30CA013696-45S1
clinical_trial	NCT01137006	"An Open-Label, Dose-Escalation Study of IMC-20D7S In Participants With Malignant Melanoma"	17-Jun-19	Completed	3P30CA013696-45S1
clinical_trial	NCT03364348	4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer	25-Jan-21	"Active, not recruiting"	3P30CA013696-45S1
clinical_trial	NCT01696877	A Neoadjuvant Study of Androgen Ablation Combined With Cyclophosphamide and GVAX Vaccine for Localized Prostate Cancer	28-Mar-19	Completed	3P30CA013696-45S1
clinical_trial	NCT04053062	LIGHT-PSMA-CART in Treating Patients With Castrate-Resistant Prostate Cancer	24-Sep-21	Recruiting	3P30CA013696-45S1
clinical_trial	NCT02744287	Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors	26-Apr-21	Recruiting	3P30CA013696-45S1
clinical_trial	NCT04109924	"TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study"	23-Jul-21	Recruiting	3P30CA016056-43S5
clinical_trial	NCT00957424	Acceptability of Less Harmful Alternatives to Cigarettes	7-Feb-17	Completed	3P30CA016056-43S5
clinical_trial	NCT00849186	Sunitinib and Surgery in Treating Patients With Localized or Metastatic Kidney Cancer	6-Feb-15	Completed	3P30CA016056-43S5
clinical_trial	NCT00736164	Selenomethionine in Treating Patients Undergoing Surgery or Internal Radiation Therapy for Stage I or Stage II Prostate Cancer	6-Feb-12	Withdrawn	3P30CA016056-43S5
clinical_trial	NCT01892930	Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Kidney Cancer Undergoing Surgery	10-Feb-17	Completed	3P30CA016056-43S5
clinical_trial	NCT01892930	Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Kidney Cancer Undergoing Surgery	10-Feb-17	Completed	3P30CA016056-43S5
clinical_trial	NCT00690924	Calcitriol in Preventing Lung Cancer in Smokers and Former Smokers at High Risk of Lung Cancer	4-Jun-18	Completed	3P30CA016056-43S5
clinical_trial	NCT01769885	Tivozanib Before Surgery in Treating Patients With Localized Kidney Cancer	11-Apr-17	Withdrawn	3P30CA016056-43S5
clinical_trial	NCT00560495	"Radiation Therapy and Ammonium Tetrathiomolybdate in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer"	10-Feb-12	Withdrawn	3P30CA016056-43S5
clinical_trial	NCT01555268	Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia	15-Feb-17	Completed	3P30CA016056-43S5
clinical_trial	NCT00217516	Selenium in Treating Patients Who Are Undergoing Brachytherapy for Stage I or Stage II Prostate Cancer	9-Feb-12	Completed	3P30CA016056-43S5
clinical_trial	NCT03018405	A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications (THINK)	19-Sep-19	Unknown	3P30CA016056-43S5
clinical_trial	NCT03795779	"CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies"	19-May-21	Recruiting	3P30CA016056-43S5
clinical_trial	NCT02405338	DC Vaccination for Post-remission Therapy in AML	7-Jul-20	Completed	3P30CA016056-43S5
clinical_trial	NCT03144245	Study of AMV564 in Patients With AML	12-Oct-21	Completed	3P30CA016056-43S5
clinical_trial	NCT03516591	A Phase 1 Study of AMV564 in Patients With Intermediate or High-Risk Myelodysplastic Syndromes	12-Oct-21	Completed	3P30CA016056-43S5
clinical_trial	NCT03262662	EVarQuit: Extended Pre-quit Varenicline to Assist in Quitting Smoking (EVarQuit)	25-Nov-20	Recruiting	3P30CA016056-43S5
clinical_trial	NCT01847001	Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy	10-Sep-21	Completed	3P30CA016056-43S5
clinical_trial	NCT02013492	Propranolol Hydrochloride in Treating Patients With Locally Recurrent or Metastatic Solid Tumors That Cannot Be Removed By Surgery	3-Mar-21	"Active, not recruiting"	3P30CA016056-43S5
clinical_trial	NCT03076372	A Study Evaluating MM-310 in Patients With Solid Tumors	27-Feb-18	Unknown	3P30CA016056-43S5
clinical_trial	NCT01835223	Tivozanib in Treating Patients With Liver Cancer That Is Metastatic or Cannot Be Removed by Surgery	28-Oct-20	Completed	3P30CA016056-43S5
clinical_trial	NCT01835223	Tivozanib in Treating Patients With Liver Cancer That Is Metastatic or Cannot Be Removed by Surgery	28-Oct-20	Completed	3P30CA016056-43S5
clinical_trial	NCT03970616	A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma (DEDUCTIVE)	10-Sep-21	Recruiting	3P30CA016056-43S5
clinical_trial	NCT03329950	A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies	10-Sep-21	Recruiting	3P30CA016056-43S5
clinical_trial	NCT00057733	Stress Management Training in Patients Undergoing Radiation Therapy for Cancer	30-May-13	Completed	3P30CA016056-43S5
clinical_trial	NCT03538223	Music Listening in Radiotherapy Treatment (MuLi_RT)	3-Dec-18	Unknown	3P30CA016056-43S5
clinical_trial	NCT03728205	Yoga for Solid Tumor	27-Apr-21	Withdrawn	3P30CA016056-43S5
clinical_trial	NCT03823144	Intravital Microscopy in Human Solid Tumors	25-Mar-21	Recruiting	3P30CA016056-43S5
clinical_trial	NCT03517852	Intravital Microscopy (IVM) in Patients With Peritoneal Carcinomatosis (PC)	29-Jan-21	"Active, not recruiting"	3P30CA016056-43S5
clinical_trial	NCT01886235	Intravital Microscopy for Identifying Tumor Vessels in Patients With Stage IA-IV Melanoma That is Being Removed by Surgery	7-Aug-20	Completed	3P30CA016056-43S5
clinical_trial	NCT01829971	"A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection"	27-Sep-16	Terminated	3P30CA016056-43S5
clinical_trial	NCT01698294	Biomarkers in Post-Menopausal Women Receiving Flaxseed	23-Jul-20	Completed	3P30CA016056-43S5
clinical_trial	NCT01527136	Entolimod in Treating Patients With Locally Advanced or Metastatic Solid Tumors That Cannot Be Removed By Surgery	12-Jan-16	Completed	3P30CA016056-43S5
clinical_trial	NCT02752074	A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)	27-Aug-20	Completed	3P30CA016056-43S5
clinical_trial	NCT03384836	Propranolol Hydrochloride and Pembrolizumab in Treating Patients With Stage IIIC-IV Melanoma That Cannot Be Removed by Surgery	12-Oct-21	Recruiting	3P30CA016056-43S5
clinical_trial	NCT03561207	3D Prediction of Patient-Specific Response (3D-PREDICT)	7-Oct-21	Recruiting	3P30CA016056-43S5
clinical_trial	NCT00843726	Radiation Therapy in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer	15-Jun-21	Completed	3P30CA016056-43S5
clinical_trial	NCT02861300	CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer	6-May-21	Suspended	3P30CA177558-08S2
clinical_trial	NCT04250545	Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer	1-Oct-21	Recruiting	3P30CA177558-08S2
clinical_trial	NCT03047993	Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome	15-Jan-21	Recruiting	3P30CA177558-08S2
clinical_trial	NCT03528642	CB-839 With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma	15-Oct-21	Recruiting	3P30CA177558-08S2
clinical_trial	NCT03109661	N/A	N/A	N/A	3P30CA177558-08S2
clinical_trial	NCT03109561	Apolipoprotein E (ApoE) and Metabolism	23-Jul-20	Completed	3P30CA177558-08S2
clinical_trial	NCT00095927	Randomized Amifostine For SCCHN	4-Jan-17	Completed	3P30CA006516-55S9
clinical_trial	NCT00095901	Capecitabine For Nasopharyngeal Cancer	29-Mar-18	Completed	3P30CA006516-55S9
clinical_trial	NCT00084838	Chemotherapy Combined With Radiation Therapy for Newly Diagnosed CNS AT/RT	24-Dec-15	Completed	3P30CA006516-55S9
clinical_trial	NCT00069940	Vaccine Therapy and Sargramostim in Treating Patients With Sarcoma or Brain Tumor	28-Dec-10	Completed	3P30CA006516-55S9
clinical_trial	NCT03029325	Molecular and Genetic Analysis of Lung Cancer	4-Mar-21	Recruiting	3P30CA006516-55S9
clinical_trial	NCT00429910	Natural History Study of Patients With Chronic Myelogenous Leukemia	2-Jan-17	Completed	3P30CA006516-55S9
clinical_trial	NCT00357500	"Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer"	1-Oct-14	Completed	3P30CA006516-55S9
clinical_trial	NCT00101075	Title XELOX FOR SALIVARY GLAND CANCERS	27-Feb-17	Terminated	3P30CA006516-55S9
clinical_trial	NCT00098865	Thalidomide and Temozolomide in Relapsed or Progressive CNS Disease or Neuroblastoma	7-Oct-14	Completed	3P30CA006516-55S9
clinical_trial	NCT00095875	Combination Chemotherapy and Radiation in Treating Patients With Stage III or IV Head and Neck Cancer (Paradigm Trial)	19-Nov-13	Completed	3P30CA006516-55S9
clinical_trial	NCT03974217	Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts	24-Aug-21	Recruiting	3P30CA006516-55S9
clinical_trial	NCT04485130	DISulfiram for COvid-19 (DISCO) Trial (DISCO)	10-May-21	Recruiting	3P30CA006516-55S9
clinical_trial	NCT04594343	Clinical Study to Evaluate the Effects of Disulfiram in Patients With Moderate COVID-19	8-Oct-21	Completed	3P30CA006516-55S9
